Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
42 "Iodine"
Filter
Filter
Article type
Keywords
Publication year
Authors
Funded articles
Original Article
Thyroid
Investigating Birth and Thyroid Outcomes of Maternal-Fetal Environmental Exposures (IBM-E): A Cohort Protocol for Dietary Iodine and Endocrine Disruptors
Yun Ji Jung, Jeong Eun Shin, Ju-hee Yoon, Suhra Kim, Hayan Kwon, Sungbo Shim, Dong Yeob Shin, Minseo Gim, Younglim Kho, JoonHo Lee
Endocrinol Metab. 2025;40(6):940-949.   Published online September 25, 2025
DOI: https://doi.org/10.3803/EnM.2025.2475
  • 1,059 View
  • 62 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Endocrine-disrupting chemicals (EDCs) are environmental pollutants that may impair maternal and fetal health by disrupting hormonal systems, including the thyroid. Both iodine deficiency and excess are associated with thyroid dysfunction and adverse obstetrical outcomes. However, the combined impacts of EDCs and iodine exposure on maternal-fetal thyroid homeostasis remain undetermined. We established the Investigating Birth and Thyroid Outcomes of Maternal-Fetal Environmental Exposures (IBM-E) cohort to prospectively assess the effects of maternal exposures to dietary iodine and EDCs on thyroid function, pregnancy complications, and offspring growth and development.
Methods
In this prospective observational study, we aim to enroll 556 pregnant women between 2024 and 2027 at a tertiary hospital in Korea. Maternal blood and urine samples will be collected at six time points, spanning from early pregnancy through 15 months postpartum, with infant samples collected at three time points. EDCs will be quantified using ultra-high performance liquid chromatography-tandem mass spectrometry. Thyroid function and urinary iodine concentration will be measured in both mothers and infants.
Results
As of the current interim analyses of 193 mothers and 229 neonates, 15.0% of mothers had thyroid dysfunction and 11.4% developed preeclampsia. Preterm birth occurred in 23.8% of cases, and 16.6% of neonates were small for gestational age.
Conclusion
The IBM-E cohort is designed to enable the longitudinal assessment of gestational environmental exposures and their potential impacts on maternal and fetal thyroid function, as well as pregnancy and neonatal outcomes. The findings of this study may inform preventive strategies and guide policy development in perinatal environmental health.
Close layer
Review Article
Thyroid
2025 Korean Thyroid Association Management Guidelines for Radioactive Iodine Therapy in Patients with Hyperthyroidism
Kyeong Jin Kim, Eyun Song, Mijin Kim, Hyemi Kwon, Eu Jeong Ku, Hyun Woo Kwon, Jee Hee Yoon, Eun Kyung Lee, Won Woo Lee, Young Joo Park, Dong-Jun Lim, Sun Wook Kim, Ho-Cheol Kang, Jae Hoon Chung, Tae Yong Kim, Sin Gon Kim, Dong Gyu Na, Jee Soo Kim
Endocrinol Metab. 2025;40(3):342-356.   Published online June 24, 2025
DOI: https://doi.org/10.3803/EnM.2025.2464
  • 9,266 View
  • 350 Download
AbstractAbstract PDFPubReader   ePub   
Hyperthyroidism is a condition marked by excessive thyroid hormone production, most commonly due to Graves’ disease. Treatment options include antithyroid drugs (ATD), radioactive iodine (RAI) therapy, and thyroidectomy. To develop standardized clinical recommendations for RAI therapy with a focus on safety, efficacy, and monitoring, the Korean Thyroid Association formed a task force to create evidence-based guidelines. Six key clinical questions were identified through expert consensus, and a systematic literature review from 2013 to 2022 was conducted. Clinical indications for RAI therapy were categorized into three groups: strongly recommended, may be considered, and not recommended. A fixed dose of 10 to 15 mCi is recommended. Although a strict low-iodine diet is unnecessary, iodine-rich foods should be avoided for at least 1 week before treatment. ATD should be stopped 3 to 7 days before RAI and may be resumed in select cases. Prophylactic glucocorticoids are recommended for patients with mildly active thyroid eye disease and may be considered for others at risk. Thyroid function should be monitored at 4–6 weeks post-treatment, every 2–3 months until stabilized, and then every 6–12 months. These guidelines highlight recent advances and underscore the importance of individualized treatment based on clinical features, comorbidities, and patient preferences in Korea.
Close layer
Original Articles
Thyroid
Comparison of Thyroid Size-Specific Radioiodine Dose and New Modified Dose Calculation in the Treatment of Graves’ Disease
Alisara Wongsuttilert, Ruchirek Thamcharoen, Yoswanich Maiprasert, Sathapakorn Siriwong
Endocrinol Metab. 2024;39(5):758-766.   Published online October 14, 2024
DOI: https://doi.org/10.3803/EnM.2024.1950
  • 3,710 View
  • 116 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Previous studies of fixed-dose radioiodine therapy (RIT) for Graves’ disease (GD) have utilized a variety of techniques and reported differing success rates. This study sought to compare the efficacy of RIT using two fixed-dose protocols and to estimate the optimal radioiodine (RAI) activity for the treatment of GD.
Methods
This retrospective trial enrolled 658 patients with GD who received RIT between January 2014 and December 2021. Participants were divided into two groups: protocol 1, which utilized a thyroid size-specific RAI dose, and protocol 2, which employed a modified dose calculation approach. The primary outcome assessed was the presence of euthyroidism or hypothyroidism at the 6-month follow-up. The success rates of RIT were compared between the two protocols.
Results
The RIT success rate was marginally lower for protocol 2 than for protocol 1 (63.6% vs. 67.2%); however, the risk of treatment failure did not differ considerably between the groups (relative risk, 1.1089; 95% confidence interval, 0.8937 to 1.3758; P=0.3477). The median RAI activity associated with protocol 2 was lower than that for protocol 1 (10.7 mCi vs. 15.0 mCi, P=0.0079), and the frequency of hypothyroidism was significantly lower in the protocol 2 group (39.0% vs. 48.9%, P=0.0117).
Conclusion
The success rate of the modified dose calculation protocol was comparable to that of the thyroid size-specific RAI dose protocol. The former approach reduced RAI activity and the incidence of hypothyroidism following RIT without compromising the success rate.
Close layer
Thyroid
Efficacy and Safety of Long-Term Methimazole versus Radioactive Iodine in the Treatment of Toxic Multinodular Goiter
Fereidoun Azizi, Navid Saadat, Mir Alireza Takyar, Hengameh Abdi, Ladan Mehran, Atieh Amouzegar
Endocrinol Metab. 2022;37(6):861-869.   Published online November 23, 2022
DOI: https://doi.org/10.3803/EnM.2022.1476
  • 11,965 View
  • 499 Download
  • 6 Web of Science
  • 7 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
This study compared the degree of sustained control of hyperthyroidism in patients with toxic multinodular goiter (TMNG) treated with long-term methimazole (LT-MMI) or radioactive iodine (RAI).
Methods
In this clinical trial, 130 untreated patients with TMNG were randomized to either LT-MMI or RAI treatment. Both groups were followed for 108 to 148 months, with median follow-up durations of 120 and 132 months in the LT-MMI and RAI groups, respectively. Both groups of patients were followed every 1 to 3 months in the first year and every 6 months thereafter.
Results
After excluding patients in whom the treatment modality was changed and those who were lost to follow-up, 53 patients in the LT-MMI group and 54 in the RAI group completed the study. At the end of the study period, 50 (96%) and 25 (46%) patients were euthyroid, and two (4%) and 25 (46%) were hypothyroid in LT-MMI and RAI groups, respectively. In the RAI group, four (8%) patients had subclinical hyperthyroidism. The mean time to euthyroidism was 4.3±1.3 months in LT-MMI patients and 16.3± 15.0 months in RAI recipients (P<0.001). Patients treated with LT-MMI spent 95.8%±5.9% of the 12-year study period in a euthyroid state, whereas this proportion was 72.4%±14.8% in the RAI-treated patients (P<0.001). No major treatment-related adverse events were observed in either group.
Conclusion
In patients with TMNG, LT-MMI therapy is superior to RAI treatment, as shown by the earlier achievement of euthyroidism and the longer duration of sustained normal serum thyrotropin.

Citations

Citations to this article as recorded by  
  • Analysis of the Clinical Characteristics of 45 Patients with Toxic Goiter in a Single Center
    秋娥 刘
    Advances in Clinical Medicine.2025; 15(03): 2091.     CrossRef
  • Antithyroid drugs and the dose–risk balance: a meta-analysis on agranulocytosis in hyperthyroidism
    Luis Agustín Ramírez Stieben, Lucas Ricardo Brun, Paula Nasazzi Doddi, María Lorena Brance
    Endocrine.2025; 90(2): 391.     CrossRef
  • Methimazole-Induced Agranulocytosis: A Clinical Case Report
    João Menino, Inês Meira, Juliana Gonçalves, Sara Ribeiro, Jorge Pedro, Joana Queirós
    Endocrinology Insights.2025; 20(2): 112.     CrossRef
  • Effects of iodine and fluorine levels in the environment on thyroid function indicators in Hebei Province, China
    Yanguo Li, Ruixia Yan, Yuan Zhou, Wen Tang, Qiannan Li, Shuzhen Li, Liping Zhang
    Annals of Human Biology.2025;[Epub]     CrossRef
  • Control rate of hyperthyroidism and its associated factors after prolonged use of anti-thyroid drugs in a hospital setting, Northwest Ethiopia
    Seyoum Mengesha, Abilo Tadesse, Biruk Mulat Worku, Kifle Alamrew, Tesfaye Yesuf, Yonas Gedamu
    Medicine.2024; 103(23): e38201.     CrossRef
  • Approach to the Patient Considering Long-term Antithyroid Drug Therapy for Graves’ Disease
    Fereidoun Azizi, Ladan Mehran, Hengameh Abdi, Atieh Amouzegar
    The Journal of Clinical Endocrinology & Metabolism.2024; 109(10): e1881.     CrossRef
  • Mechanism of Huatan Sanjie Fang in improving goiter in Graves' disease mice based on the Hippo signaling pathway
    Huimin Yuan, Wenxin Ma, Yifei Song, Hang Wang, Shuxin Yan, Silan Hao, Xiaoyun Zhu, Yang Tang
    Journal of Traditional Chinese Medical Sciences.2023; 10(3): 289.     CrossRef
Close layer
Thyroid
Clinical Outcomes of Repeated Radioactive Iodine Therapy for Graves’ Disease
Min Joo Kim, Sun Wook Cho, Ye An Kim, Hoon Sung Choi, Young Joo Park, Do Joon Park, Bo Youn Cho
Endocrinol Metab. 2022;37(3):524-532.   Published online June 16, 2022
DOI: https://doi.org/10.3803/EnM.2022.1418
  • 10,757 View
  • 296 Download
  • 5 Web of Science
  • 7 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Radioactive iodine (RAI) therapy is a successful therapeutic modality for Graves’ disease. However, RAI therapy can fail, and RAI therapy after antithyroid drugs (ATDs) has a lower remission rate. Therefore, many patients require repeated RAI therapy. This study investigated the clinical outcomes of repeated RAI therapy for Graves’ disease.
Methods
Patients who underwent RAI therapy as second-line therapy after failure of ATD treatment between 2001 and 2015 were reviewed. Remission was defined as hypothyroid or euthyroid status without ATD, and with or without levothyroxine at 12 months after RAI therapy.
Results
The 1-year remission rate after 2nd RAI therapy (66%, 152/230) is significantly higher than that after 1st RAI therapy (48%, 393/815) or long-term ATD treatment after 1st RAI therapy failure (42%). The clinical response to 2nd RAI therapy was more rapid. The median time intervals from the 2nd RAI therapy to ATD discontinuation (1.3 months) and to the start of levothyroxine replacement (2.5 months) were significantly shorter than those for the 1st RAI therapy. A smaller goiter size, a longer time interval between the 1st and 2nd RAI therapies, and a longer ATD discontinuation period predicted remission after the 2nd RAI therapy. Finally, in 78 patients who failed the 2nd RAI therapy, the mean ATD dosage significantly reduced 5.1 mg over 12 months.
Conclusion
Repeated RAI therapy can be a good therapeutic option, especially in patients with smaller goiters and those who are more responsive to the 1st RAI therapy.

Citations

Citations to this article as recorded by  
  • Outcomes of Fixed-Dose Radioactive Iodine Therapy in Hyperthyroidism and Optimization of Follow-Up After Treatment Failure With Low-Dose Antithyroid Medication
    Panita Kantikool, Naphat Buraphanawibun
    Cureus.2025;[Epub]     CrossRef
  • Tingkat Keberhasilan Terapi Radioiodin Pertama pada Pasien Graves’ Disease
    Aliya Khadijah Kemaleratu, Yuliana Rahmah Retnaningrum, Yudanti Riastiti
    Jurnal Sains dan Kesehatan.2025; 6(1): 1.     CrossRef
  • Association of high‐dose radioactive iodine therapy with PPM1D‐mutated clonal hematopoiesis in older individuals
    Jaeryuk Kim, Sungwoo Bae, Jaeyong Choi, Sun‐Wha Im, Bukyoung Cha, Gyeongseo Jung, Sun Wook Cho, Eul‐Ju Seo, Young Ah Lee, Jin Chul Paeng, Young Joo Park, Jong‐Il Kim
    Molecular Oncology.2025; 19(11): 3079.     CrossRef
  • Characteristics of Japanese patients with Graves’ disease who fail first radioiodine therapy
    Yuki Yamamoto, Hiroshi Fukazawa, Jun Ito, Kei Ito, Masanao Fujii, Aiko Hosoda, Yoshinori Osaki, Hiroaki Yagyu
    Thyroid Science.2025; 2(4): 100028.     CrossRef
  • Prospective study to evaluate radioactive iodine of 20 mCi vs 10–15 mCi in Graves’ disease
    Wasit Kanokwongnuwat, Nawarat Penpong
    BMC Endocrine Disorders.2024;[Epub]     CrossRef
  • The Early Changes in Thyroid-Stimulating Immunoglobulin Bioassay over Anti-Thyroid Drug Treatment Could Predict Prognosis of Graves’ Disease
    Jin Yu, Han-Sang Baek, Chaiho Jeong, Kwanhoon Jo, Jeongmin Lee, Jeonghoon Ha, Min Hee Kim, Jungmin Lee, Dong-Jun Lim
    Endocrinology and Metabolism.2023; 38(3): 338.     CrossRef
  • Effect of liver dysfunction on outcome of radioactive iodine therapy for Graves’ disease
    Yuyang Ze, Fei Shao, Xuefeng Feng, Shanmei Shen, Yan Bi, Dalong Zhu, Xiaowen Zhang
    BMC Endocrine Disorders.2022;[Epub]     CrossRef
Close layer
Thyroid
Seaweed and Iodine Intakes and SLC5A5 rs77277498 in Relation to Thyroid Cancer
Tung Hoang, Eun Kyung Lee, Jeonghee Lee, Yul Hwangbo, Jeongseon Kim
Endocrinol Metab. 2022;37(3):513-523.   Published online May 24, 2022
DOI: https://doi.org/10.3803/EnM.2021.1306
  • 8,779 View
  • 168 Download
  • 7 Web of Science
  • 7 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
This study aims to elucidate the associations among dietary seaweed (gim and miyeok/dashima) and iodine intakes, the rs77277498 polymorphism of the SLC5A5 gene codifying the sodium/iodine symporter, and thyroid cancer risk in a Korean population.
Methods
We conducted a case-control study of 117 thyroid cancer cases and 173 controls who participated in the Cancer Screenee Cohort between 2002 and 2014 at the National Cancer Center, Korea. The amount of seaweed and iodine consumption (g/day) was estimated using the residual energy adjustment method. We calculated odds ratios (ORs) and their 95% confidence intervals (CIs) using a multivariable logistic regression model for the separate and combined effect of dietary iodine-based intake and SLC5A5 polymorphism (rs77277498, C>G) on thyroid cancer.
Results
Dietary gim and iodine intakes were inversely associated with thyroid cancer, with ORs of 0.50 (95% CI, 0.30 to 0.83) and 0.57 (95% CI, 0.35 to 0.95), respectively, whereas the associations for dietary miyeok/dashima and total seaweed intakes were not significant. However, compared with individuals carrying the C/C genotype of the rs77277498 polymorphism with a low intake of all dietary factors, those carrying the G allele with a high intake had a lower risk of thyroid cancer, with ORs of 0.25 (95% CI, 0.10 to 0.56), 0.31 (95% CI, 0.12 to 0.77), 0.26 (95% CI, 0.10 to 0.62), and 0.30 (95% CI, 0.12 to 0.73) for the consumption of gim, miyeok/dashima, total seaweed, and iodine, respectively.
Conclusion
In summary, our results supported the evidence of the protective effects of dietary gim and iodine intake against thyroid cancer risk, and this association can be strengthened by SLC5A5 rs77277498 genotypes.

Citations

Citations to this article as recorded by  
  • The influence of nutrition in nodular thyroid pathology: a systematic review
    Vanessa Neto, Catarina Leitão, Marta Estrela, Margarida Fardilha, Maria Teresa Herdeiro, Alexandra Nunes
    Critical Reviews in Food Science and Nutrition.2025; 65(24): 4634.     CrossRef
  • Effects of Trace Elements on Endocrine Function and Pathogenesis of Thyroid Diseases—A Literature Review
    Łukasz Bryliński, Katarzyna Kostelecka, Filip Woliński, Olga Komar, Agata Miłosz, Justyna Michalczyk, Jan Biłogras, Anna Machrowska, Robert Karpiński, Marcin Maciejewski, Ryszard Maciejewski, Gabriella Garruti, Jolanta Flieger, Jacek Baj
    Nutrients.2025; 17(3): 398.     CrossRef
  • Dissecting the causal association of diet with thyroid cancer: a systematic review with meta-analysis and mendelian randomization analysis.
    Chao Kang, Yongyao Du, Jiaxin Li, Yi Yang, Jingping Li, Manping Zhou, Jiaojiao Shi, Ning Lin, Xin Ma, Xiaoli Peng
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Calcium and Gastrointestinal Disorders: Mechanistic Insights and Therapeutic Interventions
    Yuanchao Zheng, Ziwei Gao, Lei Sun, Jieyi Shi, Jingru Song, Wei Ye
    International Journal for Vitamin and Nutrition Research.2025;[Epub]     CrossRef
  • Iodine Intake and Risk of Mortality: Evidence from a Nationally Representative Korean Cohort
    Jung-Hwan Cho, Jun Young Kim, Nak Gyeong Ko, Hanaro Park, Byung Soo Kwan, Ji Min Han, Sunghwan Suh, Ji Cheol Bae, Tae Hyuk Kim, Sun Wook Kim, Jae Hoon Chung, Hye Rang Bak, Hye In Kim
    Nutrients.2025; 17(24): 3859.     CrossRef
  • Evaluation of the Bioavailability of Iodine and Arsenic in Raw and Cooked Saccharina japonica Based on Simulated Digestion/Caco-2 Cell Model
    Na Li, Zhaomeng Geng, Yingying Guo, Xinyue Dai, Wenjia Zhu, Lin Yao, Yanhua Jiang, Xiaojuan Wang, Hao Dong, Huijie Wang, Lianzhu Wang
    Foods.2024; 13(18): 2864.     CrossRef
  • Iodine nutrition and papillary thyroid cancer
    Xueqi Zhang, Fan Zhang, Qiuxian Li, Chuyao Feng, Weiping Teng
    Frontiers in Nutrition.2022;[Epub]     CrossRef
Close layer
Thyroid
Big Data Articles (National Health Insurance Service Database)
Risk of Diabetes in Patients with Long-Standing Graves’ Disease: A Longitudinal Study
Eyun Song, Min Ji Koo, Eunjin Noh, Soon Young Hwang, Min Jeong Park, Jung A Kim, Eun Roh, Kyung Mook Choi, Sei Hyun Baik, Geum Joon Cho, Hye Jin Yoo
Endocrinol Metab. 2021;36(6):1277-1286.   Published online December 16, 2021
DOI: https://doi.org/10.3803/EnM.2021.1251
  • 10,948 View
  • 218 Download
  • 14 Web of Science
  • 14 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
The detrimental effects of excessive thyroid hormone on glucose metabolism have been widely investigated. However, the risk of diabetes in patients with long-standing hyperthyroidism, especially according to treatment modality, remains uncertain, with few longitudinal studies.
Methods
The risk of diabetes in patients with Graves’ disease treated with antithyroid drugs (ATDs) for longer than the conventional duration (≥2 years) was compared with that in age-and sex-matched controls. The risk was further compared according to subsequent treatment modalities after a 24-month course of ATD: continuation of ATD (ATD group) vs. radioactive iodine ablation (RIA) group.
Results
A total of 4,593 patients were included. Diabetes was diagnosed in 751 (16.3%) patients over a follow-up of 7.3 years. The hazard ratio (HR) for diabetes, after adjusting for various known risk factors, was 1.18 (95% confidence interval [CI], 1.10 to 1.28) in patients with hyperthyroidism. Among the treatment modality groups, the RIA group (n=102) had a higher risk of diabetes than the ATD group (n=4,491) with HR of 1.56 (95% CI, 1.01 to 2.42). Further, the risk of diabetes increased with an increase in the ATD treatment duration (P for trend=0.019).
Conclusion
The risk of diabetes was significantly higher in patients with long-standing Graves’ disease than in the general population, especially in patients who underwent RIA and prolonged ATD treatment. Special attention to hyperglycemia during follow-up along with effective control of hyperthyroidism may be necessary to reduce the risk of diabetes in these patients.

Citations

Citations to this article as recorded by  
  • Graves’ Disease and the Risk of Type 2 Diabetes: A Korean Population-Based Study
    Yoon Young Cho, Bongseong Kim, Sang-Man Jin, Chan-Hee Jung, Ji Oh Mok, Sun Wook Kim, Jae Hoon Chung, Kyung-Do Han, Tae Hyuk Kim
    Thyroid®.2025; 35(1): 60.     CrossRef
  • Diabetes mellitus secondary to endocrine diseases: a position statement of the working group of the club of the Italian society of endocrinology (SIE)-Nutrition hormones and metabolism
    Luigi Barrea, Massimiliano Caprio, Sebastio Perrini, Elisabetta Camajani, Andrea Crafa, Elena Gangitano, Stefania Gorini, Laura Sciacca, Ludovica Verde, Manuela Albertelli, Diego Ferone, Francesco Giorgino, Annamaria Colao, Gianluca Aimaretti, Giovanna Mu
    Journal of Endocrinological Investigation.2025; 48(8): 1739.     CrossRef
  • The Effect of Metformin on Prolactin Concentration in Women with Hyperprolactinemia and Subclinical Hyperthyroidism
    Robert Krysiak, Karolina Kowalcze, Bogusław Okopień
    Neuroendocrinology.2025; 115(6-7): 553.     CrossRef
  • Safety of non-standard regimen of systemic steroid therapy in patients with Graves’ orbitopathy: a single-centre experience
    Nadia Sawicka-Gutaj, Dawid Gruszczyński, Natalia Zawalna, Kacper Nijakowski, Agnieszka Skiba, Mateusz Pochylski, Jerzy Sowiński, Marek Ruchała
    Pharmacological Reports.2024; 76(1): 185.     CrossRef
  • Increased risk of diabetes mellitus and hyperlipidemia in patients with differentiated thyroid cancer
    Hwa Young Ahn, Jooyoung Lee, Jinmo Kang, Eun Kyung Lee
    European Journal of Endocrinology.2024; 190(3): 248.     CrossRef
  • Evaluation of the Dysregulation of Cholesterol and Glucose Levels in Graves' Disease Using Clinical Data Analysis
    Zainab Razaq Kareem, Fatin Fadhel Al-Kazazz, Ahmed Mahdi Rheima, Ameer Radhi Sultan
    Reports of Biochemistry and Molecular Biology.2024; 13(2): 159.     CrossRef
  • Prevalencia de diabetes en personas con disfunción tiroidea
    Juan J. Díez, Pedro Iglesias
    Medicina Clínica.2023; 160(8): 333.     CrossRef
  • Control of Thyroid Dysfunction in Spanish Population Registered in the Primary Care Clinical Database: An Analysis of the Proportion of Patients with Thyrotropin Values Outside the Reference Range
    Juan J. Díez, Pedro Iglesias
    Hormone and Metabolic Research.2023; 55(03): 184.     CrossRef
  • Prevalence of thyroid dysfunction and its relationship to income level and employment status: a nationwide population-based study in Spain
    Juan J. Díez, Pedro Iglesias
    Hormones.2023; 22(2): 243.     CrossRef
  • Prevalence of diabetes in people with thyroid dysfunction
    Juan J. Díez, Pedro Iglesias
    Medicina Clínica (English Edition).2023; 160(8): 333.     CrossRef
  • Diabetes Mellitus Secondary to Endocrine Diseases: An Update of Diagnostic and Treatment Particularities
    Mihaela Simona Popoviciu, Lorena Paduraru, Raluca Marinela Nutas, Alexandra Maria Ujoc, Galal Yahya, Kamel Metwally, Simona Cavalu
    International Journal of Molecular Sciences.2023; 24(16): 12676.     CrossRef
  • Thyroid Eye Disease and Its Association With Diabetes Mellitus: A Major Review
    Roshmi Gupta, Pramila Kalra, Lakshmi B. Ramamurthy, Suryasnata Rath
    Ophthalmic Plastic & Reconstructive Surgery.2023; 39(6S): S51.     CrossRef
  • Metabolite Changes during the Transition from Hyperthyroidism to Euthyroidism in Patients with Graves’ Disease
    Ho Yeop Lee, Byeong Chang Sim, Ha Thi Nga, Ji Sun Moon, Jingwen Tian, Nguyen Thi Linh, Sang Hyeon Ju, Dong Wook Choi, Daiki Setoyama, Hyon-Seung Yi
    Endocrinology and Metabolism.2022; 37(6): 891.     CrossRef
  • Diabetes and Hyperthyroidism: Is There a Causal Link?
    Sang Yong Kim
    Endocrinology and Metabolism.2021; 36(6): 1175.     CrossRef
Close layer
Thyroid
Association between Iodine Intake, Thyroid Function, and Papillary Thyroid Cancer: A Case-Control Study
Kyungsik Kim, Sun Wook Cho, Young Joo Park, Kyu Eun Lee, Dong-Wook Lee, Sue K. Park
Endocrinol Metab. 2021;36(4):790-799.   Published online August 11, 2021
DOI: https://doi.org/10.3803/EnM.2021.1034
  • 9,535 View
  • 296 Download
  • 24 Web of Science
  • 25 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
This study aimed to assess the effects of iodine intake, thyroid function, and their combined effect on the risk of papillary thyroid cancer (PTC) and papillary thyroid microcarcinoma (PTMC).
Methods
A case-control study was conducted including 500 community-based controls who had undergone a health check-up, and 446 overall PTC cases (209 PTC and 237 PTMC) from the Thyroid Cancer Longitudinal Study. Urinary iodine concentration (UIC), was used as an indicator of iodine intake, and serum for thyroid function. The risk of PTC and PTMC was estimated using unconditional logistic regression.
Results
Excessive iodine intake (UIC ≥220 μg/gCr) was associated with both PTC (odds ratio [OR], 18.13 95% confidence interval [CI], 8.87 to 37.04) and PTMC (OR, 8.02; 95% CI, 4.64 to 13.87), compared to adequate iodine intake (UIC, 85 to 219 μg/gCr). Free thyroxine (T4) levels ≥1.25 ng/dL were associated with PTC (OR, 1.97; 95% CI, 1.36 to 2.87) and PTMC (OR, 2.98; 95% CI, 2.01 to 4.41), compared to free T4 levels of 0.7 to 1.24 ng/dL. Individuals with excessive iodine intake and high free T4 levels had a greatly increased OR of PTC (OR, 43.48; 95% CI, 12.63 to 149.62), and PTMC (OR, 26.96; 95% CI, 10.26 to 70.89), compared to individuals with adequate iodine intake and low free T4 levels.
Conclusion
Excessive iodine intake using creatinine-adjusted UIC and high free T4 levels may have a synergistic effect on PTC and PTMC. Considering both iodine intake and thyroid function is important to assess PTC and PTMC risk.

Citations

Citations to this article as recorded by  
  • Thyroid cancer in Asia: incidence, mortality in 2022, and future projections to 2050
    Mengxia Fu, Zhiming Peng, Min Wu
    European Journal of Cancer Prevention.2026; 35(2): 126.     CrossRef
  • Association of iodine nutritional status with thyroid nodules and papillary thyroid carcinoma in women from an iodine-sufficient region in Brazil: A cross-sectional center study
    Ivia Fonseca, Aline Larcher de Almeida, Patrícia Borges dos Santos, Natalia Treistman, Tales Aprigio, Mario Vaisman, Ana Paula Aguiar Vidal, Patrícia de Fátima dos Santos Teixeira, Nathalie Silva de Morais
    Journal of Trace Elements in Medicine and Biology.2026; 93: 127816.     CrossRef
  • Enhancing CEUS Value in Papillary Thyroid Carcinoma: A Dual-Model Framework for Patient Selection Based on Conventional Ultrasound Characteristics
    Liyuan He, Yinghua Li, Delin Zhong, Jing Gao, Yuan Yuan, Shuhuan Zhang, Jianyuan Wang
    Ultrasound in Medicine & Biology.2026; 52(3): 714.     CrossRef
  • Dietary and Urinary Iodine in Relation to Thyroid Cancer Risk: A Meta-Analysis
    Shitao Li, Hengxu Yu
    Cancer Control.2026;[Epub]     CrossRef
  • Continued rise in the incidence of thyroid cancer in Iran: true increase or overdiagnosis?
    Mahnaz Pejman Sani, Shahrzad Mohseni, Hilda Samimi, Shirzad Nasiri, Babak Fallahi, Mohammadreza Mohajeri-Tehrani, Seyed Mohammad Tavangar, Mahmood Naderi, Nooshin Shirzad, Bagher Larijani, Sayed Mahmoud Sajjadi-Jazi, Gholamreza Roshandel, Vahid Haghpanah
    Journal of Diabetes & Metabolic Disorders.2025;[Epub]     CrossRef
  • Heavy metals in seaweed: Implications for health benefits, risks, and safety regulations
    Lori Huang, Ji-Young Lee, Young-Ki Park, Jaeeun Lee
    Journal of Agriculture and Food Research.2025; 21: 101830.     CrossRef
  • The association between per-fluoroalkyl and poly-fluoroalkyl substances exposure and thyroid cancer: a meta-analysis
    Ruyu Wang, Mengze Lv, Siqi Chen, Yueran Zheng, Zeyuan Fu, Xupu Yang, Jingjing Wang, Qianyu Liu, Yi Liu, Xiaolin Zhang, Huicai Guo, Xuehui Liu
    Journal of Environmental Health Science and Engineering.2025;[Epub]     CrossRef
  • Bridging the deficit: Assessing knowledge gaps in thyroid cancer management amongst physicians in the Democratic Republic of Congo
    John Bukasa-Kakamba, Ayrton I Bangolo, Nickson Poka, Christian Bompongo, Shruti Wadhwani, Nikita Wadhwani, Isis Kapinga Kalambayi, Manasse Bukasa Mutombo, Pierre Fwelo, Pascal Bayauli, Gael Menga, Andy Sifa, Cute Diazabakana, Guy Kingebeni, Mbuyi Mulumba,
    World Journal of Clinical Oncology.2025;[Epub]     CrossRef
  • Risks of Iodine Excess
    Seo Young Sohn, Kosuke Inoue, Connie M Rhee, Angela M Leung
    Endocrine Reviews.2024; 45(6): 858.     CrossRef
  • The influence of micronutrients and macronutrients excess or deficiency on thyroid function
    K. Brzdęk, S. Wiśniewski, O. Domańska, W. Baran, M. Brzdęk
    The Ukrainian Biochemical Journal.2024; 96(4): 5.     CrossRef
  • Association between Thyroid Profile Levels and Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Retrospective Study
    Yu-Shan Hsieh, Ting-Teng Yang, Chung-Huei Hsu, Yan-Yu Lin
    Reports.2024; 7(3): 78.     CrossRef
  • Consequences of acute and long‐term excessive iodine intake: A literature review focusing on seaweed as a potential dietary iodine source
    Marthe Jordbrekk Blikra, Inger Aakre, Jessica Rigutto‐Farebrother
    Comprehensive Reviews in Food Science and Food Safety.2024;[Epub]     CrossRef
  • Iodine Excess Is Associated with Thyroid Dysfunction Among the Elderly
    Qi Jin, Zhangzhao Wang, Junjing Li, Hexi Zhang, Mengxin Liu, Chunxi Wang, Wenxing Guo, Wanqi Zhang
    Biological Trace Element Research.2024; 203(7): 3470.     CrossRef
  • Association between urinary iodine concentration and the risk of papillary thyroid cancer by sex and age: a case–control study
    Yerin Hwang, Hyun-Kyung Oh, Jae Hoon Chung, Sun Wook Kim, Jung-Han Kim, Jee Soo Kim, Myung-Hee Shin
    Scientific Reports.2023;[Epub]     CrossRef
  • Association between iodine nutrition and cervical lymph node metastasis of papillary thyroid microcarcinoma
    Hengqiang Zhao, Jin Hu, Le Cui, Yiping Gong, Tao Huang
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Sex-specific Associations between Body Mass Index and Thyroid Cancer Incidence among Korean Adults
    Kyoung-Nam Kim, Kyungsik Kim, Sangjun Lee, Sue K. Park
    Cancer Epidemiology, Biomarkers & Prevention.2023; 32(9): 1227.     CrossRef
  • Nomogram Model Based on Iodine Nutrition and Clinical Characteristics of Papillary Thyroid Carcinoma to Predict Lateral Lymph Node Metastasis
    Junrong Wang, Yuzhang Gao, Yuxuan Zong, Weitong Gao, Xueying Wang, Ji Sun, Susheng Miao
    Cancer Control.2023;[Epub]     CrossRef
  • Content of Copper, Iron, Iodine, Rubidium, Strontium and Zinc in Thyroid Malignant Nodules and Thyroid Tissue adjacent to Nodules
    Vladimir Zaichick, Qiping Dong
    Journal of Clinical and Diagnostic Pathology.2022; 1(4): 7.     CrossRef
  • Distinguish Thyroid Malignant from Benign Alterations using Trace Element Contents in Nodular Tissue determined by Neutron Activation and Inductively Coupled Plasma Mass Spectrometry
    Vladimir Zaichick
    Journal of Clinical and Diagnostic Pathology.2022; 1(4): 18.     CrossRef
  • Seaweed and Iodine Intakes and SLC5A5 rs77277498 in Relation to Thyroid Cancer
    Tung Hoang, Eun Kyung Lee, Jeonghee Lee, Yul Hwangbo, Jeongseon Kim
    Endocrinology and Metabolism.2022; 37(3): 513.     CrossRef
  • Iodine nutrition and papillary thyroid cancer
    Xueqi Zhang, Fan Zhang, Qiuxian Li, Chuyao Feng, Weiping Teng
    Frontiers in Nutrition.2022;[Epub]     CrossRef
  • The relationship between urinary iodine concentration and papillary thyroid cancer: A systematic review and meta-analysis
    Xueqi Zhang, Fan Zhang, Qiuxian Li, Renaguli Aihaiti, Chuyao Feng, Deshi Chen, Xu Zhao, Weiping Teng
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Screening and validation of lymph node metastasis risk-factor genes in papillary thyroid carcinoma
    Qiaoyue Zhang, Jing Li, Hengyan Shen, Xinyu Bai, Tao Zhang, Ping Liu
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Diagnosis of Thyroid Malignancy using Levels of Chemical Element Contents in Nodular Tissue
    Vladimir Zaichick
    Journal of Health Care and Research.2022; 3(1): 16.     CrossRef
  • Associations of Habitual Mineral Intake with New-Onset Prediabetes/Diabetes after Acute Pancreatitis
    Claire F. Norbitt, Wandia Kimita, Juyeon Ko, Sakina H. Bharmal, Maxim S. Petrov
    Nutrients.2021; 13(11): 3978.     CrossRef
Close layer
Thyroid
Evaluation of Iodine Status among Korean Patients with Papillary Thyroid Cancer Using Dietary and Urinary Iodine
Ji Yeon Choi, Joon-Hyop Lee, YoonJu Song
Endocrinol Metab. 2021;36(3):607-618.   Published online June 21, 2021
DOI: https://doi.org/10.3803/EnM.2021.1005
  • 7,456 View
  • 141 Download
  • 3 Web of Science
  • 5 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
Concerns have been raised regarding thyroid disorders caused by excessive iodine in Koreans, who have iodine-rich diets. This study evaluated iodine status using dietary iodine intake and urinary iodine in papillary thyroid cancer (PTC) patients.
Methods
Dietary data of PTC patients were assessed using a 24-hour recall and food frequency questionnaire (FFQ), and urinary iodine concentrations (UICs) were also obtained. To compare the iodine status of PTC patients, Korean adults with or without thyroid disease from the Korea National Health and Nutrition Examination Survey, which had 24-hour recall data and urinary iodine measurements, were analyzed.
Results
The median daily iodine intake by 24-hour recall was 341.7 μg/day in PTC patients, similar to the levels of other Korean adults. Based on UICs, the prevalence of excessive iodine was 54.4% in PTC patients, which was similar to the prevalence among subjects with thyroid disease (55.4%) but slightly higher than that in subjects without thyroid disease (47.7%). Based on dietary iodine by 24-hour recall, the prevalence of excessive iodine intake was 7.2%, which was higher than that among subjects with (4.4%) or without (3.9%) thyroid disease. The dietary iodine intake based on 24-hour recall was closely correlated with the UIC (r=0.4826) in PTC patients, but dietary iodine by FFQ was not significantly correlated with either 24-hour recall or UIC-based dietary iodine.
Conclusion
Excessive iodine intake was more common in PTC patients than in subjects without thyroid disease. Further longitudinal research is necessary to elucidate the role of dietary iodine in PTC.

Citations

Citations to this article as recorded by  
  • Dietary Practices of Cancer Outpatients at Nyeri County Referral Hospital, Kenya; A Cross Sectional Survey
    Dorothy Bundi, Peter Chege, Regina Kamuhu
    International Journal of Nutrition and Food Sciences.2024; 13(5): 209.     CrossRef
  • Association Between the Dietary Practices and the Nutrition Status of Adult Cancer Outpatients at Nyeri County Referral Hospital, Kenya; A Cross Sectional Survey
    Dorothy Bundi, Peter Chege, Regina Kamuhu
    International Journal of Nutrition and Food Sciences.2024; 13(6): 239.     CrossRef
  • Association between iodine nutrition and cervical lymph node metastasis of papillary thyroid microcarcinoma
    Hengqiang Zhao, Jin Hu, Le Cui, Yiping Gong, Tao Huang
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Effect of iodine restriction on short-term changes in thyroid function in patients with subclinical hypothyroidism
    Obin Kwon, Dong Yeob Shin, Eun Jig Lee
    Journal of Nutrition and Health.2022; 55(2): 250.     CrossRef
  • Iodine nutrition and papillary thyroid cancer
    Xueqi Zhang, Fan Zhang, Qiuxian Li, Chuyao Feng, Weiping Teng
    Frontiers in Nutrition.2022;[Epub]     CrossRef
Close layer
Review Article
Thyroid
Antithyroid Drug Treatment in Graves’ Disease
Jae Hoon Chung
Endocrinol Metab. 2021;36(3):491-499.   Published online June 16, 2021
DOI: https://doi.org/10.3803/EnM.2021.1070
  • 15,017 View
  • 473 Download
  • 13 Web of Science
  • 18 Crossref
AbstractAbstract PDFPubReader   ePub   
Graves’ disease is associated with thyrotropin (TSH) receptor stimulating antibody, for which there is no therapeutic agent. This disease is currently treated through inhibition of thyroid hormone synthesis or destruction of the thyroid gland. Recurrence after antithyroid drug (ATD) treatment is common. Recent studies have shown that the longer is the duration of use of ATD, the higher is the remission rate. Considering the relationship between clinical outcomes and iodine intake, recurrence of Graves’ disease is more common in iodine-deficient areas than in iodine-sufficient areas. Iodine restriction in an iodine-excessive area does not improve the effectiveness of ATD or increase remission rates. Recently, Danish and Korean nationwide studies noted significantly higher prevalence of birth defects in newborns exposed to ATD during the first trimester compared to that of those who did not have such exposure. The prevalence of birth defects was lowest when propylthiouracil (PTU) was used and decreased by only 0.15% when methimazole was changed to PTU in the first trimester. Therefore, it is best not to use ATD in the first trimester or to change to PTU before pregnancy.

Citations

Citations to this article as recorded by  
  • Autoimmune Thyrotoxicosis Treated by Individualised Homoeopathy
    Faruk Bin Ansar, Abhijit Dutta, Navin Kumar Singh, Faiza Khan
    Journal of Medical Evidence.2025; 6(1): 65.     CrossRef
  • Unveiling Risk Factors for Treatment Failure in Patients with Graves’ Disease: A Nationwide Cohort Study in Korea
    Jung A Kim, Kyeong Jin Kim, Jimi Choi, Kyoung Jin Kim, Eyun Song, Ji Hee Yu, Nam Hoon Kim, Hye Jin Yoo, Ji A Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Sin Gon Kim
    Endocrinology and Metabolism.2025; 40(1): 125.     CrossRef
  • Risk of psychiatric disorders in patients with graves' disease: A nationwide population-based analysis
    Ju-Yeun Lee, Minha Hong, Young Hee Jung, Seo Young Sohn
    Journal of Affective Disorders.2025; 385: 119386.     CrossRef
  • 2025 Korean Thyroid Association Management Guidelines for Radioactive Iodine Therapy in Patients with Hyperthyroidism
    Kyeong Jin Kim, Eyun Song, Mijin Kim, Hyemi Kwon, Eu Jeong Ku, Hyun Woo Kwon, Jee Hee Yoon, Eun Kyung Lee, Won Woo Lee, Young Joo Park, Dong-Jun Lim, Sun Wook Kim, Ho-Cheol Kang, Jae Hoon Chung, Tae Yong Kim, Sin Gon Kim, Dong Gyu Na, Jee Soo Kim
    International Journal of Thyroidology.2025; 18(1): 65.     CrossRef
  • 2025 Korean Thyroid Association Management Guidelines for Radioactive Iodine Therapy in Patients with Hyperthyroidism
    Kyeong Jin Kim, Eyun Song, Mijin Kim, Hyemi Kwon, Eu Jeong Ku, Hyun Woo Kwon, Jee Hee Yoon, Eun Kyung Lee, Won Woo Lee, Young Joo Park, Dong-Jun Lim, Sun Wook Kim, Ho-Cheol Kang, Jae Hoon Chung, Tae Yong Kim, Sin Gon Kim, Dong Gyu Na, Jee Soo Kim
    Endocrinology and Metabolism.2025; 40(3): 342.     CrossRef
  • Hyperthyroidism treatment: A brief review with recommendations
    Wissal Abassi, Nejmeddine Ouerghi, Nidhal Jebabli, Moncef Feki, Anissa Bouassida, Katja Weiss, Beat Knechtle
    Endocrine and Metabolic Science.2025; 19: 100282.     CrossRef
  • A survey on the management practices of graves’ disease by Egyptian physicians and a comparison to similar reports from USA, Italy, China, and Brazil
    Tamer Mohamed Elsherbiny, Aliaa Aly El-Aghoury
    The Egyptian Journal of Internal Medicine.2024;[Epub]     CrossRef
  • Control rate of hyperthyroidism and its associated factors after prolonged use of anti-thyroid drugs in a hospital setting, Northwest Ethiopia
    Seyoum Mengesha, Abilo Tadesse, Biruk Mulat Worku, Kifle Alamrew, Tesfaye Yesuf, Yonas Gedamu
    Medicine.2024; 103(23): e38201.     CrossRef
  • Dynamic Risk Model for the Medical Treatment of Graves’ Hyperthyroidism according to Treatment Duration
    Meihua Jin, Chae A Kim, Min Ji Jeon, Won Bae Kim, Tae Yong Kim, Won Gu Kim
    Endocrinology and Metabolism.2024; 39(4): 579.     CrossRef
  • Выраженность окислительного стресса и энзиматическая активность нейтрофилов крови у пациентов с болезнью Грейвса в зависимости от компенсации гипертиреоза
    М. А. Дудина, С. А. Догадин, А. А. Савченко, И. И. Гвоздев
    Ateroscleroz.2023; 18(4): 411.     CrossRef
  • Application of oral inorganic iodine in the treatment of Graves’ disease
    Yixuan Huang, Yihang Xu, Murong Xu, Xiaotong Zhao, Mingwei Chen
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Sex-specific risk factors associated with graves’ orbitopathy in Korean patients with newly diagnosed graves’ disease
    Jooyoung Lee, Jinmo Kang, Hwa Young Ahn, Jeong Kyu Lee
    Eye.2023; 37(16): 3382.     CrossRef
  • Methimazole, an Effective Neutralizing Agent of the Sulfur Mustard Derivative 2-Chloroethyl Ethyl Sulfide
    Albert Armoo, Tanner Diemer, Abigail Donkor, Jerrod Fedorchik, Severine Van slambrouck, Rachel Willand-Charnley, Brian A. Logue
    ACS Bio & Med Chem Au.2023; 3(5): 448.     CrossRef
  • Increased risk of incident gout in patients with hyperthyroidism: a nationwide retrospective cohort study
    Ju-Yeun Lee, So-Yeon Park, Seo Young Sohn
    Rheumatology International.2023; 44(3): 451.     CrossRef
  • The influence of thionamides on intra-thyroidal uptake of 131I during radioiodine-131 treatment of Graves’ disease
    Christian Happel, Benjamin Bockisch, Britta Leonhäuser, Amir Sabet, Frank Grünwald, Daniel Groener
    Scientific Reports.2023;[Epub]     CrossRef
  • Usefulness of Real-Time Quantitative Microvascular Ultrasonography for Differentiation of Graves’ Disease from Destructive Thyroiditis in Thyrotoxic Patients
    Han-Sang Baek, Ji-Yeon Park, Chai-Ho Jeong, Jeonghoon Ha, Moo Il Kang, Dong-Jun Lim
    Endocrinology and Metabolism.2022; 37(2): 323.     CrossRef
  • The chemiluminescent and enzymatic activity of blood neutrophils in patients with Graves' disease depending on hyperthyroidism compensation
    M. A. Dudina, A. A. Savchenko, S. A. Dogadin, I. I. Gvozdev
    Clinical and experimental thyroidology.2022; 18(1): 4.     CrossRef
  • Risk of Diabetes in Patients with Long-Standing Graves’ Disease: A Longitudinal Study
    Eyun Song, Min Ji Koo, Eunjin Noh, Soon Young Hwang, Min Jeong Park, Jung A Kim, Eun Roh, Kyung Mook Choi, Sei Hyun Baik, Geum Joon Cho, Hye Jin Yoo
    Endocrinology and Metabolism.2021; 36(6): 1277.     CrossRef
Close layer
Original Articles
Clinical Study
Clinical Outcomes after Early and Delayed Radioiodine Remnant Ablation in Patients with Low-Risk Papillary Thyroid Carcinoma: Propensity Score Matching Analysis
Jonghwa Ahn, Meihua Jin, Eyun Song, Min Ji Jeon, Tae Yong Kim, Jin-Sook Ryu, Won Bae Kim, Young Kee Shong, Ji Min Han, Won Gu Kim
Endocrinol Metab. 2020;35(4):830-837.   Published online November 18, 2020
DOI: https://doi.org/10.3803/EnM.2020.747
  • 7,605 View
  • 149 Download
  • 8 Web of Science
  • 9 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
The clinical outcomes of delayed radioiodine remnant ablation (RRA) therapy in patients with low-risk papillary thyroid carcinoma (PTC) are unclear. We aimed to evaluate the clinical impact of the interval between total thyroidectomy (TT) and RRA therapy in patients with low-risk PTC.
Methods
We included 526 patients who underwent TT and RRA for low-risk PTC with a primary tumor size of >1 cm between 2000 and 2012. Patients were divided into the early (<90 days) and the delayed (≥90 days) RRA groups based on the interval between TT and RRA. The results of diagnostic whole-body scan (DxWBS), ongoing risk stratification (ORS; response to therapy), and disease-free survival (DFS) were evaluated before and after propensity score matching (PSM).
Results
Among the 526 patients, 75 (14.3%) patients underwent delayed RRA; they had more cervical lymph node metastasis and received a higher RRA dose than those who underwent early RRA. The median follow-up period was 9.1 years after initial therapy, and the structural recurrence rate was 1.9%. In DxWBS, 60 patients had focal iodine uptake limited in operative bed, with no significant difference between groups. According to ORS, 78%, 20%, 1%, and 1% patients were classified into excellent, indeterminate, biochemical incomplete, and structural incomplete response groups, respectively. There was no significant difference in ORS or DFS between groups before and after PSM.
Conclusion
The timing of the first RRA had no clinical impact in patients with low-risk PTC. Thus, the clinical decision for RRA can be determined >3 months after TT considering other prognostic factors.

Citations

Citations to this article as recorded by  
  • Dynamic risk assessment in patients with differentiated thyroid cancer
    Erika Abelleira, Fernando Jerkovich
    Reviews in Endocrine and Metabolic Disorders.2024; 25(1): 79.     CrossRef
  • Ablation Rates and Long-Term Outcome Following Low-Dose Radioiodine for Differentiated Thyroid Cancer in the West of Scotland: A Retrospective Analysis
    Kathryn Graham, Fay Tough, Helena Belikova, Irene Wotherspoon, David Colville, Nicholas Reed
    Endocrine Practice.2024; 30(4): 327.     CrossRef
  • Radioiodine ablation after thyroidectomy could be safely abandoned or postponed in selected stage I papillary thyroid carcinoma patients of low-risk group: an observational prospective study
    S.M. Cherenko, A.Yu. Glagolieva, D.E. Makhmudov
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2024; 20(1): 7.     CrossRef
  • Analysis of delayed initial radioactive iodine therapy and clinical outcomes in papillary thyroid cancer: a two-center retrospective study
    Tao He, Ming Li, Zheng-lian Gao, Xiang-yu Li, Hai-rong Zhong, Cui-shuang Ding, Hua-wei Cai
    Nuclear Medicine Communications.2024; 45(9): 779.     CrossRef
  • Advances in the selection and timing of postoperative radioiodine treatment in patients with differentiated thyroid carcinoma
    Xin Dai, Xinyi Ren, Jinyu Zhang, Yuxin Zheng, Zhengjie Wang, Gang Cheng
    Annals of Nuclear Medicine.2024; 38(9): 688.     CrossRef
  • Comparative evaluation of low and high radioiodine doses in differentiated thyroid carcinoma management: A multicenter study
    M.B. Al-Osaimi, E.M. Abdelrazek, Ehab M. Attalla, Hosam Salaheldin
    Journal of Radiation Research and Applied Sciences.2024; 17(4): 101206.     CrossRef
  • Patient Preparation and Radiation Protection Guidance for Adult Patients Undergoing Radioiodine Treatment for Thyroid Cancer in the UK
    J. Wadsley, N. Armstrong, V. Bassett-Smith, M. Beasley, R. Chandler, L. Cluny, A.J. Craig, K. Farnell, K. Garcez, N. Garnham, K. Graham, A. Hallam, S. Hill, H. Hobrough, F. McKiddie, M.W.J. Strachan
    Clinical Oncology.2023; 35(1): 42.     CrossRef
  • Delay of initial radioactive iodine therapy beyond 3 months has no effect on clinical responses and overall survival in patients with thyroid carcinoma: A cohort study and a meta‐analysis
    Fang Cheng, Juan Xiao, Fengyan Huang, Chunchun Shao, Shouluan Ding, Canhua Yun, Hongying Jia
    Cancer Medicine.2022; 11(12): 2386.     CrossRef
  • Delayed (>3 Months) Postoperative Radioactive Iodine Ablation Does Not Impact Clinical Response or Survival in Differentiated Thyroid Cancers
    Tatiana Fedorova, Lilah F. Morris-Wiseman
    Clinical Thyroidology.2022; 34(10): 456.     CrossRef
Close layer
Clinical Study
A Phase II Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial Protocol
Eun Kyung Lee, You Jin Lee, Young Joo Park, Jae Hoon Moon, Ka Hee Yi, Koon Soon Kim, Joo Hee Lee, Sun Wook Cho, Jungnam Joo, Yul Hwangbo, Sujeong Go, Do Joon Park
Endocrinol Metab. 2020;35(3):571-577.   Published online September 22, 2020
DOI: https://doi.org/10.3803/EnM.2020.681
  • 7,548 View
  • 134 Download
  • 1 Web of Science
  • 2 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Radioactive iodine (RAI) remnant ablation is recommended in patients with papillary thyroid cancer (PTC) and extrathyroidal extension or central lymph node metastasis. However, there exists little evidence about the necessity of remnant ablation in PTC patients with low- to intermediate-risk, those have been increasing in recent decades.
Methods
This multicenter, prospective, non-randomized, parallel group clinical trial will enroll 310 eligible patients with low- to intermediate-risk of thyroid cancer. Inclusion criteria are patients who recently underwent total thyroidectomy for PTC with 3 or less tumors of size 1≤ to ≤2 cm with no microscopic extension and N0/x, or size ≤2 cm with microscopic extension and/or N1a (number of lymph node ≤3, size of tumor foci ≤0.2 cm, and lymph node ratio <0.4). Patients choose to undergo RAI ablation (131I, dose 1.1 GBq) or diagnostic whole-body scan (DxWBS) (131I or 123I, dose 0.074 to 0.222 GBq), followed by subsequent measurement of stimulated thyroglobulin (sTg) within 1 year. Survey for quality of life (QOL) will be performed at baseline and at 1 year after follow-up. The total enrollment period is 5 years, and patients will be followed up for 1 year. The primary endpoint is the non-inferiority of surgery alone to surgery with ablation in terms of biochemical remission (BCR) rate (sTg ≤2 ng/mL) without evidence of structural recurrence. The secondary endpoint was the difference of QOL.
Conclusion
This study will evaluate whether surgery alone achieves similar BCR and improved QOL compared to RAI ablation in patients with low- to intermediate-risk PTC within 1 year.

Citations

Citations to this article as recorded by  
  • Radioactive Iodine Therapy in Differentiated Thyroid Cancer: Summary of the Korean Thyroid Association Guidelines 2024 from Nuclear Medicine Perspective, Part-II
    So Won Oh, Sohyun Park, Ari Chong, Keunyoung Kim, Ji-In Bang, Youngduk Seo, Chae Moon Hong, Sang-Woo Lee
    Nuclear Medicine and Molecular Imaging.2025; 59(1): 8.     CrossRef
  • Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part I. Initial Management of Differentiated Thyroid Cancers - Chapter 6. Radioactive Iodine Treatment after Thyroidectomy 2024
    Sohyun Park, Ari Chong, Ho-Cheol Kang, Keunyoung Kim, Sun Wook Kim, Dong Gyu Na, Young Joo Park, Ji-In Bang, Youngduk Seo, Young Shin Song, So Won Oh, Eun Kyung Lee, Dong-Jun Lim, Yun Jae Chung, Chae Moon Hong, Sang-Woo Lee
    International Journal of Thyroidology.2024; 17(1): 97.     CrossRef
Close layer
Review Article
Thyroid
Update on Thyroid Hormone Levels and Thyroid Dysfunction in the Korean Population Based on Data from the Korea National Health and Nutrition Examination Survey VI (2013 to 2015)
Jae Hoon Chung
Endocrinol Metab. 2020;35(1):7-13.   Published online March 19, 2020
DOI: https://doi.org/10.3803/EnM.2020.35.1.7
  • 11,149 View
  • 191 Download
  • 12 Web of Science
  • 11 Crossref
AbstractAbstract PDFPubReader   ePub   

In 2017, the first Korean nationwide data on serum thyroid stimulating hormone (TSH) levels, serum free thyroxine (fT4) levels, and urinary iodine concentration (UIC) were published based on a population of 7,061 Koreans who participated in the Korea National Health and Nutrition Examination Survey VI. The mean TSH level was 2.16 mIU/L, with a reference interval of 0.59 to 7.03 mIU/L (men 2.09 mIU/L, women 2.24 mIU/L, P<0.001). A U-shaped association was found between serum TSH levels and age. The mean fT4 level was 1.25 ng/dL, and its reference interval was 0.92 to 1.60 ng/dL (men 1.29 ng/dL, women 1.20 ng/dL, P<0.0001). Serum fT4 levels decreased with age (P for trend <0.0001). Serum thyroid peroxidase antibody (TPOAb) was detected in 7.30% of participants (men 4.33%, women 10.62%). TPOAb titers tended to increase with age, and were higher in women than in men. The median UIC was 294 µg/L, and UIC showed a U-shaped relationship with age. According to the World Health Organization recommendations, only 23% of participants were in the adequate range of iodine intake, while 65% were in the above requirements or excessive, and 12% in insufficient. The prevalence of overt hyperthyroidism and hypothyroidism in Koreans was 0.34% to 0.54% and 0.73% to 1.43%, respectively.

Citations

Citations to this article as recorded by  
  • Lifetime Atopic Dermatitis is Associated With Risk of Autoimmune Thyroid Disease: Evidence From a Nationwide Study
    Taehun Kim, Haeun Kim, Wonjin Lee, Jinhee Kim, Hyungryul Lim, Seri Hong, Young-Min Ye
    Allergy, Asthma & Immunology Research.2026; 18(1): 145.     CrossRef
  • Antithyroid Antibodies and Reproductive Parameters of Women with Hashimoto’s Thyroiditis
    Rafaela Silveira Ximenes de Souza, Alessandra Quintino-Moro, Denise Engelbrecht Zantut-Wittmann, Arlete Fernandes
    Endocrine Research.2025; 50(1): 57.     CrossRef
  • The Role of the Parametric Thyroid Feedback Quantile Index in Cardiovascular Risk Evaluation Among Euthyroid Koreans
    Hun Jee Choe, Yun Mi Choi, Yeonjung Ha, Jinseob Kim, Minhyuk Kim, Ho Jin Cha, Jiwoo Lee, Mi Kyung Kwak, Eun-Gyoung Hong
    The Journal of Clinical Endocrinology & Metabolism.2025; 110(10): e3401.     CrossRef
  • Association between Thyroid Function and Insulin Resistance Indices in Korean Adolescents: Findings from the 2014–2015 Korea National Health and Nutrition Examination Survey
    Eunji Mun, Hye Ah Lee, Jung Eun Choi, Rosie Lee, Kyung Hee Kim, Hyesook Park, Hae Soon Kim
    Children.2024; 11(3): 370.     CrossRef
  • Diagnostic Value of Carotid Plaque Assessment with AIS Based on Quantitative Parameters of Dual-Layer Detector Spectral CT
    Xiaoying Meng, Fei Li, Wenpei Wu, Juncang Wu
    International Journal of General Medicine.2024; Volume 17: 1263.     CrossRef
  • Reference Standards for C-Peptide in Korean Population: A Korean Endocrine Hormone Reference Standard Data Center Study
    Jooyoung Cho, Ho-Chan Cho, Ohk-Hyun Ryu, Hyo-Jeong Kim, Chang Geun Kim, Young Ran Yun, Choon Hee Chung
    Endocrinology and Metabolism.2024; 39(3): 489.     CrossRef
  • Frequency of Dyslipidemia in Patients Having Subclinical Hypothyroidism
    Mehwash Iftikhar, Mian Mufarih Shah, Nazeer Shah, Bilal Khattak, Imran Khan, Sheraz Jamal Khan
    Journal of Gandhara Medical and Dental Science.2024; 11(4): 21.     CrossRef
  • Hyperthyroidism
    Sun Y. Lee, Elizabeth N. Pearce
    JAMA.2023; 330(15): 1472.     CrossRef
  • Exploring the Association between Thyroid Function and Frailty: Insights from Representative Korean Data
    Youn-Ju Lee, Min-Hee Kim, Dong-Jun Lim, Jung-Min Lee, Sang Ah Chang, Jeongmin Lee
    Endocrinology and Metabolism.2023; 38(6): 729.     CrossRef
  • Subclinical Hypothyroidism: Prevalence, Health Impact, and Treatment Landscape
    Won Sang Yoo, Hyun Kyung Chung
    Endocrinology and Metabolism.2021; 36(3): 500.     CrossRef
  • Association between Iodine Intake, Thyroid Function, and Papillary Thyroid Cancer: A Case-Control Study
    Kyungsik Kim, Sun Wook Cho, Young Joo Park, Kyu Eun Lee, Dong-Wook Lee, Sue K. Park
    Endocrinology and Metabolism.2021; 36(4): 790.     CrossRef
Close layer
Original Articles
Clinical Study
Quality of Life in Patients with Papillary Thyroid Microcarcinoma According to Treatment: Total Thyroidectomy with or without Radioactive Iodine Ablation
Jonghwa Ahn, Min Ji Jeon, Eyun Song, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Won Gu Kim
Endocrinol Metab. 2020;35(1):115-121.   Published online March 19, 2020
DOI: https://doi.org/10.3803/EnM.2020.35.1.115
  • 8,765 View
  • 128 Download
  • 17 Web of Science
  • 19 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

Recently, there has been some controversy regarding the role of radioactive iodine (RAI) ablation in the treatment of low-risk differentiated thyroid carcinoma (DTC), especially papillary thyroid microcarcinoma (PTMC). This study aimed to compare quality of life (QoL) parameters between patients with PTMC who underwent total thyroidectomy (TT) alone and those who underwent TT with RAI ablation.

Methods

In this cross-sectional study, patients with PTMC who underwent TT with/without RAI remnant ablation were prospectively enrolled between June 2016 and October 2017. All patients completed three questionnaires: the 12-item short-form health survey (SF-12), thyroid cancer-specific quality of life (THYCA-QoL) questionnaire, and fear of progression (FoP) questionnaire.

Results

The TT and TT with RAI groups comprised 107 and 182 patients, respectively. The TT with RAI group had significantly lower serum thyrotropin (TSH) levels than the TT group. However, after matching for TSH levels between the groups (n=100 in both groups), there were no significant differences in baseline characteristics. According to the SF-12, the score for general health was significantly lower in the TT with RAI group than in the TT group (P=0.047). The THYCA-QoL also showed a significant difference in the “felt chilly” score between groups (P=0.023). No significant differences in FoP scores were observed between the groups.

Conclusion

Patients with PTMC who underwent TT with RAI ablation experienced more health-related problems than those managed with TT alone. These findings support the idea that RAI ablation should be carefully considered in patients with low-risk DTCs.

Citations

Citations to this article as recorded by  
  • Patient‑reported outcome measures for assessing health‑related quality of life in patients with differentiated thyroid cancer: a systematic review
    Lujing Xiong, Lei Liu, Yuqing Xiang, Chao Li, Wei Dai, Jinchuan Hu, Chunyan Shui, Yuqiu Zhou, Xu Wang, Yongcong Cai
    International Journal of Surgery.2025; 111(1): 1311.     CrossRef
  • A comprehensive analysis of health-related quality of life in thyroid cancer patients using the THYCA-24 questionnaire
    Thi Huyen Dinh, Hoang-Bac Nguyen, Thi Bang-Suong Nguyen, Hong Tuan-Nam Pham, Lam Doan-Van, Trung-Thong Luu-Nguyen, Thi Hoe Nguyen, Hoang-Quan Pham, Thi Xuan-Thao Le, Kim-Hai Nguyen
    Scientific Reports.2025;[Epub]     CrossRef
  • Impact of Scar on Quality of Life in Well‐Differentiated Thyroid Carcinoma: A Systematic Review
    Aníbal Ariza, Alvaro Sanabria
    OTO Open.2025;[Epub]     CrossRef
  • From screening to follow-up: a review of quality of life and psychological status across the clinical care continuum in patients with differentiated thyroid cancer
    Zifeng Kuang, Hao Zhao, Chenjia Zhang, Xiaoyi Li
    Frontiers in Psychology.2025;[Epub]     CrossRef
  • Thyroid Lobectomy and Neck Dissection for N1b Papillary Thyroid Carcinoma
    Daniel W. Scholfield, Lillian A. Boe, Alana Eagan, Helena Levyn, Fergal Kavanagh, R. Michael Tuttle, Ashok R. Shaha, Jennifer R. Cracchiolo, Jatin P. Shah, Richard J. Wong, Snehal G. Patel, Ian Ganly
    JAMA Otolaryngology–Head & Neck Surgery.2025;[Epub]     CrossRef
  • Quality of life of patients with thyroid cancer in Colombia
    Oscar Gómez, Alvaro Sanabria
    Endocrinología, Diabetes y Nutrición.2024; 71(2): 61.     CrossRef
  • Quality of life of patients with thyroid cancer in Colombia
    Oscar Gómez, Alvaro Sanabria
    Endocrinología, Diabetes y Nutrición (English ed.).2024; 71(2): 61.     CrossRef
  • Fear of Cancer Recurrence in Differentiated Thyroid Cancer Survivors: A Systematic Review
    Jacob Hampton, Ahmad Alam, Nicholas Zdenkowski, Christopher Rowe, Elizabeth Fradgley, Christine J. O'Neill
    Thyroid®.2024; 34(5): 541.     CrossRef
  • Short‐Term Postoperative Depression and Anxiety in Patients with Differentiated Thyroid Carcinoma: Assessment of Potential Oncologic‐Psycho Relevance
    Lin Chen, Ningning Ren, Qing Yang, Xingsong Tian, Henrik Falhammar
    International Journal of Endocrinology.2024;[Epub]     CrossRef
  • Perception of health and illness and quality of life after total thyroidectomy for differentiated thyroid carcinoma: the PERSAM study
    Elena Groff, Beatrice Soccal, Fabiola Carrossa, Federica Vianello, Sara Talomo, Alessandra Feltrin, Giovanni Scarzello, Honoria Ocagli, Dario Gregori, Matteo Martinato
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Review: Improving quality of life in patients with differentiated thyroid cancer
    Pia Pace-Asciak, Jonathon O. Russell, Ralph P. Tufano
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Health-Related Quality of Life and Thyroid Cancer-Specific Symptoms in Patients Treated for Differentiated Thyroid Cancer: A Single-Center Cross-Sectional Survey from Mainland China
    Changlian Chen, Jiayan Cao, Yueyang Wang, Xuya Han, Yaju Zhang, Shumei Zhuang
    Thyroid.2023; 33(4): 474.     CrossRef
  • The "not so good" thyroid cancer: a scoping review on risk factors associated with anxiety, depression and quality of life
    Kyle Alexander, Sum-Yu Christina Lee, Stelios Georgiades, Constantina Constantinou
    Journal of Medicine and Life.2023; 16(3): 348.     CrossRef
  • Comparison of health‐related quality of life and cosmetic outcome between traditional gasless trans‐axillary endoscopic thyroidectomy and modified gasless trans‐axillary endoscopic thyroidectomy for patients with papillary thyroid microcarcinoma
    Deenraj Kush Dhoomun, HuiLan Cai, Ning Li, YanHuan Qiu, XingRui Li, XiaoPeng Hu, WenZhuang Shen
    Cancer Medicine.2023; 12(15): 16604.     CrossRef
  • Risk of Adverse Pregnancy Outcomes in Young Women with Thyroid Cancer: A Systematic Review and Meta-Analysis
    Shinje Moon, Ka Hee Yi, Young Joo Park
    Cancers.2022; 14(10): 2382.     CrossRef
  • Health-related quality of life following FDG-PET/CT for cytological indeterminate thyroid nodules
    Elizabeth J de Koster, Olga Husson, Eveline W C M van Dam, G Sophie Mijnhout, Romana T Netea-Maier, Wim J G Oyen, Marieke Snel, Lioe-Fee de Geus-Oei, Dennis Vriens, _ _
    Endocrine Connections.2022;[Epub]     CrossRef
  • Is a four-week hormone suspension necessary for thyroid remnant ablation in low and intermediate risk patients? A pilot study with quality-of-life assessment
    Poliane A.L. Santos, Maria E.D.M. Flamini, Felipe A. Mourato, Fernando R.A. Lima, Joelan A.L. Santos, Fabiana F. Lima, Estelita T.B. Albuquerque, Alexandra C. De Freitas, Simone C.S. Brandão
    Brazilian Journal of Radiation Sciences.2022; 10(4): 1.     CrossRef
  • Health-related quality of life after transoral robotic thyroidectomy in papillary thyroid carcinoma
    Chang Myeon Song, Hyang Sook Bang, Hyung Gu Kim, Hae Jin Park, Kyung Tae
    Surgery.2021; 170(1): 99.     CrossRef
  • Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in Papillary Thyroid Microcarcinoma
    Min Ji Jeon, Yea Eun Kang, Jae Hoon Moon, Dong Jun Lim, Chang Yoon Lee, Yong Sang Lee, Sun Wook Kim, Min-Hee Kim, Bo Hyun Kim, Ho-Cheol Kang, Minho Shong, Sun Wook Cho, Won Bae Kim
    Endocrinology and Metabolism.2021; 36(2): 359.     CrossRef
Close layer
A Study on the Urinary Iodine Excretion in Normal subjects and Patients with Thyroid disease.
Seong Yeon Kim, Bo Youn Cho, Hong Kyu Lee, Seok In Lee, Woon Bae Kim, Hye Young Park, Chang Soon Koh
J Korean Endocr Soc. 1995;10(4):386-394.   Published online November 7, 2019
  • 2,168 View
  • 72 Download
AbstractAbstract PDF
An adequate supply of dietary iodine is essential for the synthesis of the thyroid hormons. The measurement of dietary iodine intake is important for the clinical assessment of thyroid disease, especially in areas where iodine intake is excessive or deficient.To evaluate dietary iodine intake in Korean and its effects on thyroid function, we measured urinary iodine excretion with morning urine by electrode method in 184 normal subjects, 96 postpartum women and 181 patients with thyroid disease from October 1994 to February 1995. The results were as follows;1) In normal control, the mean value of urinary iodine excretion was 3.8+-2.7mg/L (range 0.1-15.0mg/L). However, there was no sex and age differences in the urinary iodine excretion.2) In postpartum women, the urinary iodine excretion was 9.0+-10.8mg/L who were not taken high iodine diet(Miyok-Guk), the mean value was statistically higher than normal control(p<0.01) and significant increased the urinary iodine excretion after eating of high iodine diet(p<0.01).3) In volunteer, there were increase of urinary iodine excretion more than 10 folds after high iodine diet and medication.4) The urinary iodine excretion in patients with thyroid diseases was not different from normal control, and there were no significant differences of urinary iodine excretion among the patient groups. The urinary iodine excretion in the acute stage of patients with subactue thyroiditis or painless thyroiditis was significantly increased compared to the recovery stage. However, it was not significantly different from that of normal control.In conclusion, urinary iodine excretion in Korean population is very high comparing to the reported data in Western population but similar with Japanese. The urinary iodine excretion is significant increase( more than 10-folds of basal level) after high iodine diet or high iodine containing medication in postpartum women or healthy persons. As a clue of destruction induced thyrotoxicosis, the urinary iodine excretion measurement is not valid in area where iodine intake is excessive like Korea.
Close layer
Analysis of Daily Intake and Urinary Excretion of Iodine normal Control and Patient with Thyroid Disease.
Yong Wook Cho, Young Sun Kim, Seung Ho Baick, Do Yeon Oh, Whyui Joon Kim, Myung Wha Kang, Kyung Sook Kim
J Korean Endocr Soc. 1994;9(4):307-317.   Published online November 6, 2019
  • 1,923 View
  • 47 Download
AbstractAbstract PDF
Iodine in physiological dosage is necessary for thyroid hormone. But insufficient or excessive intake of iodine could affect on thyroid function. However, little study is available on the current iodine state in Korea. To evaluate the current state of iodine intake and its effects on thyroid function, we measured the iodine intake, urinary excretion and thyroid status in 67 normal controls and 110 patients with thyroid disease from June 1991 to August 1993.The result were as follows; 1) There were no differences in the physical and daily intake of calorie between controls and patients with thyroid disease. 2) The mean daily intake of iodine was 391.4 ug in normal controls, 695.0 ug in patients with simple goiter, 672.0 ug in hypothyroidism, 453.5 ug in hyperthyroidism, and 297.4 ug in thyroid nodule. 3) The mean urinary iodine excretion was 640 ug/L in normal controls, 875 ug/L in patients with hyperthyroidism, 612 ug/L in thyroid nodule, 563 ug/L in hypothyroidism, and 549 ug/L in simple goiter. 4) There was decreasing tendency of the serum T_3, t_4 and significant increase in TSH concentration in subjects who ingest the dietary iodine above 1000 ug/day compared with the subjects who ingest below 150 ug/day(p<0.05). 5) Subjects who live in coastal area had much intake of iodine(1.8-2.5 times)than those of subjects live in inland area.In conculsion, Korean ingested more iodine than Europian and American but fewer than Japanese. Some of the patients with simple goiter and hypothyroidism patients may associated with excessive ingestion of iodine, but further systemized study will be required.
Close layer
Review Article
Thyroid
Graves' Disease: Can It Be Cured?
Wilmar M. Wiersinga
Endocrinol Metab. 2019;34(1):29-38.   Published online March 21, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.1.29
  • 35,677 View
  • 745 Download
  • 56 Web of Science
  • 60 Crossref
AbstractAbstract PDFPubReader   ePub   

Whether or not Graves' hyperthyroidism can be really cured, depends on the definition of “cure.” If eradication of thyroid hormone excess suffices for the label “cure,” then all patients can be cured because total thyroidectomy or high doses of 131I will abolish hyperthyroidism albeit at the expense of creating another disease (hypothyroidism) requiring lifelong medication with levothyroxine. I would not call this a “cure,” which I would like to define as a state with stable thyroid stimulating hormone (TSH), free thyroxine, and triiodothyronine serum concentrations in the normal range in the absence of any thyroid medication. Surgery and radioiodine are unlikely to result in so-defined cures, as their preferable aim as stated in guidelines is to cause permanent hypothyroidism. Discontinuation of antithyroid drugs is followed by 50% recurrences within 4 years; before starting therapy the risk of recurrences can be estimated with the Graves' Recurrent Events After Therapy (GREAT) score. At 20-year follow-up about 62% had developed recurrent hyperthyroidism, 8% had subclinical hypothyroidism, and 3% overt hypothyroidism related to TSH receptor blocking antibodies and thyroid peroxidase antibodies. Only 27% was in remission, and might be considered cured. If the definition of “cure” would also include the disappearance of thyroid antibodies in serum, the proportion of cured patients would become even lower.

Citations

Citations to this article as recorded by  
  • Exploring successful treatments for upper eyelid retraction in thyroid eye disease: A scoping review
    Dominique Salh, Megan Roy Pickard, Adil Al-Mehiawi, Robin Parker, Ahsen Hussain
    Survey of Ophthalmology.2026;[Epub]     CrossRef
  • Predictors of Remission in Graves’ Disease Patients Treated With Antithyroid Drugs: A Retrospective Study
    Raghad S Alzahrani, Yazeed H Aljabri, Wasan S Alzahrani, Feras M Fatani, Loay J Alghamdi, Ali S Alsudais, Suhaib Radi
    Cureus.2025;[Epub]     CrossRef
  • Treatment of Graves’ Disease: Faster Remission or Longer but Safe, That Is the Question
    Chan-Hee Jung
    Endocrinology and Metabolism.2025; 40(1): 70.     CrossRef
  • Thyroid peroxidase antibodies and their role in predicting outcomes in Graves’ disease treatment
    Klara Gewert, Geriolda Topi, Tereza Planck, Jan Calissendorff
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Bacteroides fragilis and propionate synergize with low-dose methimazole to treat Graves’ disease
    Xinjie Zhang, Qingxin Pan, Guixiang Yao, Danxia Kong, Haiyan Chen, Qunye Zhang, Zhe Wang, Jan Claesen
    Microbiology Spectrum.2025;[Epub]     CrossRef
  • Graves’ disease: is hyperthyroidism still present 6 months after radioactive iodine treatment really a failure?
    Merve Nur Acar Tayyar, Ercan Uyanik, Mehmet Mülazimoğlu, Müge Öner Tamam, Savaş Karyağar, Meryem Eslem Biçen Altin, Fatma Zehra Yildiz Kabaca, Merve Cinoğlu Karaca
    Nuclear Medicine Communications.2025; 46(11): 1037.     CrossRef
  • Increased risk of hyperthyroidism induced by immune checkpoint inhibitors in patients with existing or prior Graves’ disease: a nested prospective cohort study with propensity score matching
    Koji Suzuki, Tomoko Kobayashi, Tetsushi Izuchi, Takanori Murase, Masahiko Ando, Tomoko Handa, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Hiroshi Arima, Shintaro Iwama
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Outcomes of Radioactive Iodine Versus Surgery for the Treatment of Graves’ Disease: a Systematic Review and Meta-analysis
    Mohamed AbdAlla Salman, Mohamed Moustafa Assal, Ahmed Salman, Mohammed Elsherbiney
    Indian Journal of Surgery.2024; 86(S1): 18.     CrossRef
  • Multifunctional nanoparticle-mediated combining therapy for human diseases
    Xiaotong Li, Xiuju Peng, Makhloufi Zoulikha, George Frimpong Boafo, Kosheli Thapa Magar, Yanmin Ju, Wei He
    Signal Transduction and Targeted Therapy.2024;[Epub]     CrossRef
  • Prenatal double-hit with aluminium and cadmium mediate testicular atrophy and hypothalamic hypoplasia: the role of oxido-nitrergic stress and endocrine perturbations
    Emmanuel Okhue, Helen Ejiro Kadiri, Patrick Chukwuyenum Ichipi-Ifukor, Benneth Ben-Azu, Samuel Ogheneovo Asagba, Fidelis Ifeakachuku Achuba, John Chukwuma Oyem
    BioMetals.2024; 37(2): 477.     CrossRef
  • Surgical outcome after thyroidectomy due to Graves’ disease and Lugol iodine treatment: a retrospective register-based cohort study
    Fredric Hedberg, Henrik Falhammar, Jan Calissendorff, Robert Bränström
    Endocrine.2024; 85(1): 272.     CrossRef
  • Graves disease is associated with increased risk of clinical Alzheimer’s disease: evidence from the Medicare system
    Arseniy Pavlovich Yashkin, Stanislav Kolpakov, Svetlana Ukraintseva, Anatoliy Yashin, Igor Akushevich
    Clinical Diabetes and Endocrinology.2024;[Epub]     CrossRef
  • A 2023 International Survey of Clinical Practice Patterns in the Management of Graves Disease: A Decade of Change
    Danilo Villagelin, David S Cooper, Henry B Burch
    The Journal of Clinical Endocrinology & Metabolism.2024; 109(11): 2956.     CrossRef
  • Histopathological changes in salivary glands after radioactive iodine treatment for thyroid diseases
    Xiao Li, Jia-Zeng Su, Yan Gao, Deng-Gao Liu, Guang-Yan Yu
    Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.2024; 138(3): 384.     CrossRef
  • Etiologocal Analysis and Research Progress of Refractory Hypothyroidism with Thyroid Eye Disease and Thyroid Acropachy
    晓晴 戴
    Advances in Clinical Medicine.2024; 14(05): 801.     CrossRef
  • The main principles of managing patients with Graves’ disease in clinical practice
    E. D. Pesheva, Yu. I. Khruleva, S. M. Deunezhewa, K. R. Enikeeva, D. Mukhambet, T. B. Morgunova, V. V. Fadeev
    Clinical and experimental thyroidology.2024; 19(3): 29.     CrossRef
  • Targeting Thyroid-Stimulating Hormone Receptor: A Perspective on Small-Molecule Modulators and Their Therapeutic Potential
    Yu Zhang, Ye Tan, Zian Zhang, Xi Cheng, Jia Duan, Yi Li
    Journal of Medicinal Chemistry.2024; 67(18): 16018.     CrossRef
  • Best practices in the laboratory diagnosis, prognostication, prediction, and monitoring of Graves’ disease: role of TRAbs
    Sanjay Kalra, Shahjada Selim, Dina Shrestha, Noel Somasundaram, Syed Abbas Raza, Manash P. Baruah, Saptarshi Bhattacharya, Sharvil Gadve, Ganapathi Bantwal, Rakesh Sahay
    BMC Endocrine Disorders.2024;[Epub]     CrossRef
  • Long-Term Antithyroid Drug Therapy in Smoldering or Fluctuating-Type Graves’ Hyperthyroidism with Potassium Iodide
    Ken Okamura
    Endocrinology and Metabolism.2024; 39(6): 827.     CrossRef
  • A Comprehensive Review of Thyroid Dysfunction: Hidden Player in Male Infertility
    Elizabeth Moyinoluwa Babatunde, Mathias Abiodun Emokpae
    Fertility & Reproduction.2024; 06(04): 166.     CrossRef
  • Predictors of Prolonged Euthyroidism After Radioactive Iodine Treatment for Graves’ Disease: A Pilot Study
    Jin-Ying Lu, Kuan-Hua Chen, Shyang-Rong Shih, Fang-Yu Wen, Wan-Chen Wu, Ting-Chu Chen, Fu-Chang Hu
    Endocrine Practice.2023; 29(2): 89.     CrossRef
  • Case of Graves’ disease recovery
    Andrey Valerievich Ushakov
    Journal of Clinical and Translational Endocrinology: Case Reports.2023; 27: 100139.     CrossRef
  • Association between high mobility group box-1 circulation level and Graves' ophthalmopathy
    Mohammad Robikhul Ikhsan, Nyoman Kertia, Supanji Supanji, Bambang Udji djoko Rianto, Dhite Bayu Nugroho
    F1000Research.2023; 12: 767.     CrossRef
  • New-onset and relapsed Graves’ disease following COVID-19 vaccination: a comprehensive review of reported cases
    Kan Chen, Yiyang Gao, Jing Li
    European Journal of Medical Research.2023;[Epub]     CrossRef
  • REVIEW OF SARS-CORONAVIRUS-2 REPERCUSSIONS ON THYROID GLAND IN THE CONTEXT OF HYPERTHYROIDISM
    SHUBHAM SINGH, MONIKA, RUPA MAZUMDER, AVIJIT MAZUMDER
    International Journal of Applied Pharmaceutics.2023; : 17.     CrossRef
  • Effectiveness and potential mechanism of Jiawei-Xiaoyao-San for hyperthyroidism: a systematic review
    Wenxin Ma, Xiaowen Zhang, Ruotong Zhao, Yang Tang, Xiaoyun Zhu, Longkun Liu, Mingyuan Xu, Ge Wang, Peiyue Peng, Jianping Liu, Zhaolan Liu
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Associations of serum keratin 1 with thyroid function and immunity in Graves’ disease
    Chao-Wen Cheng, Wen-Fang Fang, Jiunn-Diann Lin, Appuwawadu Mestri Nipun Lakshitha de Silva
    PLOS ONE.2023; 18(11): e0289345.     CrossRef
  • Management of Graves’ hyperthyroidism: present and future
    Luigi Bartalena, Eliana Piantanida, Daniela Gallo, Silvia Ippolito, Maria Laura Tanda
    Expert Review of Endocrinology & Metabolism.2022; 17(2): 153.     CrossRef
  • The Prediction Model Using Thyroid-stimulating Immunoglobulin Bioassay For Relapse of Graves’ Disease
    Han-Sang Baek, Jaejun Lee, Chai-Ho Jeong, Jeongmin Lee, Jeonghoon Ha, Kwanhoon Jo, Min-Hee Kim, Jae Hyoung Cho, Moo Il Kang, Dong-Jun Lim
    Journal of the Endocrine Society.2022;[Epub]     CrossRef
  • Efficacy of Radioiodine Therapy in Patients With Primary Hyperthyroidism: An Institutional Review From Pakistan
    Asim Munir Alvi, Umal Azmat, Waqas Shafiq, Abdul Hannan Ali Rasheed, Ahmed Imran Siddiqi, Sardar Khan, Sara Ashfaq, Hira Irfan , Humayun Bashir, Muhammad Abu Bakar, Kashif Asghar
    Cureus.2022;[Epub]     CrossRef
  • Clinical Outcomes of Repeated Radioactive Iodine Therapy for Graves’ Disease
    Min Joo Kim, Sun Wook Cho, Ye An Kim, Hoon Sung Choi, Young Joo Park, Do Joon Park, Bo Youn Cho
    Endocrinology and Metabolism.2022; 37(3): 524.     CrossRef
  • Endocrine Surgery and Pediatic Surgery Partnership Reduces Complication Rate of Pediatric Thyroidectomy
    Ali Sayan, Mehmet Üstün, Mehmet Mert, Cem Karaali, Gökhan Köylüoğlu
    Journal of Dr Behcet Uz Children s Hospital.2022; 12(2): 164.     CrossRef
  • Thyroid-related adverse events induced by immune checkpoint inhibitors
    Alexandra Chera, Andreea Lucia Stancu, Octavian Bucur
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • A case of Hashimoto's thyroiditis following Graves' disease
    Ibtissem Oueslati, Salma Salhi, Meriem Yazidi, Fatma Chaker, Melika Chihaoui
    Clinical Case Reports.2022;[Epub]     CrossRef
  • Changes in the T and B lymphocyte subset profiles upon treatment of patients with Graves’ disease with radioactive iodine
    A. A. Savchenko, M. A. Dudina, S. A. Dogadin, A. G. Borisov, I. V. Kudryavtsev, D. V. Fomina, V. D. Belenyuk
    Medical Immunology (Russia).2022; 24(5): 1007.     CrossRef
  • A survey of the young person’s experience of Graves’ disease and its management
    Laura Claire Lane, Judith Rankin, Tim Cheetham
    Clinical Endocrinology.2021; 94(2): 330.     CrossRef
  • Serum T3 Level and Duration of Minimum Maintenance Dose Therapy Predict Relapse in Methimazole-Treated Graves Disease
    Yotsapon Thewjitcharoen, Krittadhee Karndumri, Waralee Chatchomchuan, Sriurai Porramatikul, Sirinate Krittiyawong, Ekgaluck Wanothayaroj, Siriwan Butadej, Soontaree Nakasatien, Rajata Rajatanavin, Thep Himathongkam
    Journal of the Endocrine Society.2021;[Epub]     CrossRef
  • Dosimetry-guided radioiodine therapy of hyperthyroidism: long-term experience and implications for guidelines
    Thomas Leitha, Manuela Schartel, Ingrid Hurtl, Rudolf Bednar, Franz König, Karl Mayrhofer, Flavia Pietschmann
    Nuclear Medicine Communications.2021; 42(2): 150.     CrossRef
  • Practice patterns and outcomes in the management of Thai patients with Graves’ disease
    Yotsapon Thewjitcharoen, Krittadhee Karndumri, Waralee Chatchomchuan, Sriurai Porramatikul, Sirinate Krittiyawong, Ekgaluck Wanathayanoroj, Nampetch Lekpittaya, Worawit Kittipoom, Tawee Anuntakulnatee, Somboon Vongterapak, Siriwan Butadej, Soontaree Nakas
    Thyroid Research.2021;[Epub]     CrossRef
  • Un case report letterario di tireotossicosi in La coscienza di Zeno di Italo Svevo
    Francesco Trimarchi, Luigi Bartalena, Stefano Arieti, Roberto Toni
    L'Endocrinologo.2021; 22(2): 149.     CrossRef
  • Medical treatment of thyrotoxicosis
    Lorenzo SCAPPATICCIO, Giuseppe BELLASTELLA, Maria I. MAIORINO, Luca GIOVANELLA, Katherine ESPOSITO
    The Quarterly Journal of Nuclear Medicine and Molecular Imaging.2021;[Epub]     CrossRef
  • Hiccups as a Rare Presentation of Thyrotoxicosis Triaged by an Epidural Steroid Injection
    Omar Al-Radideh, Iyad Farouji, Theodore DaCosta, Hossam Abed, Nicholas Baranestky
    Cureus.2021;[Epub]     CrossRef
  • Long-term antithyroid drug therapy
    David S. Cooper
    Current Opinion in Endocrinology, Diabetes & Obesity.2021; 28(5): 510.     CrossRef
  • The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries
    Maria V. Deligiorgi, Sofia Sagredou, Lampros Vakkas, Dimitrios T. Trafalis
    Cancers.2021; 13(21): 5277.     CrossRef
  • Recurrence of Graves’ Disease: What Genetics of HLA and PTPN22 Can Tell Us
    Daniela Vejrazkova, Josef Vcelak, Eliska Vaclavikova, Marketa Vankova, Katerina Zajickova, Jana Vrbikova, Michaela Duskova, Petra Pacesova, Zdenek Novak, Bela Bendlova
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Most Patients with Graves’ Disease Treated with Antithyroid Drugs Eventually Require Additional Therapies
    Mary H. Samuels
    Clinical Thyroidology.2020; 32(1): 9.     CrossRef
  • Patterns of Use, Efficacy, and Safety of Treatment Options for Patients with Graves' Disease: A Nationwide Population-Based Study
    Juan P. Brito, Stephanie Payne, Naykky Singh Ospina, Rene Rodriguez-Gutierrez, Spyridoula Maraka, Lindsey R. Sangaralingham, Nicole M. Iñiguez-Ariza, Victor M. Montori, Marius N. Stan
    Thyroid.2020; 30(3): 357.     CrossRef
  • Long-Term Treatment of Hyperthyroidism with Antithyroid Drugs: 35 Years of Personal Clinical Experience
    Fereidoun Azizi
    Thyroid.2020; 30(10): 1451.     CrossRef
  • Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves’ disease patients
    Rui-Ting Hu, De-Shan Liu, Bin Li
    BMC Endocrine Disorders.2020;[Epub]     CrossRef
  • The Concept of Cure in Thyroid Diseases
    Fereidoun Azizi
    International Journal of Endocrinology and Metabolism.2020;[Epub]     CrossRef
  • Der Biomarker TSH bei Schilddrüsenautonomien
    K. Passek, N. Zulauf, E. Wanke, G. M. Oremek
    Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie.2020; 70(4): 177.     CrossRef
  • Management of Graves’ Hyperthyroidism: More Than a Century of Progression
    Hengameh Abdi, Atieh Amouzegar
    International Journal of Endocrinology and Metabolism.2020;[Epub]     CrossRef
  • Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism
    Rosario Le Moli, Pasqualino Malandrino, Marco Russo, Fabrizio Lo Giudice, Francesco Frasca, Antonino Belfiore, Riccardo Vigneri
    Frontiers in Endocrinology.2020;[Epub]     CrossRef
  • Prediction of Relapse After Antithyroid Drugs Withdrawal: A Narrative Review
    Pei-Wen Wang
    International Journal of Endocrinology and Metabolism.2020;[Epub]     CrossRef
  • Radioiodine-131 therapy (RIT) in benign thyroid diseases: Personalized prescription based on objectives with optional use of pharmacological modulators
    J. Clerc
    Médecine Nucléaire.2020; 44(4): 250.     CrossRef
  • Predicting the Risk of Graves Disease Relapse: Commentary on “Thyroid Peroxidase Antibody Positivity is Associated with Relapse-Free Survival Following Antithyroid Drug Treatment for Graves Disease”
    D. Gallo, M.L. Tanda, E. Piantanida
    Endocrine Practice.2020; 26(9): 1039.     CrossRef
  • Integrating Five Feature Types Extracted From Ultrasonograms to Improve the Prediction of Thyroid Papillary Carcinoma
    Renxiang Zhu, Zhongyu Wang, Yifan Zhang, Bingxin Yu, Mingran Qi, Xin Feng, Chenjun Wu, Yuxuan Cui, Lan Huang, Fan Li, Fengfeng Zhou
    IEEE Access.2019; 7: 101820.     CrossRef
  • Serum TSH Receptor Antibodies Fall Gradually and Only Rarely Switch Functional Activity in Treated Graves’ Disease
    Mary H. Samuels
    Clinical Thyroidology.2019; 31(8): 330.     CrossRef
  • Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy
    Yun Mi Choi, Mi Kyung Kwak, Sang Mo Hong, Eun-Gyoung Hong
    Endocrinology and Metabolism.2019; 34(3): 268.     CrossRef
  • A transgenic mouse that spontaneously develops pathogenic TSH receptor antibodies will facilitate study of antigen-specific immunotherapy for human Graves’ disease
    Sandra M. McLachlan, Basil Rapoport
    Endocrine.2019; 66(2): 137.     CrossRef
Close layer
Original Articles
Thyroid
99mTc-Pertechnetate Scintigraphy Predicts Successful Postoperative Ablation in Differentiated Thyroid Carcinoma Patients Treated with Low Radioiodine Activities
Luca Giovanella, Gaetano Paone, Teresa Ruberto, Luca Ceriani, Pierpaolo Trimboli
Endocrinol Metab. 2019;34(1):63-69.   Published online February 15, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.1.63
  • 7,333 View
  • 94 Download
  • 11 Web of Science
  • 9 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

Postoperative routine radioiodine (RAI) treatment is currently debated for patients with low-risk differentiated thyroid carcinoma (DTC) patients. If performed, a low 131I activity (i.e., 1 to 2 GBq) is recommended with the aim to ablate thyroid remnant and facilitate subsequent follow-up by thyroglobulin measurement. The purpose of this study was to evaluate the relationship between postsurgical technetium-99m (99mTc)-pertechnetate scintigraphy and the rate of successful remnant ablation after low activity radioiodine ablation in patients with DTC.

Methods

Enrolled were 193 patients with low risk DTC who underwent total thyroidectomy and RAI ablation with a fixed 1.1 GBq activity of 131I. 99mTc-pertechnetate scans were done and thyrotropin stimulated thyroglobulin (sTg) levels measured just before ablation. Ablation effectiveness was assessed 6 to 12 months later by sTg measurement, neck ultrasound and diagnostic whole body scan.

Results

A negative 99mTc-perthecnetate scans was the best predictor of successful ablation (P<0.001) followed by preablative sTg levels <0.8 ng/mL (P=0.008) and 99mTc-pertechnetate uptake rate values <0.9% (P=0.065). Neither sex nor age of the patient at the time of ablation or tumor histology and size showed a significant association with the rate of successful ablation.

Conclusion

The 99mTc-pertechnetate scintigraphy is a simple and feasible tool to predict effectiveness of low activity 131I thyroid to ablate thyroid remnants in patients with DTC.

Citations

Citations to this article as recorded by  
  • Predicting thyroid cancer ablation success: Pre-ablative 99mTc-Pertechnetate and post-ablative 131I scan comparison
    G. Mutevelizade, Y. Parlak, B.C. Bozdemir, C. Sezgin, G. Gumuser, E. Sayit
    Médecine Nucléaire.2025; 49(3): 179.     CrossRef
  • Combined clinical variable and radiomics of post-treatment total body scan for prediction of successful I-131 ablation in low-risk papillary thyroid carcinoma patients
    Maythinee Chantadisai, Jirarot Wongwijitsook, Napat Ritlumlert, Yothin Rakvongthai
    Scientific Reports.2024;[Epub]     CrossRef
  • Unexpected 99mTc-pertechnetate avidity of lymph node metastases redicts better response to radioiodine therapy in differentiated hyroid cancer patients with lymph node metastases
    Jie Liu
    American Journal of Nuclear Medicine and Molecular Imaging.2024; 14(1): 63.     CrossRef
  • Sufficiency of a Single Negative Thyroglobulin Standard for Judging the Success of Ablation in Low- and Intermediate-risk Differentiated Thyroid Cancer: A Retrospective Study
    Yahong Long, Jianhua Jin, Wanchun Zhang
    Endocrine, Metabolic & Immune Disorders - Drug Targets.2024; 24(10): 1204.     CrossRef
  • Predicting excellent response to radioiodine in differentiated thyroid cancer using machine learning
    Ogün Bülbül, Demet Nak
    Acta Otorhinolaryngologica Italica.2024; 44(4): 261.     CrossRef
  • The prognostic value of post thyroidectomy Tc-99m pertechnetate thyroid scan in patients with differentiated thyroid cancer
    L.M. Eloteify, Samy M. Algizawy, Aya K.M. Abdelnaim, Nesreen Mekkawy
    Nuclear Medicine Communications.2023; 44(1): 38.     CrossRef
  • Correlation analysis of I-131 SPECT/CT uptake parameters with the success ablation treatment of thyroid remnant in patients with low-intermediate-risk differentiated thyroid cancer
    Qian Zhang, Weina Xu
    Nuclear Medicine Communications.2022; 43(10): 1051.     CrossRef
  • Clinical significance of extra-thyroid 99mTc-pertechnetate uptake before initial radioiodine therapy for differentiated thyroid carcinoma
    Bin Long, Li-Fang Yao, Shou-Cong Chen, Jin Shui, Xue-Mei Ye, He-Qing Yi, Cen Lou
    Journal of International Medical Research.2021;[Epub]     CrossRef
  • Thyroglobulin Changes are Highly Dependent on TSH in Low-risk DTC Patients not Treated with Radioiodine
    Antonio Matrone, Alessio Faranda, Francesco Latrofa, Carla Gambale, Delio Stefani Donati, Eleonora Molinaro, Laura Agate, David Viola, Paolo Piaggi, Liborio Torregrossa, Fulvio Basolo, Rossella Elisei
    The Journal of Clinical Endocrinology & Metabolism.2020; 105(8): e2845.     CrossRef
Close layer
Thyroid
Thyroid-Stimulating Hormone Reference Ranges in the First Trimester of Pregnancy in an Iodine-Sufficient Country
Carmen Castillo, Nicole Lustig, Paula Margozzini, Andrea Gomez, María Paulina Rojas, Santiago Muzzo, Lorena Mosso
Endocrinol Metab. 2018;33(4):466-472.   Published online November 30, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.4.466
  • 10,715 View
  • 118 Download
  • 10 Web of Science
  • 10 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

Thyroid dysfunction is associated with negative neonatal and obstetric outcomes. Large differences in thyroid function reference intervals exist across different populations. These differences can be explained by population-specific factors, such as iodine status. Many countries in Latin America report iodine sufficiency, but relatively few countries have published up-to-date data on iodine levels and thyroid function in the overall population, and especially in pregnant women. We evaluated the iodine status of pregnant women in Chile and determined thyroid hormone reference ranges in this population.

Methods

This was a prospective observational study of healthy Chilean women at their first prenatal visit before week 14. Thyroid-stimulating hormone (TSH), total thyroxine (T4), free T4, antithyroid peroxidase antibody (TPOAb), and iodine levels from spot urine samples were measured. Iodine status and the reference ranges for TSH were calculated.

Results

A total of 1,022 pregnant women in the first trimester were selected. Urinary iodine levels were measured in 302 randomly-selected women. The median urinary iodine concentration was 173.45 µg/L (interquartile range, 108.11 to 249.35).The reference ranges of TSH were calculated in 670 patients selected according to the National Academy of Clinical Biochemistry guidelines. The median TSH level was 1.88 µIU/mL (2.5th percentile: 0.13 to 97.5th percentile: 5.37). Using the reference range in the 1,022 women, the prevalence of clinical hypothyroidism was 1.76%, and that of subclinical hypothyroidism was 3.92%. TPOAb positivity was more common in women with TSH levels above 3.5 µIU/mL.

Conclusion

We found adequate iodine intake and a right-shifted distribution of serum TSH levels in pregnant women in Chile. The prevalence of hypothyroidism in our sample of pregnant women was higher than has been described in the literature.

Citations

Citations to this article as recorded by  
  • Impact of Subclinical Hypothyroidism on Pregnancy and Newborn
    Kamuran Suman, Ebru Gök, Musa Büyük, Murat Suman
    Phoenix Medical Journal.2024;[Epub]     CrossRef
  • Defining Trimester-Specific Reference Intervals for Thyroid Hormones: Insights from a Bulgarian Monocenter Study
    Vesselina Yanachkova, Radiana Staynova, Emilia Krassimirova Naseva
    Medicina.2024; 60(5): 801.     CrossRef
  • Long-term impact of hypothyroidism during gestation and lactation on the mammary gland
    Fiorella Campo Verde Arboccó, Fabio A. Persia, Leila Zyla, Nicolás Bernal, Verónica C. Sasso, Flavia Santiano, Silvina Gomez, Flavia Bruna, Virginia Pistone-Creydt, Constanza Lopez-Fontana, Graciela A. Jahn, María Belén Hapon, Ruben W. Carón
    Journal of Developmental Origins of Health and Disease.2023; 14(1): 122.     CrossRef
  • Evaluation of first and second trimester maternal thyroid profile on the prediction of gestational diabetes mellitus and post load glycemia
    Daniela Mennickent, Bernel Ortega-Contreras, Sebastián Gutiérrez-Vega, Erica Castro, Andrés Rodríguez, Juan Araya, Enrique Guzmán-Gutiérrez, Surangi Nilanka Jayakody Mudiyanselage
    PLOS ONE.2023; 18(1): e0280513.     CrossRef
  • Clinical and histopathological features of follicular thyroid cancer in Chile
    René Díaz, José Miguel Domínguez, Hernán Tala, Roberto Olmos, Pedro Pineda, Daniela Olivarí, Marcela Jiménez, Ximena Mimica, Alejandra Lanas, Gerson Ocares, Jorge Sapunar
    Archives of Endocrinology and Metabolism.2023;[Epub]     CrossRef
  • Effect of the Cut-Off Level for Thyroid-Stimulating Hormone on the Prevalence of Subclinical Hypothyroidism among Infertile Mexican Women
    Lidia Arce-Sánchez, Salvatore Giovanni Vitale, Claudia Montserrat Flores-Robles, Myrna Souraye Godines-Enriquez, Marco Noventa, Carmen Marcela Urquia-Figueroa, Nayeli Martínez-Cruz, Guadalupe Estrada-Gutierrez, Salvador Espino y Sosa, José Romo-Yañez, Ara
    Diagnostics.2021; 11(3): 417.     CrossRef
  • Subclinical hypothyroidism in pregnancy
    Freddy J.K. Toloza, Sanaz Abedzadeh-Anaraki, Spyridoula Maraka
    Current Opinion in Endocrinology, Diabetes & Obesity.2019; 26(5): 225.     CrossRef
  • Letter: Thyroid-Stimulating Hormone Reference Ranges in the First Trimester of Pregnancy in an Iodine-Sufficient Country (Endocrinol Metab 2018;33:466-72, Carmen Castillo et al.)
    Hyemi Kwon
    Endocrinology and Metabolism.2019; 34(1): 93.     CrossRef
  • Response: Thyroid-Stimulating Hormone Reference Ranges in the First Trimester of Pregnancy in an Iodine-Sufficient Country (Endocrinol Metab 2018;33:466–72, Carmen Castillo et al.)
    Lorena Mosso
    Endocrinology and Metabolism.2019; 34(2): 213.     CrossRef
  • Thyroid-Stimulating Hormone Reference Ranges in Early Pregnancy: Possible Influence of Iodine Status
    Tae Yong Kim
    Endocrinology and Metabolism.2018; 33(4): 445.     CrossRef
Close layer
Clinical Study
Effects of Maternal Iodine Status during Pregnancy and Lactation on Maternal Thyroid Function and Offspring Growth and Development: A Prospective Study Protocol for the Ideal Breast Milk Cohort
Young Ah Lee, Sun Wook Cho, Ho Kyung Sung, Kyungsik Kim, Young Shin Song, Sin Je Moon, Jung Won Oh, Dal Lae Ju, Sooyeon Choi, Sang Hoon Song, Gi Jeong Cheon, Young Joo Park, Choong Ho Shin, Sue K. Park, Jong Kwan Jun, June-Key Chung
Endocrinol Metab. 2018;33(3):395-402.   Published online September 18, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.3.395
  • 8,796 View
  • 105 Download
  • 4 Web of Science
  • 4 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

Iodine is an intrinsic element of thyroid hormone, which is essential for childhood growth and development. The Ideal Breast Milk (IBM) cohort study aims to evaluate the effects of maternal iodine status during pregnancy and lactation on maternal thyroid function, offspring growth and development, and offspring thyroid function.

Methods

The IBM cohort study recruited pregnant women from Seoul National University Hospital between June 2016 and August 2017, followed by enrollment of their offspring after delivery. For the maternal participants, iodine status is evaluated by urinary iodine concentration (UIC) and dietary records in the third trimester and at 3 to 4 weeks and 12 to 15 months postpartum. For the child participants, cord blood sampling and UIC measurements are performed at birth. At 3 to 4 weeks of age, UIC and breastmilk iodine concentrations are measured. At 12 to 15 months of age, growth and development are assessed and measurements of UIC, a thyroid function test, and ultrasonography are performed.

Results

A total of 198 pregnant women in their third trimester were recruited. Their mean age was 35.1±3.5 years, and 78 (39.4%) of them were pregnant with twins. Thirty-three (16.7%) of them had a previous history of thyroid disease.

Conclusion

Korea is an iodine-replete area. In particular, lactating women in Korea are commonly exposed to excess iodine due to the traditional practice of consuming brown seaweed soup postpartum. The study of the IBM cohort is expected to contribute to developing guidelines for optimal iodine nutrition in pregnant or lactating women.

Citations

Citations to this article as recorded by  
  • Investigating Birth and Thyroid Outcomes of Maternal-Fetal Environmental Exposures (IBM-E): A Cohort Protocol for Dietary Iodine and Endocrine Disruptors
    Yun Ji Jung, Jeong Eun Shin, Ju-hee Yoon, Suhra Kim, Hayan Kwon, Sungbo Shim, Dong Yeob Shin, Minseo Gim, Younglim Kho, JoonHo Lee
    Endocrinology and Metabolism.2025; 40(6): 940.     CrossRef
  • Exposure to and Transplacental Transfer of Per- and Polyfluoroalkyl Substances in a Twin Pregnancy Cohort in Korea
    Na-Youn Park, Sun Wook Cho, Ye Eun Seo, Heeyeon Chae, Inae Lee, Young Ah Lee, Jong Kwan Jun, Eun Na Kim, Jeong-Won Oh, Kyungho Choi, Younglim Kho
    Environmental Science & Technology.2024; 58(48): 21120.     CrossRef
  • High intakes of iodine among women during pregnancy and the postpartum period has no adverse effect on thyroid function
    Dal Lae Ju, Sun Wook Cho, Chae Won Chung, Young Ah Lee, Gi Jeong Cheon, Young Joo Park, Choong Ho Shin, Jong Kwan Jun, June-Key Chung, Sue K. Park, YoonJu Song
    European Journal of Nutrition.2023; 62(1): 239.     CrossRef
  • Associations between maternal thyroid function in pregnancy and child neurodevelopmental outcomes at 20 months in the Seychelles Child Development Study, Nutrition Cohort 2 (SCDS NC2)
    Anna M. Monaghan, Maria S. Mulhern, Emeir M. Mc Sorley, J.J. Strain, Theresa Winter, Edwin van Wijngaarden, Gary J. Myers, Philip W. Davidson, Conrad Shamlaye, Jude Gedeon, Alison J. Yeates
    Journal of Nutritional Science.2021;[Epub]     CrossRef
Close layer
Clinical Study
Iodine Status in Filipino Women of Childbearing Age
Michael E. Serafico, Joselita Rosario C. Ulanday, Marites V. Alibayan, Glen Melvin P. Gironella, Leah A. Perlas
Endocrinol Metab. 2018;33(3):372-379.   Published online September 18, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.3.372
  • 7,591 View
  • 71 Download
  • 10 Web of Science
  • 10 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

Iodine deficiency (ID) has become a concern not only among pregnant women, but in women of childbearing age as well. In fact, a recent report suggested that women with moderate to severe ID may experience a significantly longer time to conceive. This study aimed to investigate iodine status in Filipino women of childbearing age.

Methods

The iodine status of 6,194 Filipino women aged 15 to 45 years old was assessed through urinary iodine analysis. A casual spot urine sample was collected from women in households participating in the eighth National Nutrition Survey conducted by the Food and Nutrition Research Institute. The sample was analyzed using ammonium persulfate digestion followed by the Sandell-Kolthoff colorimetric reaction. A median urinary iodine concentration (UIC) of less than 100 µg/L was used to define ID.

Results

The median UIC was 123 µg/L, indicative of adequate iodine nutrition; however, 21.5% of participants had a UIC below 50 µg/L. The median UIC of women who lived in urban areas (142 µg/L), belonged to the middle to richest class (>124 µg/L), had reached a college education (136 µg/L), and used iodized salt (15 ppm and above; 148 to 179 µg/L) reflected adequate iodine nutrition. ID was found to have been eliminated in the regions of Central Luzon, Eastern Visayas, Calabarzon, Mimaropa, and the National Capital, while mild ID was identified in Western Visayas, Southern and Western Mindanao, and in the Autonomous Region in Muslim Mindanao.

Conclusion

Pockets of ID among women of childbearing age exist in the Philippines. Proper information through education and the use of adequately iodized salt are key measures for improving the iodine status of the studied population.

Citations

Citations to this article as recorded by  
  • Nutritional Interventions for Enhancing Female Fertility: A Comprehensive Review of Micronutrients and Their Impact
    Faezeh Mashhadi, Zahra Sedghi, Ava Hemmat, Raha Rivaz, Fatemeh Roudi, Shashank Kaushik
    Nursing Research and Practice.2025;[Epub]     CrossRef
  • Global, regional, and national burden of iodine deficiency for women of reproductive age, 1990–2021: a systematic analysis based on the Global Burden of Disease Study 2021
    Taotao Wang, Jingmin Tong, Yuzhou Liu, Yanqiu Liu, Hui Xu, Yang Liu
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Adequate iodine nutrition and higher salt intake in Chinese adults aged 18–59 years recommended by international organizations
    Diqun Chen, Ying Ye, Ying Lan, Meng He, Jiani Wu, Lijin Wang, Zhihui Chen
    Scientific Reports.2024;[Epub]     CrossRef
  • Diets, Fruit and Vegetable Intake and Nutritional Status Among Children, Adolescents and Adults in the Philippines: A Scoping Review
    Taryn J. Smith, Sonja Y. Hess, Imelda Angeles‐Agdeppa, Eva Goyena, Aulo Gelli, Deanna K. Olney
    Maternal & Child Nutrition.2024;[Epub]     CrossRef
  • Burden and trends of iodine deficiency in Asia from 1990 to 2019
    R. Wei, Z. Wang, X. Zhang, X. Wang, Y. Xu, Q. Li
    Public Health.2023; 222: 75.     CrossRef
  • The Iodine Status and Prevalence of Thyroid Disorders Among Women of Childbearing Age in China: National Cross-sectional Study
    Yongze Li, Zhongyan Shan, Weiping Teng
    Endocrine Practice.2021; 27(10): 1028.     CrossRef
  • Female Fertility and the Nutritional Approach: The Most Essential Aspects
    Kinga Skoracka, Alicja Ewa Ratajczak, Anna Maria Rychter, Agnieszka Dobrowolska, Iwona Krela-Kaźmierczak
    Advances in Nutrition.2021; 12(6): 2372.     CrossRef
  • Establishing reference intervals for urine and serum iodine levels: A nationwide multicenter study of a euthyroid Chinese population
    Songlin Yu, Danchen Wang, Xinqi Cheng, Qiong Zhang, Mingxue Wang, Haipeng Guo, Benzhang Yu, Xiuming Zhang, Liangyu Xia, Dandan Sun, Qian Cheng, Pengchang Li, Yicong Yin, Chaochao Ma, Li'an Hou, Yutong Zou, Honglei Li, Dandan Li, Ling Qiu, Kiyoshi Ichihara
    Clinica Chimica Acta.2020; 502: 34.     CrossRef
  • Response: Iodine Status in Filipino Women of Childbearing Age (Endocrinol Metab 2018;33:372-9, Michael E. Serafico et al.)
    Michael E. Serafico
    Endocrinology and Metabolism.2018; 33(4): 495.     CrossRef
  • Letter: Iodine Status in Filipino Women of Childbearing Age (Endocrinol Metab 2018;33:372-9, Michael E. Serafico et al.)
    Zheng Feei Ma
    Endocrinology and Metabolism.2018; 33(4): 493.     CrossRef
Close layer
Thyroid
Prognosis of Differentiated Thyroid Carcinoma with Initial Distant Metastasis: A Multicenter Study in Korea
Hosu Kim, Hye In Kim, Sun Wook Kim, Jaehoon Jung, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Hee Kyung Kim, Ho-Cheol Kang, Ji Min Han, Yoon Young Cho, Tae Hyuk Kim, Jae Hoon Chung
Endocrinol Metab. 2018;33(2):287-295.   Published online June 21, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.2.287
  • 11,544 View
  • 96 Download
  • 38 Web of Science
  • 33 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

Most patients with differentiated thyroid cancer (DTC) have a favorable prognosis. However, patients with DTC and initial distant metastasis have not been commonly found, and their clinical characteristics have seldom been reported. In this study, we analyzed the clinical features and prognosis of patients with DTC and initial distant metastasis in Korea.

Methods

We retrospectively reviewed the clinical data of 242 patients with DTC and initial distant metastasis treated from 1994 to 2013, collected from five tertiary hospitals in Korea.

Results

The patients' median age was 51 years, and 65% were women. They were followed for a median of 7 years. Lung was the most common site of distant metastasis: only lung 149 patients (62%), only bone 49 (20%), other single site one (pleura), and combined sites 43 (40 were lung and bone, two were bone and other site, and one was lung and other site). At the time of diagnosis, 50 patients (21%) had non-radioactive iodine (RAI) avidity. Five-year disease-specific survival (DSS) was 85% and 10-year DSS was 68%, which were better than those in previous studies. After multivariate analysis, old age, male sex, metastatic site, and histologic type (follicular type) were significant factors for poor prognosis. However, negative RAI avidity status was not a significant prognostic factor after adjusting for other variables.

Conclusion

The prognosis of Korean patients with DTC and initial distant metastasis was better than in previous studies. Old age, male sex, metastasis site, and histologic type were significant prognostic factors.

Citations

Citations to this article as recorded by  
  • Characterizing thyroid carcinomas in the elderly: Histological subtypes and TERT promoter mutation analysis based on the latest WHO classification
    Myoung Ju Koh, Songmi Noh, Jin Kyong Kim, Gi Jeong Kim
    Annals of Diagnostic Pathology.2026; 80: 152578.     CrossRef
  • A new therapeutic paradigm: radioiodine combined with lenvatinib for radioiodine-avid metastatic well-differentiated thyroid cancer
    Siddharth Sharma, Aftab Hasan Nazar, Prabhakar Mishra, Manish Ora, Amitabh Arya, Sukanta Barai, Prasanta Kumar Pradhan, Sanjay Gambhir
    Nuclear Medicine Communications.2025; 46(7): 605.     CrossRef
  • Challenging diagnosis and treatment of rare paranasal sinus metastasis from thyroid cancer: a case report and literature review
    Jee Hee Yoon, Ji Yong Park, A Ram Hong, Sung Sun Kim, Hee Kyung Kim, Ho-Cheol Kang
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Prognostic Factors and Survival Outcomes in Thyroid Cancer Patients With Bone Metastasis: Insights From a Population-Based Cohort Study
    Hang Zhao, Xiao-Zhun Tang, Duo-Ping Wang, Peng-Cheng Yu, Cong He, Xu-Feng Chen, Wei-Dong Ye, Jia-Hao Wu, Jia-Qian Hu, Yu-Long Wang
    Endocrine Practice.2025; 31(10): 1274.     CrossRef
  • A Nomogram for Predicting Lung Metastasis in Papillary Thyroid Cancer Patients Aged Less Than 55 Years
    Huiyun Yang, Qiuqin Qian, Yanling Li, Wenjie Pan, Jing Peng, Zhenyu Zou, Haiqing Zhu, Feng Shi
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Case report: A case of hyperthyroidism secondary to bone metastasis of differentiated thyroid cancer
    Tingyu Gu, Zhihong Zhao, Yuanyuan Shi, Zhenhua Sun, Yao Wang, Zhiyuan He, Kun Wang
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Theranostics of Thyroid Cancer
    Luca Giovanella, Murat Tuncel, Atena Aghaee, Alfredo Campenni, Armando De Virgilio, Petra Petranović Ovčariček
    Seminars in Nuclear Medicine.2024; 54(4): 470.     CrossRef
  • Thyroid Hormone Withdrawal versus Recombinant Human TSH as Preparation for I-131 Therapy in Patients with Metastatic Thyroid Cancer: A Systematic Review and Meta-Analysis
    Luca Giovanella, Maria Luisa Garo, Alfredo Campenní, Petra Petranović Ovčariček, Rainer Görges
    Cancers.2023; 15(9): 2510.     CrossRef
  • Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
    Petra Petranović Ovčariček, Alfredo Campenni, Bart de Keizer, Desiree Deandreis, Michael C. Kreissl, Alexis Vrachimis, Murat Tuncel, Luca Giovanella
    Cancers.2023; 15(17): 4290.     CrossRef
  • Differentiating pulmonary metastasis from benign lung nodules in thyroid cancer patients using dual-energy CT parameters
    Taeho Ha, Wooil Kim, Jaehyung Cha, Young Hen Lee, Hyung Suk Seo, So Young Park, Nan Hee Kim, Sung Ho Hwang, Hwan Seok Yong, Yu-Whan Oh, Eun-Young Kang, Cherry Kim
    European Radiology.2022; 32(3): 1902.     CrossRef
  • Feasibility of Recombinant Human TSH as a Preparation for Radioiodine Therapy in Patients with Distant Metastases from Papillary Thyroid Cancer: Comparison of Long-Term Survival Outcomes with Thyroid Hormone Withdrawal
    Hsi-Chen Tsai, Kung-Chu Ho, Shih-Hsin Chen, Jing-Ren Tseng, Lan-Yan Yang, Kun-Ju Lin, Ju-Chin Cheng, Miaw-Jene Liou
    Diagnostics.2022; 12(1): 221.     CrossRef
  • Long-Term Quality of Life (5-15 Years Post-Thyroidectomy) of Thyroid Carcinoma Patients in Two Tertiary Care Hospitals
    Mohammed Yousef Alyousef, Mohammed Khaled Ghandour, Mohammed Al-Mohawes, Mosaad Alnwaisir, Tahera Islam, Khalid Al Qahtani
    Cureus.2022;[Epub]     CrossRef
  • Evaluation of Lipocalin-2 and Twist expression in thyroid cancers and its relationship with epithelial mesenchymal transition
    Pınar Celepli, İrem Bigat, Sefika Karabulut, Salih Celepli, Sema Hücümenoğlu
    Annals of Diagnostic Pathology.2022; 59: 151973.     CrossRef
  • Clinical study of ultrasonic evaluation of T/N staging of differentiated thyroid carcinoma using AJCC 8th staging criteria
    Yu Liang, Xingxiang Huang, Zhe Song, Yang Yang, Ju Lei, Mei Ren, Li Tan, Hui Zhang, Francis Moore
    PLOS ONE.2022; 17(6): e0269994.     CrossRef
  • Therapeutic challenges in metastatic follicular thyroid cancer occurring in pregnancy: A case report
    Claudio Spinelli, Beatrice Sanna, Marco Ghionzoli, Elisabetta Micelli
    World Journal of Obstetrics and Gynecology.2022; 11(3): 33.     CrossRef
  • Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study
    Juan Antonio Vallejo Casas, Marcel Sambo, Carlos López López, Manuel Durán-Poveda, Julio Rodríguez-Villanueva García, Rita Joana Santos, Marta Llanos, Elena Navarro-González, Javier Aller, Virginia Pubul, Sonsoles Guadalix, Guillermo Crespo, Cintia Gonzál
    European Thyroid Journal.2022;[Epub]     CrossRef
  • Male sex is not an independent risk factor for recurrence of differentiated thyroid cancer: a propensity score-matching study
    Joonseon Park, Kwangsoon Kim, Dong-Jun Lim, Ja Seong Bae, Jeong Soo Kim
    Scientific Reports.2021;[Epub]     CrossRef
  • Evaluation of the 2015 ATA Guidelines in Patients With Distant Metastatic Differentiated Thyroid Cancer
    Evert F S van Velsen, Merel T Stegenga, Folkert J van Kemenade, Boen L R Kam, Tessa M van Ginhoven, W Edward Visser, Robin P Peeters
    The Journal of Clinical Endocrinology & Metabolism.2020; 105(3): e457.     CrossRef
  • Usefulness of a 3D‐Printed Thyroid Cancer Phantom for Clinician to Patient Communication
    Dayeong Hong, Sangwook Lee, Taehun Kim, Jung Hwan Baek, Won Woong Kim, Ki‐Wook Chung, Namkug Kim, Tae‐Yon Sung
    World Journal of Surgery.2020; 44(3): 788.     CrossRef
  • Estimating the Growth Rate of Lung Metastases in Differentiated Thyroid Carcinoma: Response Evaluation Criteria in Solid Tumors or Doubling Time?
    Eyun Song, Jonghwa Ahn, Min Ji Jeon, Sang Min Lee, Jeong Hyun Lee, Tae Yong Kim, Jung Hwan Baek, Won Bae Kim, Young Kee Shong, Won Gu Kim
    Thyroid.2020; 30(3): 418.     CrossRef
  • Personalized management of differentiated thyroid cancer in real life – practical guidance from a multidisciplinary panel of experts
    Alfredo Campennì, Daniele Barbaro, Marco Guzzo, Francesca Capoccetti, Luca Giovanella
    Endocrine.2020; 70(2): 280.     CrossRef
  • Unusual metastases from differentiated thyroid cancers: A multicenter study in Korea
    Jee Hee Yoon, Min Ji Jeon, Mijin Kim, A. Ram Hong, Hee Kyung Kim, Dong Yeob Shin, Bo Hyun Kim, Won Bae Kim, Young Kee Shong, Ho-Cheol Kang, Domenico Albano
    PLOS ONE.2020; 15(8): e0238207.     CrossRef
  • Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study
    Hye-Seon Oh, Dong Yeob Shin, Mijin Kim, So Young Park, Tae Hyuk Kim, Bo Hyun Kim, Eui Young Kim, Won Bae Kim, Jae Hoon Chung, Young Kee Shong, Dong Jun Lim, Won Gu Kim
    Thyroid.2019; 29(12): 1804.     CrossRef
  • Clinical outcomes and prognostic factors in patients with no less than three distant organ system metastases from differentiated thyroid carcinoma
    Xin-Yun Zhang, Jian-Wen Sun, Zhong-Ling Qiu, Yang Wang, Xiao-Yue Chen, Jin-Hua Zhao, Quan-Yong Luo
    Endocrine.2019; 66(2): 254.     CrossRef
  • Molecular Profile and Clinical Outcomes in Differentiated Thyroid Cancer Patients Presenting with Bone Metastasis
    Nilma Malik, Alyaksandr V. Nikitski, Elie Klam, Jason Hunt, Benjamin Witt, Barbara Chadwick, Yuri E. Nikiforov, Devaprabu Abraham
    Endocrine Practice.2019; 25(12): 1255.     CrossRef
  • Improved survival after early detection of asymptomatic distant metastasis in patients with thyroid cancer
    Hosu Kim, So Young Park, Jaehoon Jung, Jung-Han Kim, Soo Yeon Hahn, Jung Hee Shin, Young Lyun Oh, Man Ki Chung, Hye In Kim, Sun Wook Kim, Jae Hoon Chung, Tae Hyuk Kim
    Scientific Reports.2019;[Epub]     CrossRef
  • Unusual metastases from differentiated thyroid carcinoma: analysis of 36 cases
    Anabela Zunino, Fabián Pitoia, Eduardo Faure, Adriana Reyes, Mónica Sala, Rosana Sklate, Verónica Ilera, Inés Califano
    Endocrine.2019; 65(3): 630.     CrossRef
  • The Prognosis of Papillary Thyroid Cancer with Initial Distant Metastasis is Strongly Associated with Extensive Extrathyroidal Extension: A Retrospective Cohort Study
    Young Ki Lee, Daham Kim, Dong Yeob Shin, Cho Rok Lee, Eun Jig Lee, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Cheong Soo Park
    Annals of Surgical Oncology.2019; 26(7): 2200.     CrossRef
  • Risk Factors for Distant Metastasis in Follicular Thyroid Carcinoma in Korea
    Shin Dol Jo, Joon-Hyop Lee, Suk Ha Kang, Yun Yeong Kim, Yong Soon Chun, Heung Kyu Park, Sang Tae Choi, Jin Mo Kang, Yoo Seung Chung
    Journal of Endocrine Surgery.2019; 19(1): 1.     CrossRef
  • Expression levels of ARHI and Beclin1 in thyroid cancer and their relationship with clinical pathology and prognosis
    Houwei Zhu, Yanqing Qu
    Oncology Letters.2019;[Epub]     CrossRef
  • 甲状腺腫瘍治療の最新情報

    Nippon Jibiinkoka Gakkai Kaiho.2018; 121(11): 1336.     CrossRef
  • Clinical Outcomes of Differentiated Thyroid Cancer Patients with Local Recurrence or Distant Metastasis Detected in Old Age
    Ji Min Han, Ji Cheol Bae, Hye In Kim, Sam Kwon, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Endocrinology and Metabolism.2018; 33(4): 459.     CrossRef
  • Efficacy and Affecting Factors of 131I Thyroid Remnant Ablation After Surgical Treatment of Differentiated Thyroid Carcinoma
    Chen Wang, Hongcui Diao, Ping Ren, Xufu Wang, Yangang Wang, Wenjuan Zhao
    Frontiers in Oncology.2018;[Epub]     CrossRef
Close layer
Thyroid
Star-Shaped Intense Uptake of 131I on Whole Body Scans Can Reflect Good Therapeutic Effects of Low-Dose Radioactive Iodine Treatment of 1.1 GBq
Sung Hye Kong, Jung Ah Lim, Young Shin Song, Shinje Moon, Ye An Kim, Min Joo Kim, Sun Wook Cho, Jae Hoon Moon, Ka Hee Yi, Do Joon Park, Bo Youn Cho, Young Joo Park
Endocrinol Metab. 2018;33(2):228-235.   Published online May 4, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.2.228
  • 8,938 View
  • 59 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

After initial radioactive iodine (RAI) treatment in differentiated thyroid cancer patients, we sometimes observe a star-shaped region of intense uptake of 131I on whole body scans (WBSs), called a ‘star artifact.’ We evaluated the clinical implications of star artifacts on the success rate of remnant ablation and long-term prognosis.

Methods

Total 636 patients who received 131I dose of 1.1 GBq for the initial RAI therapy and who did not show distant metastasis at the time of diagnosis were retrospectively evaluated. A negative second WBS was used for evaluating the ablation efficacy of the RAI therapy. Among them, 235 patients (36.9%) showed a star artifact on their first WBS.

Results

In patients with first stimulated thyroglobulin (sTg) levels ≤2 ng/mL, patients with star artifacts had a higher rate of negative second WBS compared with those without star artifacts (77.8% vs. 63.9%, P=0.044), and showed significantly higher recurrence-free survival (P=0.043) during the median 8.0 years (range, 1.0 to 10.0) of follow-up. The 5- and 10-year recurrence rates (5YRR, 10YRR) were also significantly lower in patients with star artifacts compared with those without (0% vs. 4.9%, respectively, P=0.006 for 5YRR; 0% vs. 6.4%, respectively, P=0.005 for 10YRR). However, ablation success rate or recurrence-free survival was not different among patients whose first sTg levels >2 ng/mL regardless of star artifacts.

Conclusion

Therefore, star artifacts at initial RAI therapy imply a good ablation efficacy or a favorable long-term prognosis in patients with sTg levels ≤2 ng/mL.

Citations

Citations to this article as recorded by  
  • Prognostic value of star-shaped intense uptake of 131I in thyroid cancer patients
    Liu Xiao, Wen Jie Zhang, Yue Qi Wang, Lin Li
    Revista Española de Medicina Nuclear e Imagen Molecular (English Edition).2021; 40(1): 30.     CrossRef
  • Valores pronósticos de la captación en estrella de 131I en pacientes con cáncer diferenciado de tiroides
    L. Xiao, W.J. Zhang, Y.Q. Wang, L. Li
    Revista Española de Medicina Nuclear e Imagen Molecular.2021; 40(1): 30.     CrossRef
  • Comparison between planar and single-photon computed tomography images for radiation intensity quantification in iodine-131 scintigraphy
    Yusuke Iizuka, Tomohiro Katagiri, Minoru Inoue, Kiyonao Nakamura, Takashi Mizowaki
    Scientific Reports.2021;[Epub]     CrossRef
Close layer
Review Article
Thyroid
Evaluation of Thyroid Hormone Levels and Urinary Iodine Concentrations in Koreans Based on the Data from Korea National Health and Nutrition Examination Survey VI (2013 to 2015)
Jae Hoon Chung
Endocrinol Metab. 2018;33(2):160-163.   Published online May 4, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.2.160
  • 7,016 View
  • 59 Download
  • 5 Web of Science
  • 5 Crossref
AbstractAbstract PDFPubReader   ePub   

No nationwide data have been published about thyroid hormone levels and urinary iodine concentrations (UICs) in Korea. The Korea Centers for Disease Control and Prevention and the Korean Thyroid Association established a project to evaluate the nationwide thyroid hormone profile and UICs in healthy Koreans as part of the Korea National Health and Nutrition Examination Survey (KNHANES) VI (2013 to 2015), a nationwide, cross-sectional survey of the Korean population that enrolled 7,061 individuals who were weighted to represent the entire Korean population. Based on the KNHANES VI, the geometric mean value of serum thyroid stimulating hormone was 2.16 mIU/L, and its reference interval was 0.59 to 7.03 mIU/L. The mean value of serum free thyroxine was 1.25 ng/dL, and its reference interval was 0.92 to 1.60 ng/dL. The median UIC in the Korean population was reported to be 294 μg/L, corresponding to ‘above requirements’ iodine intake according to the World Health Organization recommendations. A U-shaped relationship of UIC with age was found. The prevalence of overt hyperthyroidism and overt hypothyroidism in the Korean population based on the KNHANES VI was 0.54% and 0.73%, respectively.

Citations

Citations to this article as recorded by  
  • Correlation between shift work and non-alcoholic fatty liver disease among male workers in the steel manufacturing company of Korea: a cross-sectional study
    Kiseok Kim, Yong-Jin Lee, Soon-Chan Kwon, Young-Sun Min, Hyun Kyo Lee, Gwangin Baek, Sang Hyeon Kim, Eun-Chul Jang
    Annals of Occupational and Environmental Medicine.2022;[Epub]     CrossRef
  • Subclinical Hypothyroidism: Prevalence, Health Impact, and Treatment Landscape
    Won Sang Yoo, Hyun Kyung Chung
    Endocrinology and Metabolism.2021; 36(3): 500.     CrossRef
  • T4+T3 Combination Therapy: An Unsolved Problem of Increasing Magnitude and Complexity
    Wilmar M. Wiersinga
    Endocrinology and Metabolism.2021; 36(5): 938.     CrossRef
  • Update on Thyroid Hormone Levels and Thyroid Dysfunction in the Korean Population Based on Data from the Korea National Health and Nutrition Examination Survey VI (2013 to 2015)
    Jae Hoon Chung
    Endocrinology and Metabolism.2020; 35(1): 7.     CrossRef
  • Different Relationships Between Thyrotropin and Muscle Strength According to Sex and Age in Euthyroid Koreans (The 6th Korea National Health and Nutritional Examination Survey 2014–2015)
    Seong Hee Ahn, Da Hea Seo, Yongin Cho, Mihye Jung, So Hun Kim, Seongbin Hong
    Thyroid.2020; 30(12): 1710.     CrossRef
Close layer
Original Article
Clinical Study
Excessive Iodine Status among School-Age Children in Korea: A First Report
Young Sik Choi, Soyoung Ock, Sukyoung Kwon, Sang Bong Jung, Kwang-Hyuk Seok, Young Jin Kim, Bu Kyung Kim, Jee-Yeong Jeong
Endocrinol Metab. 2017;32(3):370-374.   Published online September 18, 2017
DOI: https://doi.org/10.3803/EnM.2017.32.3.370
  • 7,383 View
  • 46 Download
  • 5 Web of Science
  • 5 Crossref
AbstractAbstract PDFPubReader   
Background

Korea is considered an iodine sufficient country, and several studies have been conducted regarding iodine status in healthy Korean adults, pregnant women, and preschool children. However, data on iodine status in Korean school-age children are lacking. Therefore, the iodine nutrition status of Korean school-age children was investigated by measuring urine iodine concentration (UIC).

Methods

This cross-sectional study conducted between April and September 2016 comprised 373 school-age children. UIC was determined using a modified microplate method employing ammonium persulfate digestion followed by Sandell-Kolthoff reaction.

Results

The median UIC was 458.2 µg/L. Excessive iodine intake (>300 µg/L) was found in 286 children (76.7%), with extremely high values exceeding 1,000 µg/L in 19.6% of subjects. Insufficient iodine intake (<100 µg/L) was observed in eight children (2.1%). UIC values were not significantly different between sexes.

Conclusion

Korean school-age children showed excessive iodine intake. Therefore, education regarding adequate iodine intake in school-age children is needed.

Citations

Citations to this article as recorded by  
  • Relationship of iodine excess with thyroid function in 6-year-old children living in an iodine-replete area
    Yun Jeong Lee, Sun Wook Cho, Youn-Hee Lim, Bung-Nyun Kim, Johanna Inhyang Kim, Yun-Chul Hong, Young Joo Park, Choong Ho Shin, Young Ah Lee
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Excessive iodine status among school‐aged children in the State of Qatar: Results of the National Iodine Deficiency Disorder Survey
    Mohamed Hamad J. T. Al‐Thani, Salah Abdulla Sh. A. Alyafei, Kholoud Ateeq K. M. Al‐Motawaa, Shamseldin Ali Khalifa, Syed Hassan Bin Usman Shah, Benjamin Vinodson, Sureshbabu Kokku, Amit Mishra
    Public Health Challenges.2023;[Epub]     CrossRef
  • Changing Iodine Status and the Incidence of Thyroid Disease in Mainland China: A Prospective 20-Year Follow-Up Study
    Zhongyan Shan, Yushu Li, Yongze Li, Haoyu Wang, Di Teng, Xiaochun Teng, Wei Chong, Xiaoguang Shi, Jing Li, Jiahui Guo, Zhe Lou, Chenling Fan, Shuangning Ding, Li He, Hua Liu, Elizabeth N. Pearce, Weiping Teng
    Thyroid®.2023; 33(7): 858.     CrossRef
  • Association between urinary sodium levels and iodine status in Korea
    Jonghwa Ahn, Jang Ho Lee, Jiwoo Lee, Ji Yeon Baek, Eyun Song, Hye-Seon Oh, Mijin Kim, Suyeon Park, Min Ji Jeon, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Won Gu Kim
    The Korean Journal of Internal Medicine.2020; 35(2): 392.     CrossRef
  • Effects of Maternal Iodine Status during Pregnancy and Lactation on Maternal Thyroid Function and Offspring Growth and Development: A Prospective Study Protocol for the Ideal Breast Milk Cohort
    Young Ah Lee, Sun Wook Cho, Ho Kyung Sung, Kyungsik Kim, Young Shin Song, Sin Je Moon, Jung Won Oh, Dal Lae Ju, Sooyeon Choi, Sang Hoon Song, Gi Jeong Cheon, Young Joo Park, Choong Ho Shin, Sue K. Park, Jong Kwan Jun, June-Key Chung
    Endocrinology and Metabolism.2018; 33(3): 395.     CrossRef
Close layer
Review Article
Thyroid
Clinical Update in Aspects of the Management of Autoimmune Thyroid Diseases
Duncan J. Topliss
Endocrinol Metab. 2016;31(4):493-499.   Published online December 20, 2016
DOI: https://doi.org/10.3803/EnM.2016.31.4.493
  • 10,019 View
  • 97 Download
  • 32 Web of Science
  • 29 Crossref
AbstractAbstract PDFPubReader   

Aspects of autoimmune thyroid disease updated in this review include: immunoglobulin G4 (IgG4)-related thyroid disease (Riedel's thyroiditis, fibrosing variant of Hashimoto's thyroiditis, IgG4-related Hashimoto's thyroiditis, and Graves' disease with elevated IgG4 levels); recent epidemiological studies from China and Denmark indicating that excess iodine increases the incidence of Hashimoto's thyroiditis and hypothyroidism; immunomodulatory agents (ipilimumab, pembrolizumab, nivolumab) activate immune response by inhibiting T-cell surface receptors which down-regulate immune response, i.e., cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 pathways; alemtuzumab is a humanised monoclonal antibody to CD52 which causes immune depletion and thyroid autoimmune disease especially Graves' hyperthyroidism; small molecule ligand (SML) agonists which activate receptors, SML neutral antagonists, which inhibit receptor activation by agonists, and SML inverse agonists which inhibit receptor activation by agonists and inhibit constitutive agonist independent signaling have been identified. SML antagonism of thyroid-stimulating hormone-receptor stimulatory antibody could treat Graves' hyperthyroidism and Graves' ophthalmopathy; and thyroxine treatment of subclinical hypothyroidism can produce iatrogenic subclinical hyperthyroidism with the risk of atrial fibrillation and osteoporosis. The increased risk of harm from subclinical hyperthyroidism may be stronger than the potential benefit from treatment of subclinical hypothyroidism.

Citations

Citations to this article as recorded by  
  • The immune system in Hashimoto's thyroiditis: Updating the current state of knowledge on potential therapies and animal model construction
    Ruixi Li, Ting He, Zhichao Xing, Li Mi, Anping Su, Wenshuang Wu
    Autoimmunity Reviews.2025; 24(6): 103783.     CrossRef
  • Current Practices in Hashimoto's Thyroiditis: Differences in Attitudes Between Pediatric and Adult Endocrinologists in Türkiye: A National Survey
    Gul Yesiltepe Mutlu, Bahar Ozcabi, Aydilek Dagdeviren Cakır, Yavuz Ozer, Cengiz Kara, Thyroid Working Group
    Journal of Clinical Research in Pediatric Endocrinology.2025;[Epub]     CrossRef
  • Association of autoimmune thyroid disease with type 1 diabetes mellitus and its ultrasonic diagnosis and management
    Jin Wang, Ke Wan, Xin Chang, Rui-Feng Mao
    World Journal of Diabetes.2024; 15(3): 348.     CrossRef
  • The impact of gut microbiota on autoimmune thyroiditis and relationship with pregnancy outcomes: a review
    Yu Song, Yu Bai, Cong Liu, Xiaodan Zhai, Le Zhang
    Frontiers in Cellular and Infection Microbiology.2024;[Epub]     CrossRef
  • Exploring the diagnostic value of endothelial cell and angiogenesis-related genes in Hashimoto's thyroiditis based on transcriptomics and single cell RNA sequencing
    Yihang Li, Xiaokai Lu, Weihan Cao, Nianqiu Liu, Xin Jin, Yuting Li, Shiying Tang, Ling Tao, Qian Zhu, Gaohong Zhu, Hongmin Liang
    Archives of Biochemistry and Biophysics.2024; 757: 110013.     CrossRef
  • The Effect of a Casein and Gluten-Free Diet on the Epigenetic Characteristics of FoxP3 in Patients With Hashimoto's Thyroiditis
    Elif S Aslan, Gulsen Meral, Ece Aydin, Sinan Caglayan, Aytug Altundag, Seyda Demirkol, Gizem Gormus, Mustafa Solak, Furkan Ayaz
    Cureus.2024;[Epub]     CrossRef
  • The efficacy of Chinese patent medicine Xiaojin capsule in the treatment of Hashimoto's thyroiditis: A systematic review and meta-analysis
    Aijing Chu, Shouyao Liu, Ying Chen, Zhongyuan Xia
    European Journal of Integrative Medicine.2024; 70: 102395.     CrossRef
  • Causal validation of the relationship between 35 blood and urine biomarkers and hyperthyroidism: a bidirectional Mendelian randomization study and meta-analysis
    Wanxian Xu, Jiao Wu, Daolei Chen, Rui Zhang, Yue Yang
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Effects of vitamin D treatment on thyroid function and autoimmunity markers in patients with Hashimoto's thyroiditis—A meta‐analysis of randomized controlled trials
    Hui Jiang, Xiaoluo Chen, Xiaoqin Qian, Shihe Shao
    Journal of Clinical Pharmacy and Therapeutics.2022; 47(6): 767.     CrossRef
  • Immunoglobulin G4-Related Thyroid Disease: A Single-Center Experience and Literature Review
    Meihua Jin, Bictdeun Kim, Ahreum Jang, Min Ji Jeon, Young Jun Choi, Yu-Mi Lee, Dong Eun Song, Won Gu Kim
    Endocrinology and Metabolism.2022; 37(2): 312.     CrossRef
  • DNA Methylation in Autoimmune Thyroid Disease
    Nicole Lafontaine, Scott G Wilson, John P Walsh
    The Journal of Clinical Endocrinology & Metabolism.2022;[Epub]     CrossRef
  • Pathogenesis Markers of Hashimoto's Disease—A Mini Review
    Binghui Jin, Shuang Wang, Zhe Fan
    Frontiers in Bioscience-Landmark.2022;[Epub]     CrossRef
  • Prevalence of Components of Metabolic Syndrome Among Adults with the Presence of Autoimmune Thyroid Condition in an Iodine-Sufficient Region
    Binyu Pan, Qin Zhang, Hang Zhou, Zheng Feei Ma
    Biological Trace Element Research.2021; 199(8): 2837.     CrossRef
  • Changes in thyroid antibody and T lymphocyte subsets after radiofrequency ablation of thyroid nodules in patients with autoimmune thyroiditis
    Xiaoyin Tang, Ping Li, Bo Zhai, Xiaoli Zhu
    Journal of Cancer Research and Therapeutics.2021; 17(3): 638.     CrossRef
  • Hashimoto's thyroiditis: An update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation
    Massimo Ralli, Diletta Angeletti, Marco Fiore, Vittorio D'Aguanno, Alessandro Lambiase, Marco Artico, Marco de Vincentiis, Antonio Greco
    Autoimmunity Reviews.2020; 19(10): 102649.     CrossRef
  • Myasthenia Gravis and its Association With Thyroid Diseases
    Saba Amin, Myat Aung, Fenil R Gandhi, Julio A Pena Escobar, Azouba Gulraiz, Bilal Haider Malik
    Cureus.2020;[Epub]     CrossRef
  • Effect of large dosage of Prunella on Hashimoto's thyroiditis
    Pei Chen, Chaomin Li, Siliang Zhao, Lizhen Wang, Lingyu Liu, Qiuhong Fan
    Medicine.2020; 99(50): e23391.     CrossRef
  • Establishment of clinical diagnosis model of Graves’ disease and Hashimoto’s thyroiditis
    Zhaohui Cui, Zhixiao Wang, Xiaoyun Liu, Yun Cai, Xinyu Xu, Tao Yang
    Journal of Translational Medicine.2019;[Epub]     CrossRef
  • The value of preoperative antithyroidperoxidase antibody as a novel predictor of recurrence in papillary thyroid carcinoma
    Eyun Song, Hye‐Seon Oh, Min Ji Jeon, Ki Wook Chung, Suck Joon Hong, Jin Sook Ryu, Jung Hwan Baek, Jeong Hyun Lee, Won Gu Kim, Won Bae Kim, Young Kee Shong, Tae Yong Kim
    International Journal of Cancer.2019; 144(6): 1414.     CrossRef
  • Sonographic Characteristics of Papillary Thyroid Carcinoma with Coexistent Hashimoto's Thyroiditis: Conventional Ultrasound, Acoustic Radiation Force Impulse Imaging and Contrast-Enhanced Ultrasound
    Qinghai Peng, Chengcheng Niu, Meixiang Zhang, Qiang Peng, Sijie Chen
    Ultrasound in Medicine & Biology.2019; 45(2): 471.     CrossRef
  • The incidental thyroid nodule
    Sarah B. Fisher, Nancy D. Perrier
    CA: A Cancer Journal for Clinicians.2018; 68(2): 97.     CrossRef
  • Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer
    Hye In Kim, Mijin Kim, Se-Hoon Lee, So Young Park, Young Nam Kim, Hosu Kim, Min Ji Jeon, Tae Yong Kim, Sun Wook Kim, Won Bae Kim, Sang-We Kim, Dae Ho Lee, Keunchil Park, Myung-Ju Ahn, Jae Hoon Chung, Young Kee Shong, Won Gu Kim, Tae Hyuk Kim
    OncoImmunology.2018; 7(1): e1375642.     CrossRef
  • A case report of a novel, integrative approach to Hashimoto’s thyroiditis with unexpected results
    Nicole Avard, Suzanne J. Grant
    Advances in Integrative Medicine.2018; 5(2): 75.     CrossRef
  • Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSH-Receptor Immune Response
    Mario Rotondi, Martina Molteni, Paola Leporati, Valentina Capelli, Michele Marinò, Luca Chiovato
    Frontiers in Endocrinology.2017;[Epub]     CrossRef
  • Clinical Implications of Immunoglobulin G4 to Graves' Ophthalmopathy
    Sung Hoon Yu, Jun Goo Kang, Chul Sik Kim, Sung-Hee Ihm, Moon Gi Choi, Hyung Joon Yoo, Seong Jin Lee
    Thyroid.2017; 27(9): 1185.     CrossRef
  • Articles inEndocrinology and Metabolismin 2016
    Won-Young Lee
    Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef
  • Correlation of hormonal and cytokines regulation in case of autoimmune thyroiditis
    Victoria V. Zdor
    Clinical and experimental thyroidology.2017; 13(2): 45.     CrossRef
  • Autoimmune Thyroiditis and Myasthenia Gravis
    Angela Lopomo, Sonia Berrih-Aknin
    Frontiers in Endocrinology.2017;[Epub]     CrossRef
  • Age-specific reference interval of serum TSH levels is high in adolescence in an iodine excess area: Korea national health and nutrition examination survey data
    Hyemi Kwon, Won Gu Kim, Min Ji Jeon, Minkyu Han, Mijin Kim, Suyeon Park, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Endocrine.2017; 57(3): 445.     CrossRef
Close layer
Original Articles
Clinical Study
Prevalence of Hyponatremia in Hypothyroid Patients during Radioactive 131I Ablation for Differentiated Thyroid Cancer: Single Institution Experience
Juan Carlo P. Dayrit, Elaine C. Cunanan, Sjoberg A. Kho
Endocrinol Metab. 2016;31(3):410-415.   Published online August 17, 2016
DOI: https://doi.org/10.3803/EnM.2016.31.3.410
  • 7,430 View
  • 39 Download
  • 4 Web of Science
  • 3 Crossref
AbstractAbstract PDFPubReader   
Background

Hyponatremia developing in hypothyroid patients has been encountered in clinical practice; however, its prevalence has not been well established.

Methods

Thirty patients diagnosed with differentiated thyroid cancer, rendered hypothyroid after surgery and levothyroxine withdrawal, and who are for radioactive iodine (RAI) ablation were included. Serum sodium concentrations were measured twice, at the time of admission for RAI ablation, and before discharge after increased oral fluid intake. The outcome measures were to determine the prevalence of hyponatremia among hypothyroid patients prior to RAI ablation and after oral hydration post-RAI, and to correlate the serum sodium levels pre-RAI and post-RAI with thyroid-stimulating hormone (TSH) concentration and age.

Results

Thirty patients were included, with ages from 23 to 65 years old (median, 40). Two patients (6.7%) were hyponatremic prior to RAI ablation, and eight patients (26.7%) had mild hyponatremia (130 to 134 mEq/L) after RAI and hydration. There was no significant correlation between TSH levels and serum sodium levels prior to or after RAI. There was also no significant correlation between pre- and post-RAI sodium concentration and age.

Conclusions

The prevalence of hyponatremia pre-RAI was 6.7%, and 26.7% post-RAI. No significant correlation was noted between TSH concentration and age on pre- or post-RAI sodium concentrations. Routine measurement of serum sodium post-RAI/isolation is still not advised. Measurement of sodium post-RAI may be considered in patients who are elderly, with comorbid conditions or on medications.

Citations

Citations to this article as recorded by  
  • Epidemiology, Diagnosis, and Management of Thyroid Cancer in the Philippines
    Karol Ann T. Baldo, Ruby Anne N. King, Florence Giannina F. San Juan, Cecile C. Dungog, Jea Giezl N. Solidum, Jeremy A. Ceriales, Ma. Carmela P. dela Cruz, Frances Dominique V. Ho, Nicole Picart, Aldrin Nico R. Plantado, Jessica Perez, Jervy P. Garcia, Jo
    Indian Journal of Surgical Oncology.2025;[Epub]     CrossRef
  • Is there a causal relationship between hypothyroidism and hyponatremia?
    Julie Chen
    Therapeutic Advances in Endocrinology and Metabolism.2023;[Epub]     CrossRef
  • Endocrinopathy-induced euvolemic hyponatremia
    Talia Diker-Cohen, Benaya Rozen-Zvi, Dana Yelin, Amit Akirov, Eyal Robenshtok, Anat Gafter-Gvili, Daniel Shepshelovich
    Internal and Emergency Medicine.2018; 13(5): 679.     CrossRef
Close layer
Clinical Study
Comparison of Fixed versus Calculated Activity of Radioiodine for the Treatment of Graves Disease in Adults
Abigail U. Canto, Paulette N. Dominguez, Cecilia A. Jimeno, Jerry M. Obaldo, Ruben V. Ogbac
Endocrinol Metab. 2016;31(1):168-173.   Published online March 16, 2016
DOI: https://doi.org/10.3803/EnM.2016.31.1.168
  • 8,765 View
  • 83 Download
  • 13 Web of Science
  • 14 Crossref
AbstractAbstract PDFPubReader   
Background

Radioactive iodine as a treatment modality has been shown in several studies to be a safe and effective therapy for Graves disease. However, there is still no uniformity regarding optimal dosing method. The aim of this study is to compare the efficacy of calculated and fixed dosing of radioiodine for the treatment of Graves disease.

Methods

A hundred twenty-two patients diagnosed with Graves disease were randomized to receive either fixed or calculated dose of radioiodine. Those randomized to fixed activity received either low fixed activity at 9.9 mCi for thyroid gland size <40 g or high fixed activity at 14.9 mCi for thyroid gland size 40 to 80 g, and those grouped to calculated activity received 160 µCi/g of thyroid tissue adjusted for 24 hours radioiodine uptake. Thyroid function tests (free thyroxine [T4] and thyroid stimulating hormone [TSH]) were monitored at 10, 16, and 24 weeks after radioactive iodine therapy. The primary outcome, treatment failure was defined as persistently elevated free T4 and low TSH.

Results

Of the 122 patients randomized, 56 in the fixed dose group and 56 in the calculated dose group completed the follow-up. At the end of 6 months, the percentage of treatment failure was 37.50% in the calculated dose group versus 19.64% in the fixed dose group with a relative risk of 0.53 (95% confidence interval, 0.28 to 0.98) favoring the fixed dose group.

Conclusion

Fixed dose radioiodine has a significantly lower incidence of persistent hyperthyroidism at 6 months post-radioactive therapy.

Citations

Citations to this article as recorded by  
  • Outcome and incidence of hypothyroidism in low-dose radioactive iodine treatment for hyperthyroidism
    Ku-Hung Lin, Jiun-Chang Wu, Ming-Che Wu
    Revista Española de Medicina Nuclear e Imagen Molecular (English Edition).2025; 44(2): 500056.     CrossRef
  • Resultados e incidencia de hipotiroidismo tras el tratamiento del hipertiroidismo con yodo radiactivo a dosis bajas
    K.-H. Lin, J.-C. Wu, M.-C. Wu
    Revista Española de Medicina Nuclear e Imagen Molecular.2025; 44(2): 500056.     CrossRef
  • The Presence of Anti-TPO Antibodies Increase the Likelihood of Post-I131 Hypothyroidism
    Felix Quataert, Bert Bravenboer, Marleen Keyaerts, Corina Emilia Andreescu
    Hormone and Metabolic Research.2024; 56(02): 134.     CrossRef
  • A retrospective study with long term follow-up of Graves' disease patients treated with low activities of 131Iodine
    Regina NEUMANN, Robert THOMANN, Gerhard W. GOERRES
    The Quarterly Journal of Nuclear Medicine and Molecular Imaging.2024;[Epub]     CrossRef
  • Possibility analysis of thyroid imaging parameters for dose adjustment in 131I treatment of hyperthyroidism
    Xiaonan ZHANG, Junhong LI, Hui ZHOU, Qiteng LU, Hailian WEI, Aifeng LI, Xinyu WEI, Zhixiao WEI
    The Quarterly Journal of Nuclear Medicine and Molecular Imaging.2023;[Epub]     CrossRef
  • Predictors of Hypothyroidism Following Empirical Dose Radioiodine in Toxic Thyroid Nodules: Real-Life Experience
    Busra Kuyumcu Demir, Ersen Karakilic, Emre Sedar Saygili, Nilgun Araci, Semra Ozdemir
    Endocrine Practice.2022; 28(8): 749.     CrossRef
  • Changes in Radiosensitivity to Gamma-Rays of Lymphocytes from Hyperthyroid Patients Treated with I-131
    Valentina Dini, Massimo Salvatori, Mauro Belli, Maria Elena Lago, Alessandra Nosdeo, Donatella Pia Dambra, Luisa Lo Conte, Ilaria Pecchia, Alessandro Giordano
    International Journal of Molecular Sciences.2022; 23(17): 10156.     CrossRef
  • Current controversies in the management of Graves’ hyperthyroidism
    Niroshan Francis, Thanuya Francis, John H Lazarus, Onyebuchi E Okosieme
    Expert Review of Endocrinology & Metabolism.2020; 15(3): 159.     CrossRef
  • Effect of Different 131I Dose Strategies for Treatment of Hyperthyroidism on Graves’ Ophthalmopathy
    Shahrara Ariamanesh, Narjess Ayati, Zahra Mazloum Khorasani, Zohreh Mousavi, Victoria Kiavash, Zahra Kiamanesh, Seyed Rasoul Zakavi
    Clinical Nuclear Medicine.2020; 45(7): 514.     CrossRef
  • The relationship between thyroid eye disease and radioiodine treatment
    Sarameth Thou, Sobhan Vinjamuri
    Nuclear Medicine Communications.2019; 40(3): 194.     CrossRef
  • 99mTc-pertechnetate thyroid scintigraphy predicts clinical outcomes in personalized radioiodine treatment for Graves’ disease
    Zhao Lina, Zhang Wenqi, Xin Yubo, Wen Qiang, Bail Lin, Guan Feng, Ji Bin
    Revista Española de Medicina Nuclear e Imagen Molecular (English Edition).2018; 37(6): 349.     CrossRef
  • Predicción de los resultados clínicos en el tratamiento personalizado con yodo radiactivo de la enfermedad de Graves, mediante gammagrafía tiroidea con 99mTc-pertecnetato
    L. Zhao, W. Zhang, Y. Xin, Q. Wen, L. Bail, F. Guan, Ji Bin
    Revista Española de Medicina Nuclear e Imagen Molecular.2018; 37(6): 349.     CrossRef
  • Articles inEndocrinology and Metabolismin 2016
    Won-Young Lee
    Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef
  • Clinical outcomes 1 year after empiric 131I therapy for hyperthyroid disorders
    Lavinia Vija Racaru, Charlotte Fontan, Mathilde Bauriaud-Mallet, Séverine Brillouet, Olivier Caselles, Slimane Zerdoud, Delphine Bastié, Delphine Vallot, Philippe Caron, Manuel Bardiès, Frederic Courbon
    Nuclear Medicine Communications.2017; 38(9): 756.     CrossRef
Close layer
Clinical Study
Economic Evaluation of Recombinant Human Thyroid Stimulating Hormone Stimulation vs. Thyroid Hormone Withdrawal Prior to Radioiodine Ablation for Thyroid Cancer: The Korean Perspective
Seo Young Sohn, Hye Won Jang, Yoon Young Cho, Sun Wook Kim, Jae Hoon Chung
Endocrinol Metab. 2015;30(4):531-542.   Published online December 31, 2015
DOI: https://doi.org/10.3803/EnM.2015.30.4.531
  • 6,147 View
  • 53 Download
  • 9 Web of Science
  • 9 Crossref
AbstractAbstract PDFPubReader   
Background

Previous studies have suggested that recombinant human thyroid stimulating hormone (rhTSH) stimulation is an acceptable alternative to thyroid hormone withdrawal (THW) when radioiodine remnant ablation is planned for thyroid cancer treatment, based on superior short-term quality of life with non-inferior remnant ablation efficacy. This study evaluated the cost-effectiveness of radioiodine remnant ablation using rhTSH, compared with the traditional preparation method which renders patients hypothyroid by THW, in Korean perspective.

Methods

This economic evaluation considered the costs and benefits to the Korean public healthcare system. Clinical experts were surveyed regarding the current practice of radioiodine ablation in Korea and their responses helped inform assumptions used in a cost effectiveness model. Markov modelling with 17 weekly cycles was used to assess the incremental costs per quality-adjusted life year (QALY) associated with rhTSH. Clinical inputs were based on a multi-center, randomized controlled trial comparing remnant ablation success after rhTSH preparation with THW. The additional costs associated with rhTSH were considered relative to the clinical benefits and cost offsets.

Results

The additional benefits of rhTSH (0.036 QALY) are achieved with an additional cost of Korean won ₩961,105, equating to cost per QALY of ₩26,697,361. Sensitivity analyses had only a modest impact upon cost-effectiveness, with one-way sensitivity results of approximately ₩33,000,000/QALY.

Conclusion

The use of rhTSH is a cost-effective alternative to endogenous hypothyroid stimulation prior to radioiodine ablation for patients who have undergone thyroidectomy in Korea.

Citations

Citations to this article as recorded by  
  • CLINICAL PATHWAY OF PATIENTS WITH DIFFERENTIATED THYROID CANCER USING RECOMBINANT HUMAN THYROID-STIMULATING HORMONE
    Rimma P. Tkachenko
    Clinical and Preventive Medicine.2025; (7): 71.     CrossRef
  • Comparison of Recombinant Human Thyroid-Stimulating Hormone and Thyroid Hormone Withdrawal for 131I Therapy in Patients With Intermediate- to High-Risk Thyroid Cancer
    Sohyun Park, Ji-In Bang, Keunyoung Kim, Youngduk Seo, Ari Chong, Chae Moon Hong, Dong-Eun Lee, Miyoung Choi, Sang-Woo Lee, So Won Oh
    Clinical Nuclear Medicine.2024; 49(3): e96.     CrossRef
  • Thyroid Hormone Withdrawal versus Recombinant Human TSH as Preparation for I-131 Therapy in Patients with Metastatic Thyroid Cancer: A Systematic Review and Meta-Analysis
    Luca Giovanella, Maria Luisa Garo, Alfredo Campenní, Petra Petranović Ovčariček, Rainer Görges
    Cancers.2023; 15(9): 2510.     CrossRef
  • Health-related quality of life of thyroid cancer patients undergoing radioiodine therapy: a cohort real-world study in a reference public cancer hospital in Brazil
    Jayda Eiras Ramim, Marcella Araugio Soares Cardoso, Gessen Lopes Carneiro de Oliveira, Maria Luisa Gomes, Tiago Teixeira Guimarães, Rossana Corbo Ramalho de Mello, Anke Bergmann, Priscilla Brunelli Pujatti
    Supportive Care in Cancer.2020; 28(8): 3771.     CrossRef
  • Predictive factors determining incomplete response to radioiodine therapy in patients with differentiated thyroid cancer
    Ewelina Szczepanek-Parulska, Magdalena Wojewoda-Korbelak, Martyna Borowczyk, Malgorzata Kaluzna, Barbara Brominska, Katarzyna Ziemnicka, Rafal Czepczynski, Maciej Baczyk, Marek Ruchala
    The Quarterly Journal of Nuclear Medicine and Molecular Imaging.2020;[Epub]     CrossRef
  • Initial Adoption of Recombinant Human Thyroid-Stimulating Hormone Following Thyroidectomy in the Medicare Thyroid Cancer Patient Population
    Michaela A. Dinan, Yanhong Li, Shelby D. Reed, Julie Ann Sosa
    Endocrine Practice.2019; 25(1): 31.     CrossRef
  • Triennial Report ofEndocrinology and Metabolism, 2015 to 2017
    Eun-Jung Rhee, Hey Yeon Jang, Won-Young Lee
    Endocrinology and Metabolism.2018; 33(2): 195.     CrossRef
  • Recombinant human TSH stimulated thyroglobulin levels at remnant ablation predict structural incomplete response to treatment in patients with differentiated thyroid cancer
    Jeonghoon Ha, Min Hee Kim, Kwanhoon Jo, Yejee Lim, Ja Seong Bae, Sohee Lee, Moo Il Kang, Bong Yun Cha, Dong Jun Lim
    Medicine.2017; 96(29): e7512.     CrossRef
  • Does the Risk of Metabolic Syndrome Increase in Thyroid Cancer Survivors?
    Min-Hee Kim, Jin-young Huh, Dong-jun Lim, Moo-Il Kang
    Thyroid.2017; 27(7): 936.     CrossRef
Close layer
Thyroid
The Association between Cobalt Deficiency and Endemic Goiter in School-Aged Children
Mojgan Sanjari, Ahmad Gholamhoseinian, Akram Nakhaee
Endocrinol Metab. 2014;29(3):307-311.   Published online September 25, 2014
DOI: https://doi.org/10.3803/EnM.2014.29.3.307
  • 6,652 View
  • 43 Download
  • 7 Web of Science
  • 9 Crossref
AbstractAbstract PDFPubReader   
Background

In Iran, an iodine deficiency control program was initiated in 1989 by iodizing salt. Despite this program, goiters have remained an endemic condition in most parts of Iran. Thus, it is possible that other factors aside from iodine deficiency may contribute to endemic goiter. The aim of this study was to investigate the association between cobalt deficiency and endemic goiter in a region of Iran with a high prevalence of goiter.

Methods

A cross-sectional study was conducted among school children aged 9 to 11 years in the city of Kerman, Iran. In the first phase of the study, a multistage, proportional-to-size, cluster sampling method was used to screen 5,380 out of 29,787 students. After the screening phase, 170 students (130 goitrous and 40 nongoitrous) were randomly selected, and serum and urine specimens were obtained. We measured thyroid function, serum cobalt level, and urinary iodine excretion. Univariate and multiple logistic regression analyses were performed.

Results

The prevalence of grade 2 goiters was 34.8% (95% confidence interval [CI], 31.5 to 42.5), with both sexes being equally affected. The weight and body mass index of goitrous subjects was significantly lower (P<0.001) than those of nongoitrous subjects. The serum cobalt levels were lower in goitrous subjects than in nongoitrous subjects (4.4±2.9 µg/L vs. 6.4±2.7 µg/L). The urinary iodine levels were also lower in goitrous subjects than in nongoitrous subjects (198.3±108.3 µg/L vs. 270.2±91.1 µg/L). Multiple regression analysis showed that only cobalt deficiency, not iodine deficiency, significantly contributed to the presence of goiter (odds ratio, 0.78; 95% CI, 0.61 to 0.99; P=0.042).

Conclusion

Cobalt deficiency may be an important independent predicator for goiter in endemic regions, especially areas in which goiters persist despite salt iodization programs.

Citations

Citations to this article as recorded by  
  • Volcanic environments and thyroid disruption – A review focused on As, Hg, and Co
    Nádia M.P. Coelho, Filipe Bernardo, Armindo S. Rodrigues, Patrícia Garcia
    Science of The Total Environment.2025; 993: 180018.     CrossRef
  • Assessment of trace element and mineral levels in students from Turkmenistan in comparison to Iran and Russia
    Anatoly A. Kirichuk, Anatoly V. Skalny, Dirk Schaumlöffel, Irina A. Kovaleva, Tatiana V. Korobeinikova, Andrey S. Kritchenkov, Michael Aschner, Borhan Mansouri, Andrey A. Skalny, Alexey A. Tinkov
    Journal of Trace Elements in Medicine and Biology.2024; 84: 127439.     CrossRef
  • Cartographic evaluation of the risk of natural elements’ deficiency in the soil cover provoking spatial variation of the endemic morbidity level (on example of thyroid morbidity among population of the Central Federal District, Russia)
    Elena Mikhailovna Korobova, Vladimir Sergeevich Baranchukov, Jaume Bech
    Environmental Geochemistry and Health.2024;[Epub]     CrossRef
  • The effect of a drink enriched with iodine and hydrogen on iodine supply in patients with metabolic syndrome
    Romanenko
    Experimental and Clinical Physiology and Biochemistry.2022;[Epub]     CrossRef
  • INVESTIGATION OF ELEMENT COMPOSITION IN BIOSUBSTRATES IN ORGANISM OF ADOLESCENTS OF DIFFERENT ETHNIC GROUPS LIVING IN THE NORTH OF KHABAROVSK REGION
    A. O. Nesterenko, E. D. Tselik, G. P. Evseeva
    Bulletin Physiology and Pathology of Respiration.2019; (74): 62.     CrossRef
  • Trends over 1999–2014 in the concentrations of Ba, Cs, Co, Mo, Pb, Sb, Tl, and W in urine of US children aged 6–11 years
    Ram B. Jain
    Toxicological & Environmental Chemistry.2018; 100(1): 115.     CrossRef
  • Urinary iodine concentration (UIC) could be a promising biomarker for predicting goiter among school-age children: A systematic review and meta-analysis
    Linlin Xiu, Gansheng Zhong, Xueman Ma, Stephen L. Clarke
    PLOS ONE.2017; 12(3): e0174095.     CrossRef
  • Effects of Imbalance in Trace Element on Thyroid Gland from Moroccan Children
    Sana El-Fadeli, Sabir Bouhouch, Anatoly V. Skalny, Yassir Barkouch, Alain Pineau, Mohamed Cherkaoui, Azeddine Sedki
    Biological Trace Element Research.2016; 170(2): 288.     CrossRef
  • Articles in 'Endocrinology and Metabolism' in 2014
    Won-Young Lee
    Endocrinology and Metabolism.2015; 30(1): 47.     CrossRef
Close layer
Review Articles
Thyroid
Effects of Increased Iodine Intake on Thyroid Disorders
Xin Sun, Zhongyan Shan, Weiping Teng
Endocrinol Metab. 2014;29(3):240-247.   Published online September 25, 2014
DOI: https://doi.org/10.3803/EnM.2014.29.3.240
  • 30,911 View
  • 219 Download
  • 82 Web of Science
  • 85 Crossref
AbstractAbstract PDFPubReader   

Iodine is a micronutrient essential for the production of thyroid hormones. Iodine deficiency is the most common cause of preventable mental impairment worldwide. Universal salt iodization (USI) has been introduced in many countries as a cost-effective and sustainable way to eliminate iodine deficiency disorders for more than 25 years. Currently, the relationship between USI and iodine excess has attracted more attention. Iodine excess can lead to hypothyroidism and autoimmune thyroiditis, especially for susceptible populations with recurring thyroid disease, the elderly, fetuses, and neonates. Nationwide USI was introduced in China in 1996. This review focused on the effects of iodine excess worldwide and particularly in China.

Citations

Citations to this article as recorded by  
  • Iodine and Thyroid Dysfunction in Ageing: Nutritional, Pharmacologic, and Microbial Modifiers in Older Adults
    Corina-Aurelia Zugravu, Marta Petre, Ciprian Constantin
    Geriatrics.2026; 11(1): 12.     CrossRef
  • Reference Ranges and Determinants of Thyroid Function and TSH Receptor Antibodies During Early Pregnancy in Nepal
    Kjersti S. Bakken, Apeksha Niraula, Ram K. Chandyo, Manjeswori Ulak, Laxman Shrestha, Vijay Kumar Sharma, Tor A. Strand, Tim I. M. Korevaar
    Clinical Endocrinology.2025; 102(3): 332.     CrossRef
  • Factors linked to poor self-rated health in thyroid disorder patients: findings from LASI Wave-I
    Pawan Kumar, Arunima Sen, Priyanshu Priyanshu, Mahalaqua Nazli Khatib, R. Roopashree, Mandeep Kaur, Manish Srivastava, Amit Barwal, G. V. Siva Prasad, Pranchal Rajput, Muhammed Shabil, Rukshar Syed, Gajendra Sharma, Abhay M. Gaidhane, Diptismita Jena, Gan
    Thyroid Research.2025;[Epub]     CrossRef
  • Recent insight about Biotechnological Applications of Functional Seafoods in Pharmaceutical Industry
    Senanur Taş, Naciye Yaktubay Döndaş, Sena Davran Bulut, Beyza Nur Arslan, M.Ali Tamer, Nariman Elabed, Nikheel Bhojraj Rathod, Tanaji G. Kudre, Ziye Zhang, H. Ali Döndaş, Fatih Ozogul
    Food Reviews International.2025; : 1.     CrossRef
  • The association between iodine intake and thyroid disease in iodine-replete regions: the Korean Genome and Epidemiology Study
    Seon-Joo Park, Lulu Chen, Taylor C Wallace, Hae-Jeung Lee
    Nutrition Research and Practice.2025; 19(4): 554.     CrossRef
  • The Impact of Chronic Autoimmune Thyroiditis During Pregnancy on Maternal and Fetal Outcomes
    Olesea Scrinic, Eduard Circo, Seila Musledin
    Endocrines.2025; 6(4): 56.     CrossRef
  • COVID-19 vaccine-induced autoimmune hyperthyroidism: Graves’ disease
    Avaniyapuram Kannan Murugan, Ali S. Alzahrani
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Age‐specific thyrotropin references decrease over‐diagnosis of hypothyroidism in elderly patients in iodine‐excessive areas
    Yingchai Zhang, Yu Sun, Zhiwei He, Shuhang Xu, Chao Liu, Yongze Li, Zhongyan Shan, Weiping Teng
    Clinical Endocrinology.2024; 101(5): 549.     CrossRef
  • Comparison of effects of potassium iodide and potassium chloride on structure and physicochemical properties of proteins
    Fuge Niu, Yi Gao, Xinyu Yan, Huabin Liao, Zhe Li, Yanren Cao, Mengdi Zhao, Beibei Wang, Jiao Yu, Weichun Pan
    Journal of Molecular Liquids.2024; 395: 123844.     CrossRef
  • Micronutrients throughout the Life Cycle: Needs and Functions in Health and Disease
    Mohit Kumar, Devesh Kumar, Ankita Sharma, Shivam Bhadauria, Anil Thakur, Amit Bhatia
    Current Nutrition & Food Science.2024; 20(1): 62.     CrossRef
  • Relationship Between Urinary Iodine Concentration and the Prevalence of Thyroid Nodules and Subclinical Hypothyroidism
    Huachao Zhu, Pu Chen, Xi Ding, Yanru Zhao
    Hormone and Metabolic Research.2024; 56(05): 368.     CrossRef
  • Associations of Combined Exposure to Metabolic and Inflammatory Indicators with Thyroid Nodules in Adults: A Nested Case-Control Study
    Xin-Yi Zhu, Xing-Chen Meng, Bei-Jing Cheng, Chun Wang, Jia Wang, Tian-Lin Li, Hui Li, Ke Meng, Ran Liu, Alexander Schreiber
    International Journal of Endocrinology.2024; 2024: 1.     CrossRef
  • Factors associated with inadequate urinary iodine concentration among pregnant women in Mbeya region Tanzania.
    Tedson Lukindo, Ray Masumo, Adam Hancy, Sauli E. John, Heavenlight A. Paulo, Abraham Sanga, Ramadhan Noor, Fatoumata Lankoande, Elifatio Towo, Germana H. Leyna, Gemma Bridge, Raman Bedi
    F1000Research.2024; 10: 858.     CrossRef
  • Synchronous Removal of Fluoride and Iodide on Fe–Mn Binary Oxides Interface: Competitive Adsorption Behaviors and Mechanism
    Nan Wang, He Liang, Meng Zhang, Ruiping Liu, Lina Li, Li Zhao, Huijuan Liu, Jiuhui Qu
    ACS ES&T Engineering.2024; 4(8): 2015.     CrossRef
  • Factors associated with inadequate urinary iodine concentration among pregnant women in Mbeya region Tanzania.
    Tedson Lukindo, Ray Masumo, Adam Hancy, Sauli E. John, Heavenlight A. Paulo, Abraham Sanga, Ramadhan Noor, Fatoumata Lankoande, Elifatio Towo, Germana H. Leyna, Gemma Bridge, Raman Bedi
    F1000Research.2024; 10: 858.     CrossRef
  • STUDY OF THE CONTENT OF VITAMIN C AND IODINE IN THE FRUITS OF ZYZYPHUS JUJUBA MILL
    Y. V. Fokina
    Biosafety and Biotechnology.2024; (15): 35.     CrossRef
  • Thyroid-Stimulating Hormone Levels within the Trimester-Specific Reference Intervals Are Correlated with Non–High-Density Lipoprotein Cholesterol and Remnant Cholesterol Concentrations in Pregnant Women
    Guocheng Wang, Feng Jin, Limin Xie, Xiaofen Zhang, Yawei Zhang, Xin Ni, Wei Li, Guojun Zhang
    Laboratory Medicine.2023; 54(5): 449.     CrossRef
  • Factors associated with inadequate urinary iodine concentration among pregnant women in Mbeya region Tanzania.
    Tedson Lukindo, Ray Masumo, Adam Hancy, Sauli E. John, Heavenlight A. Paulo, Abraham Sanga, Ramadhan Noor, Fatoumata Lankoande, Elifatio Towo, Germana H. Leyna, Gemma Bridge, Raman Bedi
    F1000Research.2023; 10: 858.     CrossRef
  • Iodine status and its association with prevalence of thyroid diseases in adults from Jiangxi Province, China
    Di-en Yan, Lei Hu, Yun-feng Shen, Xiao-yang Lai, Mei-ying Zhang, Min Zhou, Chao Chen, Mei-mei Liu, Li-ting Wu, Li-qun Liu, Qi-wei Fan, Wen-lan Min, Si-cong Wan, Fang Zou, Jing Li, Xia Cai, Shui-hong Lei, Yan Xiong, Ya Yang, Rong Yu, Wei-wei Gao, Ying Zhan
    Endocrine.2023; 82(2): 335.     CrossRef
  • Autoimmune thyroid status in subclinical thyroid disorders in patients attending a tertiary care center in Nepal: a hospital-based cross-sectional study
    Vijay Kumar Sharma, Apeksha Niraula, Eans Tara Tuladhar, Aseem Bhattarai, Mithileshwer Raut, Raju Kumar Dubey, Sujata Baidya, Naresh Parajuli
    BMC Endocrine Disorders.2023;[Epub]     CrossRef
  • INFLUÊNCIA DA NUTRIÇÃO NO MANEJO DO HIPOTIREOIDISMO
    Karine Rodrigues da Silva Neumann , Isadora Neres Silva, Elaine Cristina Rocha Oliveira, Taís Cristina Macêdo de Carvalho
    Revista Saúde Dos Vales.2023;[Epub]     CrossRef
  • Relationship between Thyroid CT Density, Volume, and Future TSH Elevation: A 5-Year Follow-Up Study
    Tomohiro Kikuchi, Shouhei Hanaoka, Takahiro Nakao, Yukihiro Nomura, Takeharu Yoshikawa, Md Ashraful Alam, Harushi Mori, Naoto Hayashi
    Life.2023; 13(12): 2303.     CrossRef
  • The relationship between urinary iodine concentration and papillary thyroid cancer: A systematic review and meta-analysis
    Xueqi Zhang, Fan Zhang, Qiuxian Li, Renaguli Aihaiti, Chuyao Feng, Deshi Chen, Xu Zhao, Weiping Teng
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • The impact of the micronutrient iodine in health and diseases
    Ma. Cecilia Opazo, Irenice Coronado-Arrázola, Omar P. Vallejos, Rodrigo Moreno-Reyes, Carlos Fardella, Lorena Mosso, Alexis M. Kalergis, Susan M. Bueno, Claudia A. Riedel
    Critical Reviews in Food Science and Nutrition.2022; 62(6): 1466.     CrossRef
  • Halogens in Seaweeds: Biological and Environmental Significance
    Hanan Al-Adilah, Martin C. Feiters, Lucy J. Carpenter, Puja Kumari, Carl J. Carrano, Dhia Al-Bader, Frithjof C. Küpper
    Phycology.2022; 2(1): 132.     CrossRef
  • Solid sorbents for gaseous iodine capture and their conversion into stable waste forms
    R. Pénélope, L. Campayo, M. Fournier, A. Gossard, A. Grandjean
    Journal of Nuclear Materials.2022; 563: 153635.     CrossRef
  • Secular Trends in the Prevalence of and Disability-Adjusted Life Years Due to Common Micronutrient Deficiencies in China From 1990 to 2019: An Age-Period-Cohort Study and Joinpoint Analysis
    Haiying Chen, Jinxin Lu, Yongze Li
    Frontiers in Nutrition.2022;[Epub]     CrossRef
  • Iodine Concentrations in Conventional and Organic Milk in the Northeastern U.S.
    Nobumitsu Sakai, Ola Yetunde Esho, Motoko Mukai
    Dairy.2022; 3(2): 211.     CrossRef
  • Effect of iodine restriction on short-term changes in thyroid function in patients with subclinical hypothyroidism
    Obin Kwon, Dong Yeob Shin, Eun Jig Lee
    Journal of Nutrition and Health.2022; 55(2): 250.     CrossRef
  • Excessive iodine in iodized household salt in Nepal
    Basant Giri, Shishir Pandey, Sadiksha Shakya, Bhanu Bhakta Neupane, Krishna Prasad Kandel, Chandradip Kumar Yadav, Ram Prabodh Yadav, Bishnu Prasad Neupane, Rajendra Bahadur GC, Prem Singh Saud, Meghraj Yonjan
    Annals of the New York Academy of Sciences.2022; 1514(1): 166.     CrossRef
  • Factors associated with inadequate urinary iodine concentration among pregnant women in Mbeya region Tanzania.
    Tedson Lukindo, Ray Masumo, Adam Hancy, Sauli E. John, Heavenlight A. Paulo, Abraham Sanga, Ramadhan Noor, Fatoumata Lankoande, Elifatio Towo, Germana H. Leyna, Gemma Bridge, Raman Bedi
    F1000Research.2022; 10: 858.     CrossRef
  • Iodine nutrition and papillary thyroid cancer
    Xueqi Zhang, Fan Zhang, Qiuxian Li, Chuyao Feng, Weiping Teng
    Frontiers in Nutrition.2022;[Epub]     CrossRef
  • Thyroid function disorders
    Mirjana Stojković
    Arhiv za farmaciju.2022; 72(5): 429.     CrossRef
  • Serum T3 Level and Duration of Minimum Maintenance Dose Therapy Predict Relapse in Methimazole-Treated Graves Disease
    Yotsapon Thewjitcharoen, Krittadhee Karndumri, Waralee Chatchomchuan, Sriurai Porramatikul, Sirinate Krittiyawong, Ekgaluck Wanothayaroj, Siriwan Butadej, Soontaree Nakasatien, Rajata Rajatanavin, Thep Himathongkam
    Journal of the Endocrine Society.2021;[Epub]     CrossRef
  • Factors influencing the reference interval of thyroid‐stimulating hormone in healthy adults: A systematic review and meta‐analysis
    Dongyang Xing, Delong Liu, Ri Li, Qi Zhou, Jiancheng Xu
    Clinical Endocrinology.2021; 95(3): 378.     CrossRef
  • The Iodine Status and Prevalence of Thyroid Disorders Among Women of Childbearing Age in China: National Cross-sectional Study
    Yongze Li, Zhongyan Shan, Weiping Teng
    Endocrine Practice.2021; 27(10): 1028.     CrossRef
  • Environmental and human iodine and selenium status: lessons from Gilgit-Baltistan, North-East Pakistan
    Saeed Ahmad, Elizabeth H. Bailey, Muhammad Arshad, Sher Ahmed, Michael J. Watts, Alex G. Stewart, Scott D. Young
    Environmental Geochemistry and Health.2021; 43(11): 4665.     CrossRef
  • Factors associated with inadequate urinary iodine concentration among pregnant women in Mbeya region Tanzania.
    Tedson Lukindo, Ray Masumo, Adam Hancy, Sauli E. John, Heavenlight A. Paulo, Abraham Sanga, Ramadhan Noor, Fatoumata Lankoande, Elifatio Towo, Germana H. Leyna, Gemma Bridge, Raman Bedi
    F1000Research.2021; 10: 858.     CrossRef
  • Association between Iodine Intake, Thyroid Function, and Papillary Thyroid Cancer: A Case-Control Study
    Kyungsik Kim, Sun Wook Cho, Young Joo Park, Kyu Eun Lee, Dong-Wook Lee, Sue K. Park
    Endocrinology and Metabolism.2021; 36(4): 790.     CrossRef
  • Dietary Micronutrients from Zygote to Senility: Updated Review of Minerals’ Role and Orchestration in Human Nutrition throughout Life Cycle with Sex Differences
    Mohamed A. Farag, Samia Hamouda, Suzan Gomaa, Aishat A. Agboluaje, Mohamad Louai M. Hariri, Shimaa Mohammad Yousof
    Nutrients.2021; 13(11): 3740.     CrossRef
  • Епідеміологія автоімунного тиреоїдиту
    V.I. Кravchenko, О.А. Тоvkay, О.V. Rakov, М.D. Тronko
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2021; 17(2): 136.     CrossRef
  • Association between urinary sodium levels and iodine status in Korea
    Jonghwa Ahn, Jang Ho Lee, Jiwoo Lee, Ji Yeon Baek, Eyun Song, Hye-Seon Oh, Mijin Kim, Suyeon Park, Min Ji Jeon, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Won Gu Kim
    The Korean Journal of Internal Medicine.2020; 35(2): 392.     CrossRef
  • Is heart disease a risk factor for low dementia test battery scores in older persons with Down syndrome? Exploratory, pilot study, and commentary
    Maire E. Percy, Walter J. Lukiw
    International Journal of Developmental Disabilities.2020; 66(1): 22.     CrossRef
  • A cross-sectional research of iodine status of pregnant women in Chongqing, south-west China
    Ning Yao, Chunbei Zhou, Jun Xie, Shuang Zhou
    Public Health Nutrition.2020; 23(5): 769.     CrossRef
  • The Diverse Upper Reference Limits of Serum Thyroid-Stimulating Hormone on the Same Platform for Pregnant Women in China
    Guocheng Wang, Guojun Zhang
    Laboratory Medicine.2020; 51(4): 416.     CrossRef
  • Efficacy and Safety of Long-Term Universal Salt Iodization on Thyroid Disorders: Epidemiological Evidence from 31 Provinces of Mainland China
    Yongze Li, Di Teng, Jianming Ba, Bing Chen, Jianling Du, Lanjie He, Xiaoyang Lai, Xiaochun Teng, Xiaoguang Shi, Yanbo Li, Haiyi Chi, Eryuan Liao, Chao Liu, Libin Liu, Guijun Qin, Yingfen Qin, Huibiao Quan, Bingyin Shi, Hui Sun, Xulei Tang, Nanwei Tong, Gu
    Thyroid.2020; 30(4): 568.     CrossRef
  • High prevalence of TPO-Abs and subclinical hypothyroidism in iodine-sufficient pregnant women in Northern Algeria
    Samira Akdader-Oudahmane, Zohra Hamouli-Saïd, Michael B. Zimmermann, Hanane Kherrab, Said Azzoug, Djamila Meskine
    Journal of Trace Elements in Medicine and Biology.2020; 61: 126533.     CrossRef
  • An Inverse Relationship Between Iodine Intake and Thyroid Antibodies: A National Cross-Sectional Survey in Mainland China
    Di Teng, Wenqing Yang, Xiaoguang Shi, Yongze Li, Jianming Ba, Bing Chen, Jianling Du, Lanjie He, Xiaoyang Lai, Yanbo Li, Haiyi Chi, Eryuan Liao, Chao Liu, Libin Liu, Guijun Qin, Yingfen Qin, Huibiao Quan, Bingyin Shi, Hui Sun, Xulei Tang, Nanwei Tong, Gui
    Thyroid.2020; 30(11): 1656.     CrossRef
  • Therapeutic Effects of Combination Regimens Including Methimazole on Graves Hyperthyroidism: A Network Meta-Analysis of Randomized Controlled Trials
    Maorong Wang, Yerong Yu
    Endocrine Practice.2020; 26(6): 675.     CrossRef
  • The change in the clinical presentation of Graves’ disease: a 30 years retrospective survey in an academic Brazilian tertiary center
    Wanesa Pinto, João H. Romaldini, Nicolas Perini, Roberto B. Santos, Danilo Villagelin
    Archives of Endocrinology and Metabolism.2020;[Epub]     CrossRef
  • Association between Urinary Iodine Concentration and Thyroid Nodules in Adults: A Cross‐Sectional Study in China
    Hui Sun, Hanyu Wang, Xiaolan Lian, Chao Liu, Bingyin Shi, Lixin Shi, Nanwei Tong, Shu Wang, Jianping Weng, Jiajun Zhao, Jiaoyue Zhang, Juan Zheng, Xiang Hu, Yunxia Tu, Li Yu, Zhongyan Shan, Weiping Teng, Lulu Chen, Ali Abbara
    BioMed Research International.2020;[Epub]     CrossRef
  • The effect of intake of sausages fortified with β-CD-I2 complex on iodine status and thyroid function: A preliminary study
    Maksym Polumbryk, Victor Kravchenko, Vasyl Pasichnyi, Chrystyna Omelchenko, Irina Pachitskaya
    Journal of Trace Elements in Medicine and Biology.2019; 51: 159.     CrossRef
  • Association between Iodine Nutrition Status and Thyroid Disease-Related Hormone in Korean Adults: Korean National Health and Nutrition Examination Survey VI (2013–2015)
    Sohye Kim, Yong Seok Kwon, Ju Young Kim, Kyung Hee Hong, Yoo Kyoung Park
    Nutrients.2019; 11(11): 2757.     CrossRef
  • Association Between Thyroid Nodules and Volume and Metabolic Syndrome in an Iodine-Adequate Area: A Large Community-Based Population Study
    Yue Su, Yan-ling Zhang, Meng Zhao, Hai-qing Zhang, Xu Zhang, Qing-bo Guan, Chun-xiao Yu, Shan-shan Shao, Jin Xu
    Metabolic Syndrome and Related Disorders.2019; 17(4): 217.     CrossRef
  • Analytical evaluation of the new Seal Autoanalyzer 3 High Resolution for urinary iodine determination
    Valentina Vidranski, Maja Franceschi, Dražena Krilić, Tomislav Jukić, Ivan Mihaljević, Zvonko Kusić
    Biochemia medica.2019; 29(2): 394.     CrossRef
  • Increased Incidence Rate of Hypothyroidism After Iodine Fortification in Denmark: A 20-Year Prospective Population-Based Study
    Mads Petersen, Nils Knudsen, Allan Carlé, Stig Andersen, Torben Jørgensen, Hans Perrild, Lars Ovesen, Lone Banke Rasmussen, Betina Heinsbæk Thuesen, Inge Bülow Pedersen
    The Journal of Clinical Endocrinology & Metabolism.2019; 104(5): 1833.     CrossRef
  • Relationship of gender and age on thyroid hormone parameters in a large Chinese population
    Xinxin Chen, Xulei Zheng, Zhaojun Ding, Yang Su, Shu Wang, Bin Cui, Zhen Xie
    Archives of Endocrinology and Metabolism.2019;[Epub]     CrossRef
  • Sex differences in the association between thyroid-stimulating hormone levels and depressive symptoms among the general population with normal free T4 levels
    San Lee, Sarah Soyeon Oh, Eun-Cheol Park, Sung-In Jang
    Journal of Affective Disorders.2019; 249: 151.     CrossRef
  • Reference intervals of thyroid hormones in a previously iodine-deficient area in Darfur, Sudan
    Nagi I. Ali, Abdullah O. Alamoudi, Ishag Adam
    Therapeutic Advances in Endocrinology and Metabolism.2018; 9(9): 293.     CrossRef
  • Highly sensitive electrochemical detection of iodate based on glassy carbon electrode modified with iridium oxide
    Yanna Lazarova, Ivan Shterev, Totka Dodevska
    Monatshefte für Chemie - Chemical Monthly.2018; 149(11): 1955.     CrossRef
  • Acute Delirium in a Hypothyroid Patient Precipitated by Iodine Supplements Use
    Gaby S. Gil, Bradford W. Smith, Jose R. Guerra, William T. Williams
    American Journal of Therapeutics.2018; 25(6): e717.     CrossRef
  • Iodine Deficiency in Zhejiang Pregnant Women in the Context of Universal Salt Iodization Programme
    Zhifang Wang, Mingluan Xing, Wenming Zhu, Guangming Mao, Zhe Mo, Yuanyang Wang, Zhijian Chen, Xiaoming Lou, Shichang Xia, Xiaofeng Wang
    Scientific Reports.2018;[Epub]     CrossRef
  • Age- and gender-specific reference intervals of TSH and free T4 in an iodine-replete area: Data from Korean National Health and Nutrition Examination Survey IV (2013–2015)
    So Young Park, Hae In Kim, Hyun-Kyung Oh, Tae Hyuk Kim, Hye Won Jang, Jae Hoon Chung, Myung-Hee Shin, Sun Wook Kim, Sun Y Lee
    PLOS ONE.2018; 13(2): e0190738.     CrossRef
  • Age-specific reference interval of serum TSH levels is high in adolescence in an iodine excess area: Korea national health and nutrition examination survey data
    Hyemi Kwon, Won Gu Kim, Min Ji Jeon, Minkyu Han, Mijin Kim, Suyeon Park, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Endocrine.2017; 57(3): 445.     CrossRef
  • Urinary iodine levels and dairy consumption in pre-school children in Southwest Asturias (Spain)
    Esther Arbesú Fernández, María Haydee Serrano Peraza, Hans Abdón Eguia Angeles, César Oliver Sotelo García, Claude Henrry Saint Jean, Nache Ismael Musa Martín
    Anales de Pediatría (English Edition).2017; 87(1): 18.     CrossRef
  • Association of iodized salt with goiter prevalence in Chinese populations: a continuity analysis over time
    Zhen Liang, Chen Xu, Yong-Jun Luo
    Military Medical Research.2017;[Epub]     CrossRef
  • Yodurias y consumo de lácteos en preescolares del Área Suroccidental de Asturias
    Esther Arbesú Fernández, M. Haydee Serrano Peraza, Hans Abdón Eguia Angeles, César Oliver Sotelo García, Claude Henrry Saint Jean, Nache Ismael Musa Martín
    Anales de Pediatría.2017; 87(1): 18.     CrossRef
  • Role of medical resource level in iodine deficiency disorder
    Chen Xu, Zhen Liang, Yong-Jun Luo
    Military Medical Research.2017;[Epub]     CrossRef
  • Strong association of relatively low and extremely excessive iodine intakes with thyroid cancer in an iodine-replete area
    Hye Jeong Kim, Na Kyung Kim, Hyeong Kyu Park, Dong Won Byun, Kyoil Suh, Myung Hi Yoo, Yong-Ki Min, Sun Wook Kim, Jae Hoon Chung
    European Journal of Nutrition.2017; 56(3): 965.     CrossRef
  • Excessive Iodine Intake and Thyrotropin Reference Interval: Data from the Korean National Health and Nutrition Examination Survey
    Min Ji Jeon, Won Gu Kim, Hyemi Kwon, Mijin Kim, Suyeon Park, Hye-Seon Oh, Minkyu Han, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Thyroid.2017; 27(7): 967.     CrossRef
  • Metabolic syndrome is associated with an increased incidence of subclinical hypothyroidism – A Cohort Study
    Chia-Hsuin Chang, Yi-Chun Yeh, James L. Caffrey, Shyang-Rong Shih, Lee-Ming Chuang, Yu-Kang Tu
    Scientific Reports.2017;[Epub]     CrossRef
  • Associations between thyroid dysfunction and developmental status in children with excessive iodine status
    Inger Aakre, Tor A. Strand, Khalil Moubarek, Ingrid Barikmo, Sigrun Henjum, Hiroyoshi Ariga
    PLOS ONE.2017; 12(11): e0187241.     CrossRef
  • Vitamin D deficiency affects thyroid autoimmunity and dysfunction in iodine-replete area: Korea national health and nutrition examination survey
    Mijin Kim, Eyun Song, Hye-Seon Oh, Suyeon Park, Hyemi Kwon, Min Ji Jeon, Won Gu Kim, Won Bae Kim, Young Kee Shong, Tae Yong Kim
    Endocrine.2017; 58(2): 332.     CrossRef
  • Thyroid Function Status in Indian Adult Nonpregnant Females in Ranchi, India
    Nandita Hazra, Sarvinder Singh, Binay Mitra, Bhaskar Shahbabu
    Indian journal of Medical Biochemistry.2017; 21(1): 25.     CrossRef
  • Iodine Status and Prevalence of Thyroid Disorders After Introduction of Mandatory Universal Salt Iodization for 16 Years in China: A Cross-Sectional Study in 10 Cities
    Zhongyan Shan, Lulu Chen, Xiaolan Lian, Chao Liu, Bingyin Shi, Lixin Shi, Nanwei Tong, Shu Wang, Jianping Weng, Jiajun Zhao, Xiaochun Teng, Xiaohui Yu, Yaxin Lai, Weiwei Wang, Chenyan Li, Jinyuan Mao, Yongze Li, Chenling Fan, Weiping Teng
    Thyroid.2016; 26(8): 1125.     CrossRef
  • Iodine nutrition status and thyroid disorders: a cross-sectional study from the Xinjiang Autonomous Region of China
    Y Guo, J Zynat, Z Xu, X Wang, R Osiman, H Zhao, A Tuhuti, M Abdunaimu, H Wang, X Jin, S Xing
    European Journal of Clinical Nutrition.2016; 70(11): 1332.     CrossRef
  • Effect of Prolonged Iodine Overdose on Type 2 Iodothyronine Deiodinase Ubiquitination-Related Enzymes in the Rat Pituitary
    Xiaowen Zhang, Yaqiu Jiang, Wenqing Han, Aihua Liu, Xiaochen Xie, Cheng Han, Chenling Fan, Hong Wang, Hongmei Zhang, Shuangning Ding, Zhongyan Shan, Weiping Teng
    Biological Trace Element Research.2016; 174(2): 377.     CrossRef
  • Reference intervals of thyroid hormones in a previously iodine-deficient but presently more than adequate area of Western China: a population-based survey
    Jing Cai, Yujie Fang, Da Jing, Shaoyong Xu, Jie Ming, Bin Gao, Han Shen, Rong Zhang, Qiuhe Ji
    Endocrine Journal.2016; 63(4): 381.     CrossRef
  • Urinary Iodine Excretion among Nepalese School Children in Terai Region
    Saroj Khatiwada, Basanta Gelal, Prem Raj Shakya, Madhab Lamsal, Nirmal Baral
    The Indian Journal of Pediatrics.2016; 83(1): 15.     CrossRef
  • Usefulness of Measuring Thyroid Stimulating Antibody at the Time of Antithyroid Drug Withdrawal for Predicting Relapse of Graves Disease
    Hyemi Kwon, Won Gu Kim, Eun Kyung Jang, Mijin Kim, Suyeon Park, Min Ji Jeon, Tae Yong Kim, Jin-Sook Ryu, Young Kee Shong, Won Bae Kim
    Endocrinology and Metabolism.2016; 31(2): 300.     CrossRef
  • Evaluation of energy spectrum CT for the measurement of thyroid iodine content
    Weiguang Shao, Jingang Liu, Dianmei Liu
    BMC Medical Imaging.2016;[Epub]     CrossRef
  • Iodide Residues in Milk Vary between Iodine‐Based Teat Disinfectants
    Elizabeth A. French, Motoko Mukai, Michael Zurakowski, Bradley Rauch, Gloria Gioia, Joseph R. Hillebrandt, Mark Henderson, Ynte H. Schukken, Thomas C. Hemling
    Journal of Food Science.2016;[Epub]     CrossRef
  • Total thyroidectomy as primary surgical management for thyroid disease: surgical therapy experience from 5559 thyroidectomies in a less-developed region
    Jisheng Hu, Nan Zhao, Rui Kong, Dawei Wang, Bei Sun, Lifeng Wu
    World Journal of Surgical Oncology.2015;[Epub]     CrossRef
  • Tg in Adults as a Sensitive Biomarker of Iodine Status: A 5-Year Follow up Population Study in Different Levels of Iodine Intake Regions
    Wei Chong, Xiaoguang Shi, Zhongyan Shan, Xiaochun Teng, Di Teng, Haixia Guan, Yushu Li, Ying Jin, Xiaohui Yu, Chenling Fan, Fan Yang, Hong Dai, Yang Yu, Jia Li, Yanyan Chen, Dong Zhao, Fengnan Hu, Jinyuan Mao, Xiaolan Gu, Rong Yang, Yajie Tong, Weibo Wang
    PLOS ONE.2015; 10(8): e0135553.     CrossRef
  • Articles in 'Endocrinology and Metabolism' in 2014
    Won-Young Lee
    Endocrinology and Metabolism.2015; 30(1): 47.     CrossRef
Close layer
Thyroid
Radioiodine Therapy in Differentiated Thyroid Cancer: The First Targeted Therapy in Oncology
June-Key Chung, Gi Jeong Cheon
Endocrinol Metab. 2014;29(3):233-239.   Published online September 25, 2014
DOI: https://doi.org/10.3803/EnM.2014.29.3.233
  • 10,904 View
  • 119 Download
  • 34 Web of Science
  • 34 Crossref
AbstractAbstract PDFPubReader   

Iodide uptake across the membranes of thyroid follicular cells and cancer cells occurs through an active transport process mediated by the sodium-iodide symporter (NIS). The rat and human NIS-coding genes were cloned and identified in 1996. Evaluation of NIS gene and protein expression is critical for the management of thyroid cancer, and several approaches to increase NIS levels have been tried. Identification of the NIS gene has provided a means of expanding its role in radionuclide therapy and molecular target-specific theragnosis (therapy and diagnosis using the same molecular target). In this article, we describe the relationship between NIS expression and the thyroid carcinoma treatment using I-131 and alternative therapeutic approaches.

Citations

Citations to this article as recorded by  
  • A Pilot Nonrandomized Controlled Trial Examining the Use of Artificial Tears on the Radioactivity of Tears After Radioactive Iodine Treatment for Thyroid Cancer
    Irene T. Lee, Jared V. Grice, Xiangyu Ji, Qingxia Chen, Lindsay A. Bischoff, Aaron C. Jessop, Behin Barahimi, Francois Codere, Louise A. Mawn, Rachel K. Sobel
    Thyroid®.2024; 34(1): 82.     CrossRef
  • Research progress of bone metastases: From disease recognition to clinical practice
    Wenbo Yang, Qing Pan, Fuhua Huang, Hongzhi Hu, Zengwu Shao
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Letter to the editor regarding “Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival”
    Maria José Veloza Vega, Manuela Gallo, Gonzalo Ucros, Patricia Bernal
    European Journal of Nuclear Medicine and Molecular Imaging.2022; 49(11): 3622.     CrossRef
  • Factors Associated With Radioactive Iodine Therapy–Acquired Nasolacrimal Duct Obstruction
    Irene T. Lee, Wencong Chen, Qingxia Chen, Heather A. Cole, Lindsay A. Bischoff, Aaron C. Jessop, Rachel K. Sobel
    Endocrine Practice.2022; 28(12): 1210.     CrossRef
  • RNA-Seq transcriptome analysis reveals Maackia amurensis leukoagglutinin has antitumor activity in human anaplastic thyroid cancer cells
    Suna Bektas, Engin Kaptan
    Molecular Biology Reports.2022; 49(10): 9257.     CrossRef
  • Radio-Iodide Treatment: From Molecular Aspects to the Clinical View
    Antonio De la Vieja, Garcilaso Riesco-Eizaguirre
    Cancers.2021; 13(5): 995.     CrossRef
  • Current Status and Future Perspective of the Treatment for Radioiodine Refractory Differentiated Thyroid Cancer
    Young Kee Shong
    International Journal of Thyroidology.2021; 14(2): 98.     CrossRef
  • Salivary side effects after radioiodine treatment for differentiated papillary thyroid carcinoma: Long‐term study
    Marc‐Kevin Le Roux, Nicolas Graillon, Laurent Guyot, David Taieb, Philippe Galli, Yves Godio‐Raboutet, Cyrille Chossegros, Jean‐Marc Foletti
    Head & Neck.2020; 42(11): 3133.     CrossRef
  • β-radiating radionuclides in cancer treatment, novel insight into promising approach
    Samieh Asadian, Hamed Mirzaei, Bagher Aziz Kalantari, Mohamad Reza Davarpanah, Morteza Mohamadi, Anastasia Shpichka, Leila Nasehi, Hamidreza Aboulkheyr Es, Peter Timashev, Mustapha Najimi, Nematollah Gheibi, Moustapha Hassan, Massoud Vosough
    Pharmacological Research.2020; 160: 105070.     CrossRef
  • Peptide Receptor Radionuclide Therapy in Patients With Differentiated Thyroid Cancer
    Dong Yun Lee, Yong-il Kim
    Clinical Nuclear Medicine.2020; 45(8): 604.     CrossRef
  • FDG PET/CT for the early prediction of RAI therapy response in patients with metastatic differentiated thyroid carcinoma
    Seo Young Kang, Ji-In Bang, Keon Wook Kang, Ho-young Lee, June-Key Chung, Juri G. Gelovani
    PLOS ONE.2019; 14(6): e0218416.     CrossRef
  • 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography for the prediction of radioiodine therapy response in patients with metastatic differentiated thyroid cancer
    T. M. Geliashvili, A. V. Vazhenin, T. P. Berezovskaya, N. G. Afanasyeva, E. V. Vasilyeva, P. I. Garbuzov, V. V. Krylov
    Head and neck tumors (HNT).2019; 9(4): 10.     CrossRef
  • Role of iodide metabolism in physiology and cancer
    Antonio De la Vieja, Pilar Santisteban
    Endocrine-Related Cancer.2018; 25(4): R225.     CrossRef
  • Star-Shaped Intense Uptake of 131I on Whole Body Scans Can Reflect Good Therapeutic Effects of Low-Dose Radioactive Iodine Treatment of 1.1 GBq
    Sung Hye Kong, Jung Ah Lim, Young Shin Song, Shinje Moon, Ye An Kim, Min Joo Kim, Sun Wook Cho, Jae Hoon Moon, Ka Hee Yi, Do Joon Park, Bo Youn Cho, Young Joo Park
    Endocrinology and Metabolism.2018; 33(2): 228.     CrossRef
  • Sodium Iodide Symporter (NIS) in the Management of Patients with Thyroid Carcinoma
    June-Key Chung, Hyun Woo Kim, Haewon Youn, Gi Jeong Cheon
    Nuclear Medicine and Molecular Imaging.2018; 52(5): 325.     CrossRef
  • LARP7 in papillary thyroid carcinoma induces NIS expression through suppression of the SHH signaling pathway
    Xiaomei Sui, Yana Sui, Yonghui Wang
    Molecular Medicine Reports.2018;[Epub]     CrossRef
  • Human sodium iodide transporter gene-mediated imaging and therapy of mouse glioma, comparison between 188Re and 131I
    Rui Guo, Yun Xi, Min Zhang, Ying Miao, Miao Zhang, Biao Li
    Oncology Letters.2018;[Epub]     CrossRef
  • Iodine-131 Therapy and Lacrimal Drainage System Toxicity: Nasal Localization Studies Using Whole Body Nuclear Scintigraphy and SPECT-CT
    Mohammad Javed Ali, Achyut Ram Vyakaranam, Jyotsna Eleshwarapu Rao, Giri Prasad, Palkonda Vijay Anand Reddy
    Ophthalmic Plastic & Reconstructive Surgery.2017; 33(1): 13.     CrossRef
  • Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment
    Hossein Jadvar
    American Journal of Roentgenology.2017; 209(2): 277.     CrossRef
  • Radioprotective effect of vitamin E on salivary glands after radioiodine therapy for differentiated thyroid cancer
    Arun Upadhyaya, Pingping Zhou, Zhaowei Meng, Peng Wang, Guizhi Zhang, Qiang Jia, Jian Tan, Xue Li, Tianpeng Hu, Na Liu, Sen Wang, Xiaoxia Liu, Huiying Wang, Chunmei Zhang, Fengxiao Zhao, Ziyu Yan, Xiaoran Wang, Xuemeng Zhang, Wan Zhang
    Nuclear Medicine Communications.2017; 38(11): 891.     CrossRef
  • Effects of first radioiodine ablation on functions of salivary glands in patients with differentiated thyroid cancer
    Arun Upadhyaya, Zhaowei Meng, Peng Wang, Guizhi Zhang, Qiang Jia, Jian Tan, Xue Li, Tianpeng Hu, Na Liu, Pingping Zhou, Sen Wang, Xiaoxia Liu, Huiying Wang, Chunmei Zhang, Fengxiao Zhao, Ziyu Yan
    Medicine.2017; 96(25): e7164.     CrossRef
  • Growth Kinetics of Macronodular Lung Metastases and Survival in Differentiated Thyroid Carcinoma
    Mijin Kim, Won Gu Kim, Suyeon Park, Hyemi Kwon, Min Ji Jeon, Sang Min Lee, Jeong Hyun Lee, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Thyroid.2017; 27(7): 915.     CrossRef
  • Initial Size of Metastatic Lesions Is Best Prognostic Factor in Patients with Metastatic Differentiated Thyroid Carcinoma Confined to the Lung
    Mijin Kim, Won Gu Kim, Suyeon Park, Hyemi Kwon, Min Ji Jeon, Jong Jin Lee, Jin-Sook Ryu, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Thyroid.2017; 27(1): 49.     CrossRef
  • Lack of Efficacy of Radioiodine Remnant Ablation for Papillary Thyroid Microcarcinoma: Verification Using Inverse Probability of Treatment Weighting
    Hyemi Kwon, Min Ji Jeon, Won Gu Kim, Suyeon Park, Mijin Kim, Tae Yong Kim, Minkyu Han, Dong Eun Song, Tae-Yon Sung, Jong Ho Yoon, Suck Joon Hong, Jin-Sook Ryu, Young Kee Shong, Won Bae Kim
    Annals of Surgical Oncology.2017; 24(9): 2596.     CrossRef
  • Preparation and evaluation of 131I-quercetin as a novel radiotherapy agent against dedifferentiated thyroid cancer
    Qinghua Xie, Xia Li, Guanquan Wang, Xuan Hou, Yujun Wang, Hongbo Yu, Changfa Qu, Shunzhong Luo, Yali Cui, Chuanqin Xia, Ruibing Wang
    Journal of Radioanalytical and Nuclear Chemistry.2017; 311(3): 1697.     CrossRef
  • Molecular radiotheragnostics in thyroid disease
    Nitasha Singh, Val Lewington
    Clinical Medicine.2017; 17(5): 453.     CrossRef
  • Inhibition of BRD4 suppresses tumor growth and enhances iodine uptake in thyroid cancer
    Xuemei Gao, Xinchao Wu, Xiao Zhang, Wenjuan Hua, Yajing Zhang, Yusufu Maimaiti, Zairong Gao, Yongxue Zhang
    Biochemical and Biophysical Research Communications.2016; 469(3): 679.     CrossRef
  • Hepatoprotective Effect of Dexmedetomidine Against Radioiodine Toxicity in Rats: Evaluation of Oxidative Status and Histopathologic Changes
    Kemal Kismet, Murat Sadic, Yusuf Murat Bag, Hasan Ikbal Atilgan, Gokhan Koca, Ali Kemal Onalan, Mehmet Senes, Seydi Ali Peker, Nihat Yumusak, Meliha Korkmaz
    International Surgery.2016; 101(3-4): 176.     CrossRef
  • FoxP3 in papillary thyroid carcinoma induces NIS repression through activation of the TGF-β1/Smad signaling pathway
    Siyuan Ma, Qingzhu Wang, Xiaojun Ma, Lina Wu, Feng Guo, Hongfei Ji, Fei Liu, Yanyan Zhao, Guijun Qin
    Tumor Biology.2016; 37(1): 989.     CrossRef
  • Iodine-131 Therapy and Nasolacrimal Duct Obstructions: What We Know and What We Need to Know
    Mohammad Javed Ali
    Ophthalmic Plastic & Reconstructive Surgery.2016; 32(4): 243.     CrossRef
  • I-131 remnant ablation after thyroidectomy induced hepatotoxicity in a case of thyroid cancer
    Rong Lin, Omar Banafea, Jin Ye
    BMC Gastroenterology.2015;[Epub]     CrossRef
  • Sub-Classification of Lateral Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma by Pathologic Criteria
    Min Ji Jeon, Won Gu Kim, Eun Kyung Jang, Yun Mi Choi, Dong Eun Song, Tae-Yon Sung, Jong Ho Yoon, Ki-Wook Chung, Suck Joon Hong, Jin-Sook Ryu, Ji Min Han, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Konradin Metze
    PLOS ONE.2015; 10(7): e0133625.     CrossRef
  • Targeted Radionuclide Therapy of Human Tumors
    Sergey Gudkov, Natalya Shilyagina, Vladimir Vodeneev, Andrei Zvyagin
    International Journal of Molecular Sciences.2015; 17(1): 33.     CrossRef
  • Articles in 'Endocrinology and Metabolism' in 2014
    Won-Young Lee
    Endocrinology and Metabolism.2015; 30(1): 47.     CrossRef
Close layer
Original Article
Thyroid
The Biochemical Prognostic Factors of Subclinical Hypothyroidism
Myung Won Lee, Dong Yeob Shin, Kwang Joon Kim, Sena Hwang, Eun Jig Lee
Endocrinol Metab. 2014;29(2):154-162.   Published online June 26, 2014
DOI: https://doi.org/10.3803/EnM.2014.29.2.154
  • 6,624 View
  • 61 Download
  • 14 Web of Science
  • 11 Crossref
AbstractAbstract PDFPubReader   
Background

Patients with subclinical hypothyroidism (SHT) are common in clinical practice. However, the clinical significance of SHT, including prognosis, has not been established. Further clarifying SHT will be critical in devising a management plan and treatment guidelines for SHT patients. Thus, the aim of this study was to investigate the prognostic factors of SHT.

Methods

We reviewed the medical records of Korean patients who visited the endocrinology outpatient clinic of Severance Hospital from January 2008 to September 2012. Newly-diagnosed patients with SHT were selected and reviewed retrospectively. We compared two groups: the SHT maintenance group and the spontaneous improvement group.

Results

The SHT maintenance group and the spontaneous improvement group had initial thyroid-stimulating hormone (TSH) levels that were significantly different (P=0.035). In subanalysis for subjects with TSH levels between 5 to 10 µIU/mL, the spontaneous improvement group showed significantly lower antithyroid peroxidase antibody (anti-TPO-Ab) titer than the SHT maintenance group (P=0.039). Regarding lipid profiles, only triglyceride level, unlike total cholesterol and low density lipoprotein cholesterol, was related to TSH level, which is correlated with the severity of SHT. Diffuse thyroiditis on ultrasonography only contributed to the severity of SHT, not to the prognosis. High sensitivity C-reactive protein and urine iodine excretion, generally regarded as possible prognostic factors, did not show any significant relation with the prognosis and severity of SHT.

Conclusion

Only initial TSH level was a definite prognostic factor of SHT. TPO-Ab titer was also a helpful prognostic factor for SHT in cases with mildly elevated TSH. Other than TSH and TPO-Ab, we were unable to validate biochemical prognostic factors in this retrospective study for Korean SHT patients.

Citations

Citations to this article as recorded by  
  • Exploring Serum Anti-thyroid Peroxidase Antibodies and High-Sensitivity C-reactive Protein as Inflammatory Markers in Subclinical Hypothyroidism: A Comprehensive Study
    Anantha Priya, Barani Sri, Ganesh Bala, Suganya Kannan
    Cureus.2025;[Epub]     CrossRef
  • Determinants of Levothyroxine Treatment in Patients with Hypothyroidism
    Savaş Karataş, Yalçın Hacıoğlu
    Cyprus Journal of Medical Sciences.2022; 7(5): 593.     CrossRef
  • Subclinical Hypothyroidism: Prevalence, Health Impact, and Treatment Landscape
    Won Sang Yoo, Hyun Kyung Chung
    Endocrinology and Metabolism.2021; 36(3): 500.     CrossRef
  • Thyroid disorders in Brazil: the contribution of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)
    I.M. Bensenor
    Brazilian Journal of Medical and Biological Research.2019;[Epub]     CrossRef
  • Risk factors for hypothyroidism in euthyroid thyroid nodule patients with lymphocytic thyroiditis on fine needle aspiration cytology
    Jeong-Min Lee, Jeonghoon Ha, Kwanhoon Jo, Yejee Lim, Min-Hee Kim, Chan-Kwan Jung, So-Lyung Jung, Moo-Il Kang, Bong-Yun Cha, Dong-Jun Lim
    The Korean Journal of Internal Medicine.2019; 34(6): 1287.     CrossRef
  • Analysis of the factors affecting the evolution over time of subclinical hypothyroidism in children
    Mariella Valenzise, Tommaso Aversa, Giuseppina Zirilli, Giuseppina Salzano, Domenico Corica, Simona Santucci, Filippo De Luca
    Italian Journal of Pediatrics.2017;[Epub]     CrossRef
  • Articles in 'Endocrinology and Metabolism' in 2014
    Won-Young Lee
    Endocrinology and Metabolism.2015; 30(1): 47.     CrossRef
  • Reference interval for thyrotropin in a ultrasonography screened Korean population
    Mijin Kim, Tae Yong Kim, Soo Han Kim, Yunkyoung Lee, Su-yeon Park, Hyung-don Kim, Hyemi Kwon, Yun Mi Choi, Eun Kyung Jang, Min Ji Jeon, Won Gu Kim, Young Kee Shong, Won Bae Kim
    The Korean Journal of Internal Medicine.2015; 30(3): 335.     CrossRef
  • Subclinical hypothyroidism: a historical view and shifting prevalence
    J. V. Hennessey, R. Espaillat
    International Journal of Clinical Practice.2015; 69(7): 771.     CrossRef
  • Letter: The Biochemical Prognostic Factors of Subclinical Hypothyroidism (Endocrinol Metab2014;29:154-62, Myung Won Lee et al.)
    Hwa Young Ahn, Yun Jae Chung
    Endocrinology and Metabolism.2014; 29(3): 400.     CrossRef
  • The Biochemical Prognostic Factors of Subclinical Hypothyroidism
    You Jin Lee
    Endocrinology and Metabolism.2014; 29(2): 144.     CrossRef
Close layer
Review Article
Thyroid
Low Iodine Diet for Preparation for Radioactive Iodine Therapy in Differentiated Thyroid Carcinoma in Korea
Jae Hoon Chung
Endocrinol Metab. 2013;28(3):157-163.   Published online September 13, 2013
DOI: https://doi.org/10.3803/EnM.2013.28.3.157
  • 7,086 View
  • 53 Download
  • 23 Crossref
AbstractAbstract PDFPubReader   

Preparation for radioactive iodine (RAI) therapy includes an increased serum thyroid stimulating hormone level and a low iodine diet (LID). Because of extremely high iodine intake, some physicians have advocated a more stringent LID for greater than 2 weeks in Korean patients with thyroid cancer prior to RAI therapy; however, it is very difficult to maintain a stringent LID for a longer period of time. According to recent reports in Korea, a nonstringent, simple LID for only 1 week might be enough prior to RAI therapy, if the patients can be educated intensively by specially trained staff. The measurement of simple urinary iodine concentration (UIC; µg/L) may underestimate daily iodine excretion in patients with a urinary volume of more than 1 L/day and can also be affected by dilution status. Simple UIC had a weaker correlation than the iodine/creatinine (I/Cr) ratio. Therefore, the urinary I/Cr ratio can replace 24-hour urine iodine excretion instead of simple UIC, although it may overestimate iodine intake in patients with malnutrition or poor muscle mass. The measurement of serum iodine level might be useful as an adjunct parameter for assessing LID preparation, but its sensitivity and specificity were relatively low compared to the urinary I/Cr ratio.

Citations

Citations to this article as recorded by  
  • Unveiling the hidden: acquired pediatric hypothyroidism
    Mariacarolina Salerno, Donatella Capalbo, Mariella Valenzise, Raffaella Di Mase, Letteria Anna Morabito, Chiara Centonze, Malgorzata Gabriela Wasniewska
    Frontiers in Endocrinology.2026;[Epub]     CrossRef
  • High-Dose Radioiodine Therapy Did Not Result in Better Thyroglobulin Decline in Patients with Extra-Thyroid Tumor Extension of Papillary Thyroid Cancer
    Mohamad Ghazanfari Hashemi, Mohsen Bakhshi Kashi, Mohammad Reza Ghasri, Saeed Farzanefar, Yalda Salehi, Mehrshad Abbasi
    World Journal of Nuclear Medicine.2025; 24(02): 138.     CrossRef
  • Low-iodine diet: what to eat and avoid before iodine-131 procedures?
    Gabriela O. Silva, Fernando G. Romeiro, Sonia Marta Moriguchi, Gláucia Maria F. S. Mazeto, Katia H. Koga
    Annals of Nuclear Medicine.2025; 39(7): 687.     CrossRef
  • Theranostics of Thyroid Cancer
    Luca Giovanella, Murat Tuncel, Atena Aghaee, Alfredo Campenni, Armando De Virgilio, Petra Petranović Ovčariček
    Seminars in Nuclear Medicine.2024; 54(4): 470.     CrossRef
  • Oldie but Goldie: The Fundamental Role of Radioiodine in the Management of Thyroid Cancer
    Alfredo Campennì, Massimiliano Siracusa, Rosaria Maddalena Ruggeri
    Journal of Clinical Medicine.2024; 13(21): 6400.     CrossRef
  • Patient Preparation and Radiation Protection Guidance for Adult Patients Undergoing Radioiodine Treatment for Thyroid Cancer in the UK
    J. Wadsley, N. Armstrong, V. Bassett-Smith, M. Beasley, R. Chandler, L. Cluny, A.J. Craig, K. Farnell, K. Garcez, N. Garnham, K. Graham, A. Hallam, S. Hill, H. Hobrough, F. McKiddie, M.W.J. Strachan
    Clinical Oncology.2023; 35(1): 42.     CrossRef
  • Nomogram Model Based on Iodine Nutrition and Clinical Characteristics of Papillary Thyroid Carcinoma to Predict Lateral Lymph Node Metastasis
    Junrong Wang, Yuzhang Gao, Yuxuan Zong, Weitong Gao, Xueying Wang, Ji Sun, Susheng Miao
    Cancer Control.2023;[Epub]     CrossRef
  • Is a 4-Day Low-Iodine Diet Sufficient for Radioactive Iodine Ablation in Differentiated Thyroid Cancer Treatment?
    Alex Tessnow
    Clinical Thyroidology.2022; 34(3): 123.     CrossRef
  • The Role of the Nurse in Patients on Low Iodine Diet Period
    Nedıme KOSGEROGLU, Dilek GÜMÜŞ, Handan KOYUNCU
    OSMANGAZİ JOURNAL OF MEDICINE.2022;[Epub]     CrossRef
  • The Interplay Between Thyroid Dysfunction and Kidney Disease
    Yoko Narasaki, Peter Sohn, Connie M. Rhee
    Seminars in Nephrology.2021; 41(2): 133.     CrossRef
  • Urinary Iodine Concentration and Radioactive Iodine Therapeutic Response in Patients with Differentiated Thyroid Cancer
    Yuyan Jiang, Jiahui Jin, Jingzheng Fan, Chao Huang, Qiang Jia, Jian Tan, Xianghui He, Xiangqian Zheng, Yue Zhao, Qing Zhang, Zhaowei Meng, Yan Wang
    Biomarkers in Medicine.2021; 15(11): 879.     CrossRef
  • Update on Thyroid Hormone Levels and Thyroid Dysfunction in the Korean Population Based on Data from the Korea National Health and Nutrition Examination Survey VI (2013 to 2015)
    Jae Hoon Chung
    Endocrinology and Metabolism.2020; 35(1): 7.     CrossRef
  • Contemporary considerations in adjuvant radioiodine treatment of adults with differentiated thyroid cancer
    Malik E. Juweid, Mark Tulchinsky, Ayman Mismar, Munther Momani, Ayman A. Zayed, Hussam Al Hawari, Nader Albsoul, Felix M. Mottaghy
    International Journal of Cancer.2020; 147(9): 2345.     CrossRef
  • Personalized management of differentiated thyroid cancer in real life – practical guidance from a multidisciplinary panel of experts
    Alfredo Campennì, Daniele Barbaro, Marco Guzzo, Francesca Capoccetti, Luca Giovanella
    Endocrine.2020; 70(2): 280.     CrossRef
  • Urinary iodine concentration and thyroid hormones: Korea National Health and Nutrition Examination Survey 2013–2015
    Hye In Kim, Hyun-Kyung Oh, So Young Park, Hye Won Jang, Myung-Hee Shin, Sun Wook Kim, Tae Hyuk Kim, Jae Hoon Chung
    European Journal of Nutrition.2019; 58(1): 233.     CrossRef
  • Analysis of Iodine Content in Salts and Korean Sauces for Low-Iodine Diet Education in Korean Patients with Thyroid Cancer Preparing for Radioiodine Therapy
    Soo Young Kim, Jung Mi Park, Jae Pil Hwang
    Nuclear Medicine and Molecular Imaging.2018; 52(3): 229.     CrossRef
  • Evaluation of Thyroid Hormone Levels and Urinary Iodine Concentrations in Koreans Based on the Data from Korea National Health and Nutrition Examination Survey VI (2013 to 2015)
    Jae Hoon Chung
    Endocrinology and Metabolism.2018; 33(2): 160.     CrossRef
  • The application of serum iodine in assessing individual iodine status
    Xing Jin, Peng Jiang, Lixiang Liu, Qingzhen Jia, Peng Liu, Fangang Meng, Xiaoye Zhang, Yunfeng Guan, Yi Pang, Zheng Lu, Hongmei Shen
    Clinical Endocrinology.2017; 87(6): 807.     CrossRef
  • Dietary evaluation of a low-iodine diet in Korean thyroid cancer patients preparing for radioactive iodine therapy in an iodine-rich region
    Dal Lae Ju, Young Joo Park, Hee-Young Paik, Min-Ji Kim, Seonyeong Park, Kyong Yeun Jung, Tae Hyuk Kim, Hun Sung Choi, Yoon Ju Song
    Nutrition Research and Practice.2016; 10(2): 167.     CrossRef
  • Experiences with a low-iodine diet: A qualitative study of patients with thyroid cancer receiving radioactive iodine therapy
    Kyem Ju Lee, Sung Ok Chang, Kwang Yoon Jung
    European Journal of Oncology Nursing.2016; 23: 43.     CrossRef
  • The Impact of Low Adherence to the Low-iodine Diet on the Efficacy of the Radioactive Iodine Ablation Therapy
    Dal Lae Ju, Young Joo Park, Hee-Young Paik, YoonJu Song
    Clinical Nutrition Research.2015; 4(4): 267.     CrossRef
  • Effect of Iodine Restriction on Thyroid Function in Subclinical Hypothyroid Patients in an Iodine-Replete Area: A Long Period Observation in a Large-Scale Cohort
    Ji Young Joung, Yoon Young Cho, Sun-Mi Park, Tae Hun Kim, Na Kyung Kim, Seo Young Sohn, Sun Wook Kim, Jae Hoon Chung
    Thyroid.2014; 24(9): 1361.     CrossRef
  • Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
    Won-Young Lee
    Endocrinology and Metabolism.2014; 29(3): 251.     CrossRef
Close layer
Case Reports
Thyroid
Anaplastic Thyroid Carcinoma Following Radioactive Iodine Therapy for Graves' Disease
Sun Hwa Kim, Hee Young Kim, Kwang Yoon Jung, Dong Seop Choi, Sin Gon Kim
Endocrinol Metab. 2013;28(1):61-64.   Published online March 25, 2013
DOI: https://doi.org/10.3803/EnM.2013.28.1.61
  • 6,838 View
  • 35 Download
  • 5 Crossref
AbstractAbstract PDFPubReader   

Radioactive iodine (RAI) therapy has been used as a treatment option for Graves' disease, and it has been widely accepted to be safe. On the other hand, some evidence suggests that RAI therapy is possibly associated with a small increased risk of thyroid cancer. Herein, we report a rare case of anaplastic thyroid carcinoma (ATC) associated with Graves' disease, following RAI treatment. A 42-year-old woman had been diagnosed with Graves' disease and although she was treated with an antithyroid drug, she remained in a hyperthyroid state, which led to two RAI treatments. More than 10 years later, the patient revisited our clinic due to hoarseness, dysphagia, and dyspnea, which had lasted for 2 months. Neck computed tomography suggested thyroid carcinoma and a lymph node biopsy showed metastatic papillary carcinoma. The patient underwent total thyroidectomy and was finally diagnosed as having an ATC. It is not clear if the occurrence of ATC reported here was influenced by the RAI therapy or alternatively, it may only represent the delayed recognition of a rare change in the natural history of Graves' disease. Nevertheless, this report is worthwhile since it presents a very rare case of ATC that occurred eleven years after the RAI therapy for Graves' disease.

Citations

Citations to this article as recorded by  
  • Occurrence of Newly Diagnosed Thyroid Cancer Is Not Increased After Radioactive Iodine Therapy for Graves' Disease
    Shigenori Hiruma, Natsuko Watanabe, Jaeduk Yoshimura Noh, Rei Hirose, Masakazu Koshibu, Masahiro Ichikawa, Akiko Sankoda, Hideyuki Imai, Yoshiyuki Saito, Nami Suzuki, Chie Masaki, Masako Matsumoto, Miho Fukushita, Ai Yoshihara, Kenichi Matsuzu, Hiroto Nar
    The Journal of Clinical Endocrinology & Metabolism.2025; 110(12): 3441.     CrossRef
  • V600E BRAF-mutated anaplastic thyroid carcinoma after radioactive iodine for Graves’ disease: a case report and a review of the literature
    Marta Villanova, Luigi di Filippo, Filippo Maria Bolamperti, Carlo Rodella, Laura Castellino, Raffaele Giubbini
    Clinical and Translational Imaging.2024; 12(5): 467.     CrossRef
  • Evaluation of ultrasonographical and cytological features of thyroid nodules in patients treated with radioactive iodine for hyperthyroidism
    Muhammet C. Bilginer, Didem Ozdemir, Fatma N. C. Seyrek, Nilufer Yildirim, Aylin K. Yazgan, Mehmet Kilic, Reyhan Ersoy, Bekir Cakir
    Diagnostic Cytopathology.2020; 48(1): 3.     CrossRef
  • Papillary thyroid carcinoma in cervical lymph nodes with vanished thyroid gland after ablation of Graves’ disease by radioactive iodine
    O Hamdy, S Raafat, GA Saleh, K Atallah, Mahmoud M Saleh, AM Shebl, MA Hegazy
    The Annals of The Royal College of Surgeons of England.2019; 101(5): e122.     CrossRef
  • Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
    Won-Young Lee
    Endocrinology and Metabolism.2014; 29(3): 251.     CrossRef
Close layer
Mediastinal Uptake Misinterpreted as Metastasis in Papillary Thyroid Cancer.
Eun Kyung Lee, Kyung Won Kim, So Yeon Park, Young Joo Park, Young Tae Kim, June Key Chung, Hwa Young Cho, Yun Hyi Ku, Hee Suk Min, Seong Hoe Park, Do Joon Park, Bo Youn Cho
J Korean Endocr Soc. 2007;22(6):460-464.   Published online December 1, 2007
DOI: https://doi.org/10.3803/jkes.2007.22.6.460
  • 3,303 View
  • 26 Download
  • 1 Crossref
AbstractAbstract PDF
Radioactive iodine (RAI) therapy is used for the removal of remnant thyroid tissue or metastatic thyroid cancer cells in differentiated thyroid cancer. The main mechanism of the therapy is destruction of cells by radioactive iodine that penetrates the cells though the action of the sodium-iodide symporter (NIS). We experienced a case of a 26-year-old woman with mediastinal uptake as detected on a radioiodine scan, who was previously diagnosed with papillary thyroid cancer. For diagnostic tests including chest computed tomography (CT) and a radioiodine scan, the stimulated thyroglobulin level did not show a definite cause of the mediastinal uptake. During regular follow-up, the thymus became triangular with clear margins. The patient had neither specific symptoms nor physical findings related to the presence of a thymic mass. A subsequent CT scan showed an irregular margin of the thymus, suggestive of thymic metastasis. The patient underwent a mediastinectomy. The removed specimen was composed of normal thymic tissue. Moreover, we demonstrated the presence of human NIS by immunohistochemical analysis. After thymectomy, the mediastinal uptake was markedly decreased as compared to the previous scan. This case suggests that a clinician should be suspicious for the functional uptake of thymus when metastasis is unlikely in a clinical situation.

Citations

Citations to this article as recorded by  
  • Clinical Significance of Diffuse Intrathoracic Uptake on Post-Therapy I-131 Scans in Thyroid Cancer Patients
    Hyun Su Choi, Sung Hoon Kim, Sonya Youngju Park, Hye Lim Park, Ye Young Seo, Woo Hee Choi
    Nuclear Medicine and Molecular Imaging.2014; 48(1): 63.     CrossRef
Close layer
Original Articles
A Retrospective Review of the Effectiveness of Recombinant Human TSH-Aided Radioiodine Treatment of Differentiated Thyroid Carcinoma.
Min Ah Na, Sun Hae Shin, Yang Ho Kang, Seok Man Son, In Joo Kim, Yong Ki Kim
J Korean Endocr Soc. 2006;21(4):274-280.   Published online August 1, 2006
DOI: https://doi.org/10.3803/jkes.2006.21.4.274
  • 2,660 View
  • 19 Download
AbstractAbstract PDF
BACKGROUND
The aim of the study was to evaluate the biochemical effects of recombinant human thyroid stimulating hormone (rhTSH) as an adjunct to radioiodine (RI) treatment of a differentiated thyroid carcinoma (DTC). We retrospectively reviewed the clinical response rates of DTC patients treated with RI after thyroid hormone withdrawal and compared with those after rhTSH stimulation. METHOD: We included the patients treated with RI for locally recurrent DTC from February 1, 2002 to August 31, 2005 and followed with diagnostic studies at our hospital. Forty totally (or near totally) thyroidectomized adults were included in this study. Nine patients underwent RI treatment after rhTSH stimulation while euthyoid on L-thyroxine (LT4), and 31 patients were treated with RI after thyroid hormone withdrawal. The clinical response was defined as >25% decrease in serum thyroglobulin (Tg) level on LT4 3 months after the RI treatment. RESULTS: In each group, serum Tg levels were significantly decreased 3 months after the RI treatment. And we found that 77.8 and 71.0% of those prepared by rhTSH and LT4 withdrawal, respectively, had clinical responses 3 months after the RI treatment by our criteria and there was no significant difference in response rates between two groups (P=0.238). CONCLUSIONS: Given the biases that exist in retrospective studies, at the current time we cannot recommend the routine use of rhTSH to prepare RI treatment of DTC. However, our study provided preliminary evidence that rhTSH effectively aided RI treatment of DTC at least to an equivalent degree as LT4 withdrawal.
Close layer
Analysis of the Pharmacokinetics of Recombinant Human TSH in Patients with Thyroid Papillary Carcinoma.
Tae Sik Jung, Hye Seung Jung, Jung Hwa Jung, Yun Jae Chung, Eun Young Oh, Young Ki Min, Myung Shik Lee, Moon Kyu Lee, Kwang Won Kim, Jae Hoon Chung
J Korean Endocr Soc. 2006;21(3):204-212.   Published online June 1, 2006
DOI: https://doi.org/10.3803/jkes.2006.21.3.204
  • 3,331 View
  • 26 Download
  • 1 Crossref
AbstractAbstract PDF
BACKGROUND
Individual variations of the pharmacokinetics of recombinant human TSH (rhTSH) might influence the efficacy of the radioactive iodine (RAI) uptake. We studied to investigate the individual pharmacokinetics of rhTSH and the effect of the anthropometric parameters on the serum TSH levels in patients with thyroid papillary carcinoma. METHODS: We selected 16 patients with conventional rhTSH administration for the preparation of RAI administration between June 2004 and May 2005. We measured serum TSH levels at 24-hour (prior to second rhTSH injection), 48-hour (peak level, prior to RAI administration) and 96-hour (prior to scanning) after the first rhTSH injection. We analyzed the correlation of each TSH levels with age, height, weight, creatinine clearance, body mass index (BMI), and body surface area (BSA). RESULTS: Peak TSH levels were negatively correlated with weight, BMI, and BSA. Among them, weight was an independent parameter by multivariate analysis. Decrement of serum TSH levels from the peak to the level at 96-hour was negatively correlated with weight, BMI, and BSA. It was positively correlated with increment of serum TSH levels from the level at 24-hour to the peak level. Serum TSH level at 96-hour was lower than 25 mU/L in nine of 16 patients. CONCLUSION: Body weight was inversely correlated with peak TSH level after rhTSH administration. rhTSH-stimulated TSH levels might be exaggerated to unwanted levels, and very rapidly degraded in lower-weighted patients. We should make up for the rhTSH regimen considering the individual variations of its pharmacokinetics.

Citations

Citations to this article as recorded by  
  • Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma
    Ji Young Joung, Ji Hun Choi, Yoon Young Cho, Na Kyung Kim, Seo Young Sohn, Sun Wook Kim, Jae Hoon Chung
    American Journal of Clinical Oncology.2016; 39(4): 374.     CrossRef
Close layer
Case Report
A Case of Iodine-induced Thyrotoxicosis with Acromegaly.
Kwang Hyun Kim, Kyu Hong Kim, Ho Yoel Ryu, Su Min Nam, Mi Young Lee, Jang Hyun Koh, Jang Yeol Sin, Choon Hee Chung
J Korean Endocr Soc. 2006;21(1):63-67.   Published online February 1, 2006
DOI: https://doi.org/10.3803/jkes.2006.21.1.63
  • 3,099 View
  • 23 Download
AbstractAbstract PDF
Hyperthyroidism is seen in 3.5-26% of subjects with acromegaly. Hyperthyroidism can be developed by thyroid stimulating hormone (TSH) dependent mechanism in TSH-secreting adenomas with acromegaly or by TSH independent mechanism through the stimulation of thyroid cells by growth hormone (GH). So, confirming the cause of hyperthyroidism is important to treat that. We report a case of a 56-year-old man who had acromegaly with iodine-induced thyrotoxicosis. He took the sea tangle for 4 years because he had constipation. His face and hands indicated acromegaly. Thyroid function test showed that T3 and free T4 were increased and TSH was decreased. Ultrasonography of neck showed diffuse enlargement of thyroid gland and thyroid scan showed decreased uptake of thyroid gland. So we could confirm iodine-induced thyrotoxicosis due to excessive iodine intake. Serum GH and insulin-like growth factor (IGF)-1 were markedly increased and brain MRI showed heterogenous 1 cm sized pituitary mass in right side. Acromegaly was confirmed by brain MRI, pituitary stimulation test and increased level of GH, IGF-1. He stopped iodine intake. After 6 months, T3, free T4 and TSH were normalized and he is waiting for the surgical removal of pituitary adenoma.
Close layer
Original Articles
The Incidence of Postpartum Thyroiditis and Effect of High Iodine Intake on it in Korean Women.
Won Bae Kim, Chang Hoon Yim, Kyung Soo Park, Byoung Sool Moon, Jae Hoon Lee, Hye Won Jun, Ho Jun Jin, Sung Yeon Kim, Bo Yeon Cho, Hong Gyu Lee
J Korean Endocr Soc. 1998;13(3):339-350.   Published online January 1, 2001
  • 2,069 View
  • 38 Download
AbstractAbstract PDF
BACKGROUND
Postpartum thyroiditis(PPT) is one of syndromes of thyroid dysfunction that occurs in the first year after parturition. Reported incidence of PPT is 3.9-8.2% of postpartum women in several studies from different countries. The fact that 52-100% of patients with PPT have thyroid autoantibodies, and that lymphocytic infiltration of thyroid gland is the characteristic pathological feature of PPT suggest that PPT is an autoimmune disease. High iodine intake in short term period is known to aggrevate the experimental autoimmune thyroiditis. This study was performed to investigate the incidence and clinical features of PPT in Korean postpartum women who usually ingest excessive amount of idine in immediate postpartum period and to investigate the predictive value of thyroid autoantibodies in the development of PPT in them. METHOD: Between March 1996 and February 1997, 99 women without previous history of any thyroid disease who delivered babies at Boramae hospital were enrolled. Thyroid function parameters(T3, T4, free T4, TSH), thyroid autoantibodies(anti-microsomal antibody, anti-thyroglobulin antibody) and urinary iodine excretion were measured prospectively before and 1, 3 months after delivery. Dietary iodine intake during postpartum period was evaluated by questionnaire, and clinical parameters were followed up. RESULTS: During 3 months of observation, PPT developed in 8.1%(8/99) of postpartum women. Five cases had typical course having thyrotoxic phase and the other 3 cases had hypothyroid phase without toxic phase. However, only one of those required thyroid hormone replacement therapy in the latter group. There were no differences in age, baseline thyroid function parameters, parity, percent cases with family history of thyroid disease between those developed PPT (n=8) and those did not develop PPT(n=91). Duration of high iodine intake(3.8 +- 0.5 wk. vs. 3.7 +- 0.8 wk., p>0.05), total ingested amount of high iodine diet(77 +- 28 vs. 79 +- 24 bowels of miyokguk, p)0.05), and the urinary iodine excretion(1.9 +- 1.4 mg/g creatinine vs. 3.7 +- 3.7mg/g creatinine, p0.05) at 1 month postpartum were not different between two groups. Of 99 total subjects, anti-microsomal antibody(AMA) was present in 13.1%(13/99) before delivery in their sera. Positive predictive value of the presence of AMA before delivery in predicting the development of PPT was 30.8%. CONCLUSION: The fact that incidence of PPT in normal Korean postpartum women who usually have high iodine intake in immediate postpartum period is not higher than those of other countries, and that there was no difference in the amount of iodine intake between those developed PPT and those did not suggest that high iodine intake in immediate postpartum period do not influence on the incidence of PPT. The presence of AMA before delivery had low specificity in prediction of development of PPT, so the measurement of AMA seems not to be a useful screening test.
Close layer
Changes in Properties of Thyrotropin Receptor Antibodies Following Radioiodine Treatment in Patients with Graves' Disease.
Won Bae Kim, Hyun Kyung Chung, Bo Youn Cho, Hong Kyu Lee, Chang Soon Koh, Do Joon Park, Yeon Sahng Oh
J Korean Endocr Soc. 1997;12(2):194-206.   Published online January 1, 2001
  • 1,637 View
  • 17 Download
AbstractAbstract PDF
BACKGROUND
It has been suggested that thyroid stimulation blocking antibody (TSBAb) is involved in the development of early hypothyroidism after radioiodine treatment in patient with Graves disease. However, previous studies have reported the effect of radioiodine treatment on overall changes of TSH receptor antibodies without detailed observation of changes in properties of TSH receptor antibodies. The aim of this study is to evaluate the effect of radioiodine treatment on thyroid stimulation antibody (TSAb) or on thyroid stimulation blocking antibody (TSBAb) activities and to see whether the appearance of TSBAb after radioiodine treatment is involved in the development of early hypothyroidism in patients with Graves disease. METHODS: The activities of TSAb, TSBAb were measured serially with human TSH receptor transfected Chinese hamster ovary (CHO) cells in 36 patients with Graves disease who received 131I treatment. In addition to the wild type TSH receptor-expressing cells, we used a chimeric receptor that 90-165 amino acid residues were substituted by those of rat LH/CG receptor (Mc2) for measurement of TSBAb without interference by the presence of TSAb and for evaluation of TSAb epitope spreading. We evaluated the association of early hypothyroidism after 131I treatment with changes of various immunologic parameters. RESULTS: In 14 (39%) of 36 patients, TSBAb activities were present in their sera before or after 131I treatment. Four of them had TSBAb activities before 131 treatment, and 12 newly acquired TSBAb activities after 131I treatment. The existence of TSBAb was not associated with the development of early hypothyroidism after 131I treatment but with low TSAb activities before 131 treatment, high thyroidal uptake of 131I given and with old age. The phenomena of epitope spreading measured by TSAb with Mc2 mutant clone before and after 131I treatment was not infrequent, but it had no clinical relevance. CONCLUSION: These results suggest that the existence of TSBAb may be not a major factor in the development of early hypothyroidism after radioiodine treatment in Graves disease. Other factors such as TSAb activities before radioiodine treatment, the efficiency of thyroidal uptake of 131I or old age are associated with the development of early hypothyroidism.
Close layer
Therapeutic Response to Radioactive Iodine Treatment in Graves' Disease.
Hye Young Park, Hee Sang Kong, Yon Sil Jung, Sung Kwang Lee, Hong Kyu Kim, Moon Ho Kang
J Korean Endocr Soc. 1999;14(4):679-687.   Published online January 1, 2001
  • 1,705 View
  • 20 Download
AbstractAbstract PDF
BACKGROUND
Prediction of therapeutic response to radioactive iodine (RAI) in Graves disease is poorly understood. Although thyrotropin binding inhibitor immunoglobulin (TBII) level is a strong index for relapse after antithyroid drug treatment, conflicting results are described regarding its prognostic significance in Graves disease treated with RAI. This study is to evaluate possible prognostic factors including TBII wbich affect the outcome of RAI therapy in Graves disease. METHODS: Two hundred and one patients with Graves disease who were followed for over 12 months after RAI treatment were studied retrospectively. The subjects were divided into hypothyroid, euthyroid and hyperthyroid groups, based on the thyroid function evaluated at 12 months after RAI therapy. We evaluated the association of clinical parameters including patients age, goiter size, degree of hyperthyroidism and TBII index with outcome of RAI treatment. RESULTS: In Graves disease, response rate to RAI was 70.1% (hypothyroid 22.4% and euthyroid 47.7%) until 12th month. The mean age of hypothyroid group was 40+/-11 years, significantly older than that other groups (euthyroid: 33+/-12, hyperthyroid: 35+/-13, p<0.05). Initial level of thyroid function, duration of antithyroid drug treatment prior to RAI, goiter size and dosage of RAI were not significantly different between the groups. There were 61 patients who had both TBII tests before and after RAI. Twelve had negative TBII and 49 had positive TBII before RAI admini-stration. The rate of unremitted hyperthyroidism after RAI therapy was significantly lower in patients with negative TBII than in those with positive TBII prior to RAI treatment( 0% versus 46.9%, p<0.05). CONCLUSION: Graves patients with positive TBII prior to RAI therapy were associated with lower therapeutic response to RAI than those with negatve TBII. And old age was associated with the development of early hypothyroidism after RAI therapy. These results suggest these factors be also considered in the treatment of Graves disease with RAI.
Close layer

Endocrinol Metab : Endocrinology and Metabolism
TOP